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ABSTRACT 
Mutated BRAF or NRAS genes have been found in -90% of sporadic melanomas, 
with a frequency of -65% of tumors harbouring a mutated BRAF and -25% of tumors 
bearing an activated NRAS. However, NRASQ61R and BRAFv600E are generally mutually 
exclusive, suggesting that occurrence of both mutations in the same tumor is selected 
against during tumorigenesis. Analysis of clones isolated from a rare melanoma bearing 
both mutations showed that the two activating mutations are indeed mutually exclusive at 
the single cell level. Forced co-expression of the two activating mutations in the same 
melanoma cell activated senescence and increased susceptibility to cell-mediated 
citotoxicity, consistent with a relationship of synthetic lethality between oncogenic 
NRAS and BRAF. A search for differentially expressed genes in double mutant (i.e. 
bearing NRASQ61R and BRAFv600E) vs. single mutated cells (bearing only BRAFv600E) 
allowed to identify LCN2 and LOXL3, by Microarray analysis, and activated AMPK, by 
Western blot, as potential targets involved in growth arrest of double mutant cells. AMPK 
was chosen for further analysis in panels of melanoma cells. Treatment of melanoma 
cells with either AICAR or Phenphormin, two specific activators of AMPK, led to 
inhibition of growth and of cell cycle progression in different human melanomas that was 
correlated to the up-regulation of p21 protein. Moreover, cells with activated AMPK 
showed evidence of induction of senescence. These results suggest that targeting genes 
associated with oncogenic NRAS and BRAF, and involved in regulation of cell growth 
and senescence, may allow the development of new therapeutic strategies for advanced 
melanoma. 
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1. INTRODUCTION 
1.1 Cancer 
1.1.1 Cancer cell alterations. 
Cancer is a disease involving dynamic changes in the genome. Several lines of 
evidence indicate that tumorigenesis in humans is a multistep process where every step 
reflects genetic alterations that drive the progressive transformation of normal human 
cells into highly malignant derivatives. Pathological analyses of a number of organ sites 
reveal lesions that appear to represent the intermediate steps in a process through which 
cells evolve progressively from normality through a series of premalignant states into 
invasive cancers (Foulds, 1954). A large extent of work indicates that the genomes of 
tumor cells are invariably altered at multiple sites, having suffered disruption through 
lesions such as point mutations or chromosome rearrangement (Kinzler et aI., 1996). 
Transformation of cultured cells is itself a multistep process, which may vary in different 
organisms. Taken together, observations of human cancers and animal models argue that 
tumor development proceeds through a process formally analogous to Darwinian 
evolution, in which a succession of genetic changes, each conferring one or another type 
of growth advantage, leads to the progressive conversion of normal human cells into 
cancer cells (Nowell, 2002). 
The wide array of cancer cell genotypes is a manifestation of six essential alterations in 
cell physiology that collectively dictate malignant growth (Figure 1.1): self-sufficiency in 
growth signals, insensitivity to growth-inhibitory (antigrowth) signals, evasion of 
12 
programmed cell death (apoptosis), limitless replicative potential, sustained angiogenesis, 
and tissue invasion and metastasis. Each of these novel capabilities acquired during tumor 
development represents the successful breaching of an anticancer defense mechanism 
into cells and tissues (Hanahan et aI., 2000). This multiplicity of defenses may explain 
why cancer is relatively rare during an average human lifetime. The six physiologic 
changes are shared in common by most types of human tumors. 
At genetic level, alterations in three types of genes are responsible for tumorigenesis: 
oncogenes, tumor-suppressor genes and stability genes. Since mammalian cells have 
multiple safeguards to protect against the potentially negative effects gene mutations, 
invasive cancer can develop only when several genes are defective. 
Oncogenes are mutated in such a way that renders the gene constitutively active or active 
under conditions in which the wild type gene is not. Oncogene activations can result from 
chromosomal translocations, from gene amplifications or from subtle intragenic 
mutations affecting crucial residues that regulate the activity of the gene product. For 
example, the most common activating mutation of BRAF in human cancers changes a 
valine to a glutamate at codon 600, a residue within the activation loop of the kinase 
domain (Davies et aI., 2002). An activating somatic mutation in one allele of an oncogene 
is generally sufficient to confer a selective growth advantage on the cell. 
On the other hand, tumor-suppressor genes are targeted in the opposite way by genetic 
alterations: mutations reduce the activity of the gene product. Such inactivations arise 
from missense mutations at residues that are essential for its activity, from mutations that 
result in a truncated protein, from deletions or insertions of various sizes, or from 
epigenetic silencing. Some recently described tumor-suppressor genes have been 
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hypothesized to exert a selective advantage on a cell when only one allele is inactivated 
and the other remains functional: this is the concept of haploinsufficiency (Santarosa et 
aI., 2004). Both oncogene and tumor-suppressor gene mutations operate similarly at the 
physiologic level: driving the neoplastic process by increasing tumor cell number through 
the stimulation of cell birth or the inhibition of cell death or cell cycle arrest. The increase 
can be caused by activating genes that drive the cell cycle, by inhibiting normal apoptotic 
processes or by facilitating the provision of nutrients through enhanced angiogenesis. 
The third type of genes commonly altered in cancer is represented by stability genes or 
caretakers, which promote tumorigenesis in a completely different way when mutated. 
This class includes the mismatch repair (MMR), nucleotide-excision repair (NER) and 
base-excision repair (BER) genes responsible for repairing subtle mistakes made during 
normal DNA replication or induced by exposure to mutagens. Other stability genes 
control processes involving large portions of chromosomes, such as those responsible for 
mitotic recombination and chromosomal segregation (for example, BRCAJ, BLM and 
ATM). Stability genes keep genetic alterations to a minimum, and thus, when they are 
inactivated, mutations in other genes occur at a higher rate (Friedberg, 2003). As with 
tumor suppressor genes, both alleles of stability genes generally must be inactivated for a 
physiologic effect to result. 
Mutations in these three classes of genes can occur in the germline, resulting in hereditary 
predispositions to cancer, or in single somatic cells, resulting in sporadic tumors. The first 
somatic mutation in an oncogene or tumor suppressor gene that causes a clonal expansion 
initiates the neoplastic process (Nowell, 2002). Subsequent somatic mutations result in 
additional steps of clonal expansion and thus in tumor progression (Maley et aI., 2004). 
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Indeed, the best modem definition of a neoplastic cell is a cell that has clonally expanded 
as a result of somatic mutations (Nowell, 2002; Maley et aI., 2004). Germline mutations 
of these genes can cause cancer predisposition, as a mutation that can contribute to cancer 
is already present in every cell of these persons. Such individuals therefore often develop 
multiple tumors that occur at an earlier age than in individuals whose cancer gene 
mutations have all occurred somatically (Knudson et aI.. 2002). 
In general, cancer gene mutations enhance cell growth. To achieve this effect. several 
cancer genes directly control transitions from the resting stage Go or G) to the S 
replicating phase of the cell cycle. The products of these genes include proteins like 
COK4, cyclin 01. RB and pl6 (Ortega et aI., 2002). The genes encoding RB and pl6 are 
tumor suppressor genes inactivated by mutation, whereas those encoding COK4 and 
cyclin 01 are oncogenes activated by mutation. These four genes function in a single 
pathway in human cancers. Studies on this pathway have shown that the mutations of 
these genes obey an exclusivity principle, that is, one and only one of the four genes 
noted above is generally mutated in any single tumor, exactly as predicted if the 
functional effect of each mutation was similar (Vogelstein. 2000). 
The process of tumorigenesis is initiated when a replication competent cell, such as a 
stem cell or a partially differentiated descendent of a stem cell, acquires a mutation in a 
'gatekeeping' pathway that endows it with a selective growth advantage (Vogelstein, 
2004). In some cancers, the gatekeeper has been identified (for example RB I. APe and 
NF 1 in tumors of the eye. colon and nervous system. respectively). In most common 
tumors. however. the gatekeeper is not known. It is also not known whether cancers of 
the lung. breast. prostate. bladder or brain can each be initiated through anyone of several 
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gatekeeping pathways or through only one. Many of the known gatekeepers were 
identified through the study of unusual families with predispositions to specific types of 
cancers (Knudson et aI., 2(02). As gatekeeping mutations provide fundamental insights 
into the biology and pathogenesis of particular cancers and are of singular importance to 
future diagnostic and therapeutic strategies, further research on this topic is actively going 
on. 
In addition to the genes that are mutated in a significant portion of cancers of a given 
type, there are many other genes that have been implicated in neoplasia but not shown to 
be mutated. These genes have been shown to be expressed at higher or lower levels than 
expected in normal cells (Brown et aI., 1999; Polyak et aI., 2001) and are often associated 
with epigenetic changes, that is, covalent modifications of DNA or chromatin that are 
preserved as the cancer cells divide (Jones et aI., 2002; Feinberg et aI., 2004). Unlike 
genetic changes, epigenetic changes identical to those found in cancers are often found in 
normal cells at some stage of development. 
1.1.2 Cancer Stem Cells. 
Tissues in the body are maintained by somatic stem cells. To maintain 
homeostasis in the body it is important to keep tight control over stem cell fate. The 
regulation of the balance between cell renewal and cell death is critical in carcinogenesis 
process (Sell, 2(06). There is increasing evidence that cancer initiation results from 
accumulative oncogenic mutations in long-lived stem cells or their immediate progenitor, 
followed by modification of the surrounding microenvironment (Tysnes et aI., 2007). 
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Cancer stem cells, or cancer initiating cells, have been described in the context of acute 
myeloid leukemia (Lapidot et al., 1994: Bhatia et aI., 1997; Bonnet et aI., 1997; Blair et 
aI., 1997), breast (AI-Hajj et aI., 2(03), brain (Singh et aI., 2(03), bone (Gibbs et aI., 
2005), lung (Kim et aI., 2(05), melanoma (Fang et aI., 2(05) and prostate (Collins et aI., 
2005). Similarly to normal stem cells, cancer stem cells can self-renew and differentiate 
into progeny cancer cells. Tumors contain a cellular subcomponent represented by stem 
cells. 
Indirect evidence supports the presence of melanoma stem-like cells (Fang et aI., 
2005). Melanomas show phenotypic heterogeneity both in vivo and in vitro, suggesting 
an origin from a cell with multilineage differentiation abilities; in addition, melanoma 
cells can differentiate into a wide range of cell lineages, including neural, mesenchymal, 
and endothelial cells. Like all stem cells, melanoma spheroid cells are also capable of 
proliferation, differentiation and self-renewal. Moreover, melanoma spheroid cells 
possess high tumorigenicity capability (Fang et aI., 2(05). 
Such properties suggest a stem cell origin of melanoma. This might have relevant 
implications for new efficient therapeutic strategies. In fact, the development of cancer 
therapeutics based on tumor regression may require targeting this important cell 
population (Wicha et aI., 2(06). The characterization of a cancer stem cell profile within 
diverse cancer types may open up new avenues for cancer treatment (Gudjonsson et al., 
2005). 
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1.2 Melanoma. 
1.2.1 Melanoma incidence, pathogenesis and etiology. 
Worldwide melanoma incidence is sensibly variable depending on different ethnic 
groups. In particular, incidence rates for cutaneous melanoma have risen faster than those 
for any other malignancy in Caucasian populations over the last 30 years. Mortality from 
melanoma is greater than that caused by all other types of skin cancer, especially in men 
(Giblin et aI., 2007). Over these last years, mortality rates have continued to climb, 
although survival rates are significantly different in different stages of the disease. 
Human cutaneous melanoma is hardly curable in advanced disease. Tumor thickness and 
ulceration represent the most powerful predictors of survival. Although surgical excision 
of thin «1.0 mm) primary lesions without ulceration (AlCC Stage IA) is associated with 
a to-year survival of 86% ± 0.9, survival decreases with increasing thickness of the 
primary tumor, since this in tum signals for increased probability of lymph node 
metastases. Ten-year survival in patients with >4mm primary lesions without ulceration 
(Stage lIB) is reduced to -50% (Balch et aI., 2001; Balch et aI., 2001) and decreases 
further with development of regional lymph node metastases (Stage Ill). With the 
appearance of distant and visceral metastases (Stage IV), 5-year survival drops to less 
than 10% (Balch et aI., 200 I). The striking and progressive drop in survival from Stage I 
to Stage IV highlights the urgent need for achieving a significant advancement on 
understanding the role of genes expressed/silenced in this disease and that may play a 
positive or negative role in tumor biology. 
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Melanoma arises from the malignant transformation of melanocytes, pigment-producing 
cells found in the basal layer of the epidermis and also in eye (Hurst et aI., 2003). 
Melanocytes derive from neural crest lineage and migrate to the skin during development 
(Bennett, 1993). Each melanocyte transfers pigment-containing melanosomes through 
dendritic processes that contact keratinocytes in basal and superficial layers of the skin. 
In the keratinocytes, the melanin protects the skin by absorbing and scattering harmful 
solar radiation (Jimbow et aI., 1993). 
On the basis of histological criteria, melanomas are classified according to their location 
and stage of progression. Five distinct stages have been proposed in the evolution of 
melanoma: common acquired and congenital nevi without dysplastic changes; dysplastic 
nevi with structural and architectural atypia; radial-growth phase (RGP) melanoma; 
vertical growth-phase (VGP) melanoma; and metastatic melanoma (Figure 1.2). Benign 
and dysplastic nevi are precursor lesions which progress to in situ melanoma growing 
laterally and remaining largely confined to the epidermis (RGP). In the next 
tumorigenesis step, VGP invades the upper layer of the epidermis and beyond, and then 
penetrates into the underlying dermis and subcutaneous tissue through the basement 
membrane. The transition from RGP to VGP represents the crucial step in the evolution 
of melanoma and may be significantly indicative for the clinical outcome of the disease. 
In fact, the total thickness/height of a primary melanoma lesion is still one of the most 
predictive parameters for metastatic disease and adverse clinical outcome (Balch et aI., 
2001). 
Melanoma pathogenesis is driven by both genetic and environmental risk factors and its 
incidence is influenced by skin pigmentation, sun-exposure history and geographical 
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location, indicating that ultraviolet (UV) light might have a causal role in melanoma 
development. In fact, upon exposure to UV light, keratinocytes stimulate melanocytes to 
produce the pigment melanin, which is used to protect the skin from further UV damage 
(Slominski et aI., 2004). Melanoma can be segregated into four groups according to the 
site of the primary lesion and, therefore, to the amount of UV exposure that is perceived 
to have induced the cancer (Curtin et aI., 2005). Two of these groups arise on sites of 
high UV exposure, either accumulated owing to chronic exposure throughout life (i.e. 
chronic sun damage (CSD», such as when it occurs on the face, or as a consequence of 
episodes of acute, high-intensity exposure (non-CSD), such as when it occurs on the back 
or trunk. The other two groups are from sites of low or no UV exposure, such as the 
palms of the hands or the soles of the feet (acral melanomas) or on internal sites 
involving mucosal membranes or the uveal tract of the eye (mucosal and uveal 
melanoma, respectively). 
1.2.2 The genetic basis of melanoma. 
1.2.2.1 Genetics of melanoma predisposition. 
From a genetic point of view, in which neoplastic transformation is viewed as a 
disease of genes, melanoma progression is associated to identifiable genetic mutations, 
which drive cancer cells to abnormal growth and dissemination (Chin, 2003). Genetic 
background may alter both the susceptibility to melanoma development and the disease 
course. As inherited cancer syndromes have often shed light on the genetic lesions that 
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govern the genesis of both familial and sporadic forms of a disease, the identification of 
melanoma susceptibility genes is relevant for improving disease prevention. About 10% 
of all melanoma cases are familial (Fountain et aI., 1990; Rodolfo et aI., 2004). Genetic 
analysis in familial melanoma patients has identified at least two susceptibility genes: 
CDKN2A and CDK4 (reviewed by Sharpless et aI., 2003). Another attractive possible 
candidate as a melanoma susceptibility gene is melanocortin-I receptor (MC 1 R) 
(Valverde et aI., 1996). 
The CDKN2A cancer hot spot encodes for two tumor suppressor proteins: INK4A (also 
known as p16) and ARF (also known as pI4). The inhibitor of cyelin-dependent kinase 
p16 inhibits CDK4/6-mediated phosphorylation and inactivation of RB (Serrano et aI., 
1993). The alternative reading-frame product of the locus inhibits MDM2-mediated 
ubiquitylation and subsequent degradation of p53 (Zhang et aI., 1998). Therefore, the two 
products of the CDKN2A locus negatively regulate the RB and p53 pathways, and their 
loss predisposes to the development of melanoma. The incidence of CDKN2A mutations 
among melanoma-prone families ranges from 25-40% whereas only 0.2-2% of sporadic 
melanoma patients harbor germline CDKN2A mutations (Aitken et aI., 1999). 
Few data are available on p14, the second product of the CDKN2A locus. It has been 
established that exelusive p14 mutations are very rare and that the gene may be silenced 
by hypermethylation or by post-transcriptional modifications, but the role of pl4 in 
melanoma progression remains substantially untested. The few published studies suggest 
that pl4 and pl6 loss may go together in melanoma progression (Dobrolowsky et aI., 
2002). 
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The known CDK4 point mutations are epistatic to INK4A inactivation in melanoma, 
further supporting the view that the important function of INK4A in melanoma 
suppression is the regulation of CDK4/6 activity, as the indistinguishable clinical impact 
of germline CDKN2A (INK4A) and CDK4 mutations testimonies corroborates 
(Goldstein et aI., 2000). 
The red-hair color (RHC) phenotype has long been associated with an increased risk for 
melanoma and it is linked to specific variants of MClR. The human MCIR is a seven-
transmembrane G-protein-coupled receptor (GPCR) for the a-melanocyte-stimulating 
hormone (a-MSH) expressed on epidermal melanocytes (Garcia-Borron et aI., 2005). 
MC 1 R is highly polymorphic in human population with variants that differ in signaling 
strength resulting in the variation of pigmentation phenotypes and skin phototypes (Rees 
et aI., 2003; Sturm et aI., 2002). Three common variants of MCIR (RI5IC, R160W, 
D294H) are associated with the RHC phenotype (Flanagan et aI., 2000) and individuals 
carrying these alleles have increased sensitivity to UV light (Valverde et aI., 1996). At the 
molecular level, in response to UV light, MC I R is activated by its ligand a-MSH 
produced by surrounding keratinocytes; the effect is the stimulation of the production of 
cAMP through the intracellular messenger adenylyl cyclase (AC). The second messenger 
cAMP activates protein-kinase A (PKA) which translocates to the nucleus where 
phosphorylates the CREB family of transcription factors. Among these, the 
microphtalmia-inhibitor transcription factor MITF is activated by the binding through an 
E box promoter element with PKA allowing for the transcription of pigmentary genes 
(Busca et aI., 2000; Widlund et aI., 2003). Several studies have shown MC I R variants 
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markedly modified the penetrance of mutations at the CDKN2A locus (Box et aI., 2001) 
and predispose some individuals to BRAF mutations (Landi et aI., 2006). 
1.2.2.2 Somatic mutations in melanoma. 
Neoplastic transformation and tumor progression, in all tissues, is considered as a 
multi-step process leading to accumulation of genetic and epigenetic changes affecting 
the function of genes that regulate normal programs of cell proliferation, differentiation 
and death (Hanahan et aI., 2000). Although the genetic basis of sporadic melanoma is not 
completely understood, recent developments have revealed a remarkably high frequency 
of mutations affecting NRAS and BRAF oncogenes in the mitogen-activated protein 
kinase (MAPK) signaling cascade (Polsky et aI., 2003; Pollock et aI., 2003). 
The MAPK pathway is activated through sequential phosphorylation of a number of 
kinases to rapidly and reciprocally alter cellular behavior in response to diverse 
environmental stimuli (Johnson et aI., 2002). The extracellular-signal regulated kinases 
(ERKI and ERK2) belong to this cascade that is responsible for sensing extracellular 
stimuli, including UV light (Yanase et aI., 200 I). Such stimuli activate the RAS family of 
proto-oncoproteins (HRAS, KRAS, NRAS), which in tum activates the RAF family of 
serine/threonine kinases (ARAF, BRAF, CRAF), also named MAPK kinase kinase 
(MAPKKK). Then RAF phosphorylates the MAPK kinase MEK which subsequently 
activates by phosphorylation the MAPKs ERKI and ERK2. 
Mutated BRAF or NRAS genes have been found in -90% of sporadic melanomas, with a 
frequency of -65% of tumors harboring a mutated BRAF and -25% of tumors bearing an 
activated NRAS (Davies et aI., 2002; Dong et aI., 2003). The most common alteration 
23 
involving NRAS in melanoma is the Q61 R transition, resulting from an A 182G point 
mutation, while the most common BRAF change is the V600E (TI796A) substitution. 
BRAF and NRAS mutations are generally mutually exclusive and, in addition, BRAF 
mutations appear related to progression rather than to tumor initiation, while NRAS 
mutations appear at early stages and remain during progression (Dong et aI., 2003; 
Omholt et aI., 2003). In spite of these differences, the very high frequency of alterations 
and the current knowledge on the key role of the NRAS- and BRAF-controlled pathways, 
for several cellular processes, provide compelling evidence as to the involvement of these 
two oncogenes in the development of sporadic melanoma. 
Another causal event in melanoma genesis and progression is represented by the 
loss of phosphatase and tensin homolog (PTEN) tumor suppressor gene. Loss of 
heterozygosity (LOH) and chromosomal rearrangements in the locus IOq24-26 have been 
observed in approximatively 30-50% of human melanoma cases (Wu et aI., 2003). In the 
109 regions several tumor suppressor genes are included like MXl and PTEN. PTEN 
encodes for a lipid/protein phosphatase with dual specificity: by the lipid phosphatase 
activity PTEN signals down the PI3K1AKT pathway regulating G, progression and 
apoptosis, and by the protein phosphatase activity PTEN inhibits MAPK signaling (Wu et 
aI., 2003). In melanoma, allelic loss or mutations of PTEN have been described in 5-15% 
of uncultured melanoma specimens and metastases, as well as in 30-40% of established 
melanoma cell lines (Guldberg et aI., 1997; Teng et aI., 1997). LOH frequency appears 
similar in primary and in metastatic lesions, thus suggesting that PTEN mutations occur 
in melanoma initiation, as also suggested by cytogenetic studies. Although a role of 
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PTEN gene in melanoma pathogenesis is evident in these studies. a better understanding 
of the PTEN signaling events in disease progression need to be obtained. 
Recently. MITF has been identified as a melanoma oncogene (Garraway et ai. 
2005). MITF amplification has been detected in 10% of primary cutaneous and 15%-20% 
of metastatic melanomas. MITF is a basic helix-loop-helix leucine zipper transcription 
factor and is considered to be the master regulator of melanocyte biology. Although 
MITF plays a central role in the pigmentation pathway. regulating the expression of 
melanogenic proteins such as tyrosinase. silver homologue (GP100) and melanoma-
associated antigen recognized by T cells-l (MART -llMelan-A), it also controls 
melanoblast survival and melanocyte lineage commitment. MITF has been shown to be 
directly phosphorylated by Erk kinase (Hemesath et aI., 1998; Price et ai. 1998), 
triggering its ubiquitylation and subsequent proteasome degradation (Wu et ai. 2000; Xu 
et aI., 2000). In addition. mutant BRAF has been shown to down-regulate MITF levels 
(Wellbrock et aI., 2005). and correspondingly. MITF overexpression in a specific context 
could inhibit growth-stimulatory effects of mutant BRAF (Chin et aI., 2005). On the other 
hand, MITF is not the only gene implicated in melanocyte survival. Some, such as Sox 10 
and Pax3, are transcription factors epistatically linked to MITF (Garraway et aI., 2005). 
Another group includes growth factor or receptor genes, such as endothelin 3. endothelin 
receptor B, stem cell factor and c-Kit. The former is a receptor tyrosine kinase, which is 
activated by mutations in about 2% of metastatic melanomas (Willmore-Payne et al., 
2005). The presence of both BRAF and c-Kit activating mutations in malignant 
melanoma suggests that new approaches involving specific tyrosine kinase inhibitors may 
be relevant to treat this disease. 
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Other genetic alterations, which commonly are found in melanoma, have the effect 
to reduce apoptosis. For example, frequent alterations in melanoma are the 
overexpression of Akt3, of B-cell leukemia/lymphoma 2 (Bcl-2) and of nuclear factor-kB 
(NFkB). In addition, the apoptotic peptidase activating factor-I (APAF-l), which is an 
essential component of the apoptosome complex, is frequently silenced in advanced 
melanoma (Soengas et aI., 200 I). 
1.2.3 Function of NRAS and BRAF oncogenes. 
RAS proteins (21 kOa) are guanine nucleotide-binding proteins, which control 
growth of normal and transformed cells. They cycle between an inactive GOP-bound 
state and active GTP-bound state, associating with the inner plasma membrane (Figure 
1.3) (Boguski et aI., 1999). Upon binding of growth factor ligands to receptors at the cell 
surface, RAS proteins behave as "on/off' switches, coupling extracellular signals to intra-
cellular pathways (Adjei, 200 I). In normal cells, the GTP-bound form of RAS ("on" 
state) is controlled by RAS-specific guanine nucleotide exchange factors (GEFs), while 
GTPase activating proteins (GAPs) promote hydrolysis of GTP to GDP, switching RAS 
proteins in the "off' state (McCormick, 1999). Oncogenic activation stabilizes RAS in a 
GTP-bound constitutively "on" state. 
Three RAS genes are translated into 4 RAS proteins: HRAS, NRAS, KRAS A and KRAS 
B. All the RAS proteins have a specific amino acid sequence motif at the carboxyl (C-) 
terminus, containing a cystein residue followed by two aliphatic amino acids and either a 
methionine or serine residue. This motif is essential for the post-translational processing 
of RAS proteins. A famesylation process on the C-terminus of RAS protein is needed for 
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membrane localization and for effective signal transduction capability of the protein 
(Olsen et aI., 2000). Oncogenic mutations of the RAS genes are prevalent in a large array 
of human cancers, including pancreatic adenocarcinoma (=80%), colorectal 
adenocarcinoma (=35%), lung cancer (=20%), follicular or undifferentiated carcinomas 
of the thyroid (=50%) and various hematological malignancies (Bos, 1989; Reuter et aI., 
2000). The most commonly observed mutations occur in hot-spot critical for RAS 
regulation, which are codons 12, 13 and 61 (Sprang et aI., 1997). The effect of the 
mutations is to prevent normal cycling activity of RAS by decreasing the ability of the 
protein to complex with GAP. Since RAS-GTP remains intact, the growth-stimulatory 
signal is prolonged even in the absence of growth factor receptor-ligand binding. RAS 
can also be activated in tumors by loss of GAPs, as in the case of neurofibromin (NF I) 
whose loss results in RAS activation (Weiss et aI., 1999) or through the over-expression 
of growth-factor-receptor tyrosine kinases, as the case of EGFR and ERBB2 which are 
frequently overexpressed in many types of cancer (Mendelsohn et aI., 2000). 
A multitude of signaling pathways have been linked to RAS activation, among which, the 
best characterized are the mitogen-activated protein (MAP) and the phosphoinositide 3 
(PI3) kinases pathways (Figure 1.4). 
BRAF acts downstream of RAS proteins In the RAS-RAF-MEK-ERK MAP kinase 
(MAPK) pathway. BRAF encodes a serine/threonine kinase acting in the MAPK pathway 
to transduce signals from RAS, through MEK (Mercer et a!., 2003). In mammals, there 
are three highly conserved RAF genes, ARAF, BRAF and CRAF (Pritchard et aI., 1995; 
Hagemann et aI., 1999). BRAF exists in a number of splice variants and produces 
proteins that range from 70 to 100 kDa (Barnier et aI., 1995). The three genes share a 
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common architecture of three conserved regions, CRI and CR2 in the N-terminus and 
CR3 in the C- terminus (Figure 1.5). Within CR 1 there is the RAS binding domain 
(RBD) and a cystein rich-domain (CRD). Phosphorylation of RAF proteins plays an 
important role in their regulation, with phosphorylation sites being located both in the 
regulatory domain sited in the N-terminus and the kinase domain housed in the CR3 
domain. In the CR3 domain another motif important for RAF activity is present and is 
called N-region or negative-charge regulatory-region (Figure 1.5). Unlike in ARAF and 
CRAF, where this site needs to be phosphorylated for full kinase activity, in BRAF it is 
constitutively phosphorylated thus constitutively "charged". As a consequence, BRAF is 
fully activated by RAS alone whereas ARAF and CRAF require both RAS and SRC for 
full activation (Marais et aI., 1997; King et aI., 2001). The fact that BRAF requires fewer 
steps to become activated can explain why it is the isoform that is primarily responsible 
for signaling between RAS and MAPK in the majority of cells and also why it is more 
susceptible to mutations in cancer. Recently. it has been shown that both wild type and 
mutant BRAF can activate CRAF. following a direct binding of BRAF to CRAF and a 
subsequent trans-phosphorylation of CRAF by BRAF (Wan et aI., 2004; Garnett et aI., 
2005). Wild type BRAF binds to CRAF in a RAS-dependent manner, whereas mutant 
BRAF binds in a RAS-independent manner (Garnett et aI., 2005; Weber et aI., 2001). 
Conversely, CRAF can not activate BRAF (Garnett et aI.. 2005). but both BRAF and 
CRAF subsequently signal to MEK. 
The majority of the mutations that have been found in BRAF are somatic changes that are 
presumed to be induced by environmental factors (Davies et al., 2002). The most 
common BRAF mutation. which is found in more than 90% of cases of cancer involving 
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this gene, is the glutamate versus valine substitution at codon 600 (V600E) (Davies et aI., 
2002). Upon its oncogenic activation. BRAF induces constitutive ERK signaling through 
hyperactivation of the RAS-MEK-ERK pathway and constitutive Nuclear factor kappa-B 
(NFkB) signaling, thus stimulating proliferation. survival and transformation. Although it 
can stimulate many of the hallmarks of cancer, thus being identified as an oncogene 
(Garnett et aI., 2004), BRAF is yet mutated in up to 80% of benign nevi (Pollock et aI., 
2003; Dong et aI., 2003). Indeed, BRAFv600E induces senescence in melanocytes, through 
transcriptional upregulation of the cell cycle inhibitor p16 (Michaloglou et aI., 2005; 
Gray-Schopfer et aI., 2006). Thus. BRAF plays an important role in cancer induction, 
maintenance and progression; however, by itself oncogenic BRAF is not sufficient for 
cancer and must cooperate with other processes to induce the fully cancerous state. 
1.2.4 Consequences of NRAS and BRAF activation on gene expression. 
The presence of one or the other of these activated oncogenes in neoplastic cells has 
remarkable effects on expression of several genes, since the permanent "on" state of the 
two oncogenes impacts on expression of transcription factors controlled not only by the 
MAPK pathway (common to both NRAS and BRAF), but even by the Rac/Rho and the 
PI3K cascades (under the influence of NRAS) (Khosravi-Far et aI., 1998). In particular. 
activation of the MAPK pathway influences the activity of several transcription factors, 
among which the most important is Fos, which in tum can regulate expression of a 
number of genes associated with cell proliferation, differentiation and survival, cell cycle 
regulation and integrin signaling. Moreover, recently, it has been shown that a component 
of the AP-I transcription factor is one of the targets of RAS oncogene in fibroblasts 
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(Casalino et aI., 2003). The relevance of the AP-l pathway, for tumor biology, is 
underscored by its role in regulating expression of genes coding for extracellular matrix 
components, proteolytic enzymes and their inhibitors (Poser et aI., 2004; Meadows et aI., 
2004; Castelli et aI., 1994). Two additional G-proteins, Rac and Rho, are implicated in 
the regulation of the active cytoskeleton and have been shown to be activated by RAS 
(Hanahan et aI., 2000). These proteins control critical cellular processes such as the 
formation of focal adhesion points, filopodia, stress fibers and membrane ruffling, thus 
indicating a crucial role for processes as cell migration and invasion (Adjei, 200 1). One 
additional RAS effector is PI3K, which on one hand activates Rac and on the other hand 
acts on Akt, which has numerous downstream survival and death factors targets (Adjei, 
2001). Interestingly, it has been recently demonstrated that RAS, possibly through the 
PI3K pathway, can activate angiogenic phenotype in primary endothelial cells and can 
control cell migration and metastasis (Meadows et al., 2004). Moreover, there are several 
other RAS effectors, including PKCz, PLC and RaIGDS, whose role in RAS signaling 
remains yet to be understood (Adjei, 200 I). [n addition, there are distinct lines of 
evidence suggesting that several transcriptional targets of oncogenic NRAS and BRAF 
may play a direct or indirect role in regulation of anti-tumor immunity and in the 
development of tumor escape mechanisms. For example, mutant NRAS has been shown 
to increase transcription of genes such as apoptosis inhibitors, melanoma-associated 
antigens and cytokines like IL-I, IL-6 and TNF-n. Moreover, constitutively activated 
MAPK, resulting from oncogenic NRAS or BRAF, promotes suppression of lAK-STAT 
transcriptional activity (Krasilnikov et aI., 2003). STATs transduce signals from a large 
array of cytokines (Kisseleva et aI., 2002) and several of these factors are produced by 
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melanoma cells or by the normal surrounding tissues. As a result of STAT activation, 
transcription of several genes is promoted. Interestingly, STAT regulated genes code not 
only for proteins that contribute to regulation of proliferation and apoptosis, but even to 
co-stimulation of T cell mediated response, as exemplified by the recent identification of 
STAT-I-dependent induction of CD40 in endothelial cells. Thus, it is also conceivable 
that presence/absence of either an activated NRAS or an activated BRAF in melanoma 
cell may impact on the expression of genes that are not only related to the malignant 
phenotype but could even play a role in development and regulation of immunity at 
tumor site. 
A wealth amount of sequence information, with few overlap among the different sets of 
data, is available on trascriptional changes related to the constitutive activity of mutant 
RAS genes in rat fibroblasts or to the inducible activity of RAF in human epithelial cells 
(Zuber et al., 2000; Schulze et al., 200 I). It is however known that the cellular context 
and the type of RAS isoform are important determinants in RAS signaling. Indeed 
different outputs of RAS oncogenic isoforms as well as distinct effector type recruitment 
were documented in different cell types. 
1.2.5 Gene profiling in human melanoma. 
Several studies have investigated whether human melanoma can be classified into 
distinct subsets on the basis of their gene profile resulting from microarray analysis. By 
such approaches, evidence for profiles associated with tumor stage and/or biological 
behavior has indeed been obtained (Polsky et al., 2003; Carr et aI., 2003). To this end, 
microarray expression profiling has been used to examine the sets of molecular changes 
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that occur in melanoma. Microarrays were used to distinguish different stages of 
melanoma. A comparison of naevi, primary melanomas and metastatic melanoma 
samples revealed that these lesions can be distinguished one from each other (Haqq et aI., 
2005). A molecular signature of invasion in cutaneous melanoma has been identified 
(Bittner et aI., 2000). 
On the other hand, less information is available regarding the consequences, for gene 
expression, of the presence of NRAS or BRAF mutations in the neoplastic cells. Thus, 
more comprehensive analysis is required to better understand the contribution made by 
BRAF and NRAS mutations to melanoma progression, prognosis and response to 
therapy. However, several studies have focused on defining gene profiles regulated by 
oncogenic BRAF and NRAS. In a recent study that considered the expression profile of a 
number of melanoma lines whose NRAS or BRAF mutation status was known, presence 
of the V600E activated BRAF oncogene was linked to a specific gene expression 
signature made of as few as 83 genes (Pavey et al.. 2002). In one study (Bloethner et aI., 
2005) of 10 melanoma cell lines, 65 genes were shown to distinguish wild type BRAF 
from BRAFv600E lines, whereas expression of 109 genes changed when wild type NRAS 
and NRAS261R lines were compared. Fifty-six genes were common to both the BRAF and 
NRAS sets, and many of these genes encode members or regulators of the RAS-RAF-
MEK-ERK pathway, whereas others are involved in metastasis or invasion. Despite the 
fact that it was possible to distinguish oncogenic NRAS melanomas from wild type NRAS 
melanomas, it was not possible to distinguish BRAF and NRAS melanomas from each 
other. 
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Microarrays can clearly be used to distinguish different forms of melanoma, but to date 
this approach has not convincingly allowed for identifying a BRAF or NRAS signature. 
However, these studies suggested that the transcriptional consequences resulting from 
mutation of BRAF or NRAS are different, presumably for their differential capacity to 
transduce signals through the various effectors. Indeed, more studies are therefore 
required to allow us to harness the power of this approach. 
1.2.6 Melanoma resistance to apoptosis. 
Despite efforts to promote sun protection behaviors, melanoma incidence 
continues to increase. The prognosis of advanced melanoma remains extremely poor in 
spite of treatment advances, emphasizing the importance of exploring additional 
preventive measures. One of the major consequences of the constitutive activation of the 
MAPK and PI3K1 AKT signal transduction pathway in tumor cells is the induction of 
tumor cell resistance to apoptosis. Indeed, human melanoma has been showed to be 
chemoresistant in vivo to a wide range of therapeutics acting with different mechanisms 
(Soengas et al.. 2002). These mechanisms often depend on the acquisition of defects in 
the cell death pathways. Several studies over the past 10-15 years shed light into the 
mechanisms of melanoma resistance to apoptosis promoted by several chemotherapeutic 
drugs (Okada et al.. 2004). Thus, to target and reverse this antiapoptotic mechanism is 
attractive as a component of multiple therapies. 
Apoptosis is mediated by a sequence of events that result in cell death. In cancer 
cells there is often an imbalance in favor of antiapoptotic signals. which confers cells a 
resistance to chemotherapeutic drugs and radiation. Bcl2. a family of proteins. plays an 
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important role in cancer cell survival (Kim et al., 2005). Overexpression of Bcl2 has been 
observed in many types of solid neoplasms and hematologic malignancies, including 
melanoma. Nearly 90% of melanomas present overexpression of this anti-apoptotic 
protein (Selzer et al., 1996). Members of the Bcl2 gene family as well as the inhibitor of 
apoptosis protein (lAP) families have been successfully targeted to render tumor cells 
more susceptible to apoptosis (Klasa et al., 2002; Jansen et al., 1998). To this end, Bcl2 
protein expression can be directly down-regulated by antisense oligonucleotides 
(Kirkwood et al., 2005). An alternative approach to overcome tumor cell resistance to 
apoptosis is to inhibit the function of lAPs. One of these proteins is survivin, which has 
been found to be highly expressed in most cancers. In preclinical models small molecules 
have been demonstrated to suppress the function of survivin, and that has now entered a 
Phase II trial in several solid tumors including melanoma (Becker et al., 2006). 
1.2.7 Targeted therapies for melanoma treatment. 
A recent approach for cancer therapy is represented by targeted drugs. In the last 
decade researchers have focused on the explanation of an altered signal network in cancer 
cell. The identification of pathways involved in growth regulation, which are important 
for cancer biology, allowed to act with specificity at molecular level. Protein kinases 
transmit signals to the nucleus through intracellular cascade. The activity of kinases 
involved in transmission of proliferation signals in cancer cells often becomes more 
intense. Kinase inhibitors are generally small molecules designed to act with specificity 
on intracellular protein-kinases. In particular two oral drugs, sorafenib and imatinib 
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mesylate, and an intravenous drug, temsirolimus, were tested in melanoma patients. 
MAPK pathways have been found to be altered in various malignancies (Davies et aI., 
2002). Giving its high rate of mutation in melanoma cells (Sathyamoorthy et aI., 2003), 
BRAFv600E is a suitable target for antitumor therapy (Brose et aI., 2002). Sorafenib (BAY 
43-9006), a bi-aryl urea, is a small molecule originally synthesized for BRAF and CRAF 
inhibition. It targets the A TP-binding site of the kinase and, at low concentrations, it 
inhibits in vitro both wild type and mutant BRAF. Moreover, sorafenib also inhibits other 
tyrosine-kinase receptors involved in angiogenesis and tumor progression, including 
vascular endothelial growth-factor receptor (VEGFR)-2, VEGFR-3, c-Kit and platelet-
derived growth-factor P (PDGFR-P)· 
Other drugs targeting MAPK pathway are the Ras farnesyl transferase inhibitors, 
specifically designed to block an essential post-translational modification of RAS 
(Downward,2003). 
Since beside the RAS-MAPK pathway also the PI3K-Akt pathway contributes to 
melanoma cell survival, PI3K signaling is also a good target for melanoma treatment. 
Chemical agents, which target PI3K, Akt, mTOR and other downstream components of 
this pathway, are being developed (Dancey, 2006). 
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1.3 Oncogene-Induced Proliferative Arrest. 
Normal balance between cellular proliferation and cell death is tightly regulated in 
order to maintain structural and functional stability of the tissues of multicellular 
organisms. Indeed, a complex machinery of antiproliferative signaling allows 
proliferation only under particular circumstances to avoid the undesirable effects of 
excessive cellular proliferation. To this end, specific cell cycle checkpoints preserve 
genomic integrity and cell survival. Cellular differentiation and apoptotic cell death are 
similarly subject to strict regulation. Upon the disruption of the tight regulation of cell 
cycle, cells proliferate without control and may enter and progress on the road to cancer. 
The oncogenic mutations leading to cancer development generally result in enhanced 
growth-promoting signals, disrupted anti-proliferative signals, or defective pro-apoptotic 
signaling. 
Molecular mechanisms leading to the cessation of growth of premalignant or benign 
neoplasms play relevant role in the prevention of cancer. In vitro studies revealed that, 
under certain circumstances, oncogenic signaling can elicit, paradoxically, a potent 
growth arrest response (Serrano et aI., 1997). The irreversible arrested growth IS 
characterized by distinct changes in the cellular phenotype and the phenomenon IS 
generally called senescence. Recent data supported the notion that oncogene-induced 
senescence might be an in vivo mechanism that contributes to protection against cancer 
(Braig et aI., 2005; Chen et aI., 2005; Collado et aI., 2005; Michaloglou et aI., 2005). 
Moreover, senescence has emerged recently as a drug-responsive program able to 
influence the outcome of cancer chemotherapy. Since the drug amounts required for 
induction of proliferation arrest are much lower than those necessitated for induction of 
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apoptotic cell death, forcing cancer cells to undergo senescence may represent a less 
aggressive approach to control tumor progression. However, simultaneously the ability of 
cancer cells to escape senescence and become drug resistant must be inhibited. Therefore, 
a clear understanding of the mechanisms that govern drug-induced senescence is critical 
and can lead to discovery of novel approaches to suppress drug resistance (Rebbaa, 
2005). 
1.3.1 Replicative and premature senescence. 
Normal somatic cells have a limited life span and cannot proliferate indefinitely in 
culture (Shay et al., 2000). After a certain number of cell divisions, non transformed cells 
in vitro spontaneously stop proliferating. This phenomenon is called the Hayflick limit 
(Hayflick, 1965). Cultured cells that reach the Hayflick limit become large and flat, are 
often vacuolated, and commonly activate senescence-associated acidic ~-galactosidase, 
which has recently been suggested to correspond to lysosomal ~-D-galactosidase (Lee et 
al., 2006; Dimri et al., 1995). Senescence-associated acidic ~-galactosidase activity can 
be visualized by a cytochemical reaction resulting in blue precipitate which is a widely 
used marker of cellular senescence and other types of cellular stress (Dimri et al., 1995). 
An additional characteristic of senescent cells is represented by the senescence-associated 
heterochromatin foci (SAHF), which are stretches of transcriptionally silenced DNA 
associated with a specific modification of histones (Narita et al., 2003). The Hayflick 
limit results from the fact that at each round of DNA replication, telomeres become 
slightly shorter and are eventually dysfunctional (Shay et al., 2000). When they reach a 
critical minimal length, a DNA damage response is triggered. This response is associated 
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with chromosomal instability, senescence and loss of cell viability. A causal role for 
telomeres in senescence became evident from the discovery of telomerase, a 
ribonucleoprotein that elongates telomeres, thereby blocking the progressive shortening 
of the telomeres of proliferating cells (Harley et aI., 1990). Telomerase activity allows 
various cell types to proliferate beyond the usual maximum number of cellular divisions. 
Telomere shortening might constitute a generic way to avoid the growth of cancer, since 
it emerges whenever a cell has used up a maximum number of allowed divisions. Instead, 
in cancer cells often there is an inappropriate activation of telomerase (Crute et aI., 1998) 
or an alternative mechanism that similarly results in telomere lengthening (Muntoni et al., 
2005). Whereas short telomeres can suppress tumorigenesis in mice (Gonzales-Suarez et 
aI., 2000), forced expression of telomerase contributes to malignant transformation of 
primary cells in vitro in the presence of cooperating oncogenes (Hahn et aI., 1999). 
Indeed, there is a strong link between the loss of telomere-associated senescence and 
cancer. In contrast to somatic cells, most cancer cells have extended or infinite life span. 
Escape from senescence during neoplastic transformation has been linked to inactivation 
of the tumor suppressor p53 and to constitutive activation of telomerase (Duncan et al., 
1997; Stampfer et aI., 2003). Although cancer cells are less sensitive to senescence 
induced by physiological conditions, they undergo to irreversible growth arrest when 
subjected by various cellular stresses, including DNA damage, by most artificial culture 
conditions and by uncontrolled oncogene activation. Indeed, a number of studies have 
demonstrated that exogenous stresses such as UV and IR irradiation, H202, hypoxia, and 
various chemicals, induce a senescence phenotype that is mainly characterized by 
enhanced expression of the cell cycle inhibitors p 16, p21, p27 and disruption of 
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lysosomal function through enhanced activity of the senescence associated ~­
galactosidase (SA-~-Gal). 
Approximately 20 years ago, it was noted that in untransformed fibroblasts, an 
activated mutant of the RAS gene induced the arrest of cell growth rather than oncogenic 
transformation (Franza et aI., 1986). However. if the cells already harbored certain 
oncogenic mutation, the same mutant RAS gene contributed to oncogenic transformation 
(Land et aI., 1993). Only after about 10 years, in 1997, Serrano and colleagues noticed 
that the type of proliferative arrest elicited in young diploid fibroblasts by mutant RAS 
exhibited many features of replicative (telomere-associated) cellular senescence, 
including stable maintenance of cell cycle arrest (Serrano et aI., 1997). Thus, senescence 
could be induced in non malignant cells before telomeric shortening. Such phenomenon 
was called premature senescence. Premature, or oncogene-induced, senescence is an 
irreversible process. 
The findings about in vitro senescence quickly led to speCUlation about possible in vivo 
correlations that might provide protection against cancer and account for the phenomenon 
of proliferative arrest in benign tumors (Bennett, 2003; Mooi et aI., 2002; Campisi, 2001; 
Bringold et aI., 2000; Lowe et aI., 2003). Nevertheless, it should be noticed that many 
differences exist between in vitro and in vivo cell conditions. For example, the different 
microenvironment of cultured cells in respect to the in vivo microenvironment (Sherr et 
aI., 2000) can cause a phenomenon called culture stress, which is a distinct process from 
senescence phenomenon. However, recently several studies have provided substantial 
support for the notion that oncogene-induced senescence is a physiologic mechanism for 
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protection against cancer (Braig et aI., 2005; Chen et aI., 2005; Collado et aI., 2005; 
Michaloglou et aI., 2005; Lazzerini et aI., 2005). 
Oncogene-induced senescence is accompanied by the activation of a tumor suppressor 
network. It has been shown that cell senescence can be triggered in vivo not only by 
oncogene activation, but also by inactivation of tumor suppressors such as PTEN (Chen 
et ai., 2005). Indeed, in cultured cells, premature senescence is caused by the activation of 
a set of tumor suppressor genes that are often inactivated in human cancer and various 
cancer-susceptibility syndromes: INK4A (inhibitor of cyclin-dependent kinase 4) (Gruis et 
ai., 1995; Kamb et aI, 1994), ARF (alternative reading frame) (Randerson-Moor et ai., 
2001; Rizos et ai. 2001), p53, and RB (the retinoblastoma tumor suppressor gene) 
(Palmero et ai., 1998; Tanaka et aI., 1994; Peeper et al.,200 I; Dannenberg et aI., 2000; 
Sag et ai., 2000). The INK4A protein pl6 inhibits the activation of cyclin-dependent 
kinases (CDKs). These enzymes stimulate progression of the cell cycle by 
phosphorylating the RB protein (pRB). As a result of the action of p 16, however, 
unphosphorylated RB remains tightly bound to its major effectors, the E2F transcription 
factors, thereby preventing them from stimulating replication of DNA. In this way, p 16 
blocks entry of the cell into the S phase of the cell cycle. The current thinking is that 
inactivation of the p53 and pRB tumor-suppressor pathways is essential for establishing 
tumorigenesis process in humans (Sherr et aI., 2002). Also for this reason, oncogene-
induced senescence has become the subject of intense research in order to identify new 
human oncogenes and tumor suppressor genes (Berns et aI., 2004; Peeper et ai., 2002). 
Several recent reports provide an interesting link to the induction of senescence and 
the activation of the DNA damage response in small and early neoplastic human lesions 
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of various types, including dysplastic melanocytic nevi (Bartkova et aI., 2005; Gorgoulis 
et aI., 2005; Di Micco et aI., 2006). Indeed, it has been long known that a senescence 
response also can result from DNA double-strand breaks (Di Leonardo et aI., 1994). 
Members of the DNA damage sensors and effectors have been reported to be associated 
with cellular sensitivity to stress. For example, this is the case of ATM, a mutated gene in 
patients with ataxia-telangiectasia, which is a disorder characterized by chromosomal 
instability, hypersensitivity to y-irradiation, predisposition to cancer, and premature 
senescence (Savitsky et aI., 1995). 
Collectively, these observations suggest that during tumorigenesis, before genomic 
instability emerges and results in multiple additional genetic aberrations, mammalian 
cells respond to inappropriate mitogenic signaling, DNA-replication stress or telomere 
dysfunction by activating protective cellular networks that abrogate cancer progression. 
1.3.2 Melanoma and senescence 
The first direct evidence of cellular senescence In a growth-arrested human 
neoplasm was reported for the melanocytic nevus (Michaloglou et aI., 2005). In humans, 
cutaneous melanocytes reside largely in the epidermis and hair follicles. They are long-
lived cells, despite exposure to potentially mutagenic insults such as UV radiation. 
Melanocytic nevi are exceedingly common and generally harbor an activating BRAFv600E 
mutation or, less commonly, an NRAS or HRAS mutation (Pollock et aI., 2003; Saldanha 
et aI., 2004; Bastian et aI., 2000). The BRAF mutation is also common in melanomas, 
where its silencing eliminates the transformed state (Hingorani et aI., 2003; Davies et aI., 
2(02). Indeed, mutant BRAF has attracted much attention as a potential therapeutic agent 
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in melanoma and other cancers (Tuveson et aI., 2003). However, in spite of the activation 
of the MAPK pathway, which mediates proliferative signals, benign nevi eventually lose 
all their proliferative activity, and their growth remains arrested for decades, until they 
gradually disappear (Maldonado et aI., 2004; Kuwata et aI., 1993). Human melanocytic 
nevi that have reached the end of their growth phase display the four established 
hallmarks of oncogene-induced cell senescence: expression of an activated oncogene 
(BRA FV600E) , stable proliferative arrest, up-regulated levels of a tumor suppressor (pI6) 
and elevated expression of senescence-associated acidic p-galactosidase. Of note, 
BRAFv600E can trigger the development of invasive melanoma only in the context of p53 
deficiency, suggesting that BRAFV{)()()E alone is insufficient to drive oncogenic 
transformation. Other model systems as well suggest that additional molecular defects are 
required for tumorigenesis mediated by BRAFV{)()OE (Chudnokovsky et aI., 2005). 
However, telomere length in congenital, acquired or Spitz nevi is not different from 
surrounding tissues (Miracco et aI., 2002; Gray-Schopfer et aI., 2006). These findings 
support the hypothesis of an active oncogene-driven senescence process in nevi (Figure 
1.6), rather than senescence triggered by exhaustion of replicative potential resulting from 
telomere shortening. It is conceivable that non malignant cells, like melanocytes in nevi, 
upon the acquisition of oncogenic mutations may engage in three types of responses. 
Immediately, an antiproliferative response can be activated, leading to either programmed 
cell death (apoptosis) or senescence. Alternatively, cell proliferation driven by the 
oncogenic mutation may occur and produce a lesion. At this stage, both apoptosis and 
senescence programs might be activated. In the absence of appropriate defense 
mechanisms, additional genetic events may add to the continued growth leading to a 
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malignant lesion. At this stage, cells may undergo a senescence response and do so for 
decades, like appears to be the case for melanocytic nevi. Alternatively, cells may 
infrequently escape from such a senescent state and undergo malignant transformation, 
giving rise to melanoma progression (Figure 1.6). 
Cutaneous melanocytes are exposed to mutagenic influences, are long-living and 
presumably cannot be replaced in large numbers. For this reason, there might exist 
evolutionary pressures tenting to preserve them. Senescence might be a mechanism 
leading to this aim, since it represents a response to oncogenic stress that blocks 
proliferation but allows the cell to live on and perform its physiologic function. 
However, although in principle the senescence response promotes survival by providing 
protection against cancer, it could interfere with individual long-term survival by 
promoting the accumulation of non proliferating cells. In fact, on one hand, senescence 
leads to a gradual accumulation of long-lived senescent cells, which can accumulate 
additional malignant alterations. On the other hand, senescent cells secrete matrix 
metalloproteinases and inflammatory cytokines that stimulate proliferation of 
preneoplastic epithelial cells thus contributing to the malignant transformation of nearby 
epithelial cells (Krtolica et aI., 200 I). Indeed, the beneficial anticancer effect of 
senescence process may result in negative consequences, which are manifested with 
advancing age (Campisi et ai., 2005; Kirkwood et ai., 20(0). 
1.3.3 Cellular senescence as a new anti-cancer therapy. 
Many anticancer drugs are based on the induction of apoptosis. Apoptosis is 
mediated by a sequence of events that result in cell death. In cancer cells there is often an 
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imbalance in favor of antiapoptotic signals, which confers cells a resistance to 
chemotherapeutic drugs and radiation. However, the intrinsic resistance of melanoma to 
the conventional pro-apoptotic chemotherapy has led researchers to evaluate new 
approaches. 
In this contest, cellular senescence has emerged as an alternative target to overcome or 
even to prevent drug resistance from occurring. Alterations of senescence pathways 
without disruption of apoptosis may be sufficient to enhance chemotherapy efficacy. In 
cancer cells the capability to execute senescence might be disabled for numerous reasons. 
In fact, mutations in genes that control cellular senescence might have been acquired 
already during tumor development or may not be selected for during chemotherapy 
(Schmitt et aI., 2002). Oncogenes such as activated RAS are known to provoke premature 
senescence relying on defects in this program (Serrano et aI., 1997; Brookes et aI., 2002). 
Nevertheless, tumors that preserve both an intact apoptotic and a functional senescence 
program may display a particularly robust drug response consisting of acutely inducible 
cell death in a first phase, corroborated by delayed apoptosis out of senescence at a later 
point. Although apoptosis is a fast-acting response mode, little is known about the 
possibility that apoptosis-competent cells might be sent into senescence following DNA-
damaging therapy and whether a senescent tumor could ever undergo apoptosis upon an 
additional proapoptotic signal (Wang, 1995). Finally, senescence could be used as a 
mechanism to lock temporarily arrested tumor cells into irreversible cytostasis. So far, 
cytostasis, or growth arrest, has not been widely exploited for the treatment of malignant 
tumors. However, the rational design of anticancer compounds targeting selective entities 
unique to cancer cells has been adopted in an attempt to improve efficacy and selectivity, 
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and to minimize toxicity. The pharmacologic outcome of target-based compounds is 
more likely to be cytostatic than cytotoxic (Fox et aI., 2002; Hoekstra et aI., 2003). When 
considering growth arrest in chemotherapy, the irreversibility of this process is essential 
for therapeutic efficacy (Kahlem et aI., 2004). The observation that cancer cells have 
maintained the ability to senesce in vivo has opened a new window of opportunity for 
cytostatic drugs in chemotherapy (te Poele et aI., 2002). Replicative senescence, a 
permanent growth arrest, has been extensively studied in human diploid fibroblasts 
(Chang et aI., 1999). Moreover, the induction of premature senescence was achieved both 
in vitro in tumor cell lines (Chang et aI., 2002) and also in vivo following 
chemotherapeutic treatment it has been shown (te Poele et aI., 2002). It has been 
suggested that the induction of senescence in breast cancer following adjuvant therapy is 
correlated to favorable outcome (te Poele et aI., 2002). These results enforce the need of 
further investigations on the induction of senescence in cancer by compounds that target 
specific pathways. 
For these reasons, further research needs to be directed towards a deep and clear 
understanding of how chemotherapeutic agents induce cellular senescence, and 
identification of drug targets that could be used in combination with chemotherapeutic 
drugs to facilitate irreversible growth arrest. The ultimate goal is to reach satisfactory 
levels of drug effectiveness with less toxic effects. 
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Figure 1.1. Hallmarks of cancer. 
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Figure 1.2. Melanoma hystological stages. 
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Melanomas are histologically classified according to their location and stage of progression. Five 
distinct stages have been proposed in the evolution of melanoma on the basis of such histological 
criteria: common acquired and congenital nevi without dysplastic changes; dysplastic nevi with 
structural and architectural atypia; radial-growth phase (RGP) melanoma; vertical-growth phase 
(VGP) melanoma; and metastatic melanoma. 
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Figure 1.3. RAS switch function in normal untransfonned cells . 
RAS is situated at the inner surface of the pi a rna membrane, It receives input from li gand 
timul ated membrane receptors. Guanine Nucleotide Exchange Factor (GEFs) pro mote GTP 
binding (on-switch) and GTPase-acti vating-proteins (GAPs) promote GTP hydrol ysis to GOP, 
constituting an off-switch. 
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Figure 1.4: RAS controlled signaling pathways . 
Growth factors bind to the Receptor Tyrosin Kinase (RTK) transmembrane proteins which activate downstream nucleotide exchange fac tors 
(GEFs) such as SOS . Upon GTP-bound state, RAS is active and transduces signal through diffe rent intra-cellular signaling pathways , such as 
~ RAF-MEK, PI3K-AKT, RALGDS , PLC-PKC pathways. 
Figure 1.5: Structure of RAF proteill '. 
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Figure 1.6: A working modelfor tumor progre iOIl . 
When it acquire an oncogeni mutation r mutation , a non malignant cell may engage in 
three type of re pon . n antipr liferati e re pon e can be activated, leading to either 
programmed cell death (apopt i ) r ene cence. Alternatively, in the ab ence of an 
immediated re pon e, the mutation-dri n e ll proliferatio n may produ e a Ie ion. At thi 
stage, both apopto i and ne en program might b a ti ated or gain the upper hand, 
re ulting in cell death or en n . [n lh ab n e f appropriate re pon e, they may do 0 
for decade , which appear t b the a e ~ r melano ti n vi . Cell may infrequently e cape 
from uch a ene cent tale and und rgo mal ignant tran f rmation . 
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AIMS OF THE THESIS 
Mutated BRAF or NRAS genes have been found in -90% of sporadic melanomas, 
with a frequency of -65% of tumors harbouring a mutated BRAF and -25% of tumors 
bearing an activated NRAS. In spite of their high frequency, activating NRAS and 
BRAF mutations are generally mutually exclusive at the single cell level. The aims of 
the thesis were: a) to assess whether NRAS and BRAF have a relationship of 
synthetic lethality that prevents their co-expression in the same melanom cell; b) to 
identify genes that are modulated by forced co-expression of oncogenic NRAS and 
BRAF ; c) to evaluate the role of such genes in regulating growth of melanoma cells. 
Intermediate goals: 
To verify the mutual exclusivity of NRAS/BRAF activating mutations in human 
melanomas. 
To develop an experimental system allowing simultaneous expression of 
oncogenic NRAS and BRAF in the same melanoma cells. 
To identify candidate genes which are significantly modulated when both 
oncogenic NRAS and BRAF are expressed in the same cell, compared to cells 
with single mutations, and which may mediate growth arrest in melanoma cells. 
To evaluate whether activators/inhibitors of previously identified genes can affect 
melanoma cell survivaUproliferation. 
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II. MATERIALS AND METHODS 
2.1 Melanoma cell lines. 
Short-term melanoma cell lines used in this study were established as described 
previously (Anichini et ai., 1996) from surgical specimens of lesions removed from 
patients admitted to our institute. Clinical-pathological features of melanoma specimens 
and the principal genetic alterations of the corresponding short-term cell lines have been 
previously described (Lupetti et aI., 1994; Daniotti et aI., 2004). 
Melanoma clones from 665/1, 665/2, 6651R and 5810P were derived by two-layer soft-
agarose technique as previously reported (Anichini et ai., 1986). The obtainment of 
melanoma clones derived from 665/2/21 is described below (see paragraphs 2.5 and 2.6). 
All cell lines were cultured at 3rC in a humidified 7.5% CO2 atmosphere and routinely 
tested for the absence of Mycoplasma contamination by the Mycoplasma Plus PCR 
primer set kit (Stratagene; La loll a, CA). Melanoma cells were routinely grown in 
medium RPMI 1640 (BioWhittaker, Walkersville, MD) supplemented with either 10% 
FCS (Biowhittaker- for all melanoma lines except the 665/2/21- derived clones) or FBS 
(BD Biosciences, Clontech, San lose, CA- for the 665/2/21-derived clones), 2 mM L-
glutamine (BioWhittaker), 20 mM HEPES buffer (BioWhittaker), 200 units/mL penicillin 
(Pharmacia, Milan, Italy) and 40 f.1g/mL Gentalyn (Italfarmaco, Milan, Italy). For 
fibroblasts the same colture conditions were applied, but DMEM (BioWhittaker) medium 
was used instead of RPMI. Melanocytes were cultured in Melanocyte Growth Medium 
M2 (PromoCell, Heidelberg, Germany) and 5% C02 atmosphere was used for cell 
maintenance. 
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Matrigel cultures were performed by coating dishes with BD Matrigel Basement 
Membrane Matrix (BD Biosciences, Clontech) following the manufacturer's instructions. 
2.2 Mutant-allele-specific amplification (MASA)-PCR. 
MASA-PCR for the detection of BRAFv600E and NRA~IR was conducted as 
previously described (Xu et aI., 2002; Linard et aI., 2(02) on genomic DNA isolated by 
standard methods from melanoma cells. Specific forward primers #1-#2 (Table 2.1) 
carrying a 3' -end two bases substitution were used to amplify selectively mutant NRAS or 
BRAF genes respectively, as previously described (Xu et aI., 2002; Linard et aI., 2(02). 
Forward primers #3-#4 were used as positive control to amplify wild type as well as 
mutant NRAS exon 3 or BRAF exon 15 (Table 2.1). Reverse primers used for all PCR 
were #5-#6 (Table 2.1). Amplifications were performed in a 25-I.tl PCR reaction mixture 
containing 2.5 mM of each dNTP, 0.1 ~M of each primer, 0.6U of HotMaster Taq DNA 
polymerase (Eppendorf, Hamburg, Germany) and 100 ng/sample of genomic DNA 
template. The PCR reaction was set with an initial denaturation of 3 min at 94°C 
followed by 35 cycles of template denaturation for 20 sec at 94°, primer annealing at 55° 
for 15 sec, primer extension at 65° for 30 sec and by a final elongation at 65° for 1 min. 
PCR product expected length was confirmed by a 1.5% T AE agarose gel electrophoresis 
(129 bp for BRApV600E, 215 bp for BRApwt, 106 bp for NRASQ61R and 106 bp for 
NRASwt). Samples resulted negative by 35 cycles MASA amplification were tested in the 
same conditions with 45 amplification cycles. 
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2.3 Sequence analysis of BRAF exon 15, NRAS exon 3 and plasmid constructs. 
Amplification of BRAF exon 15 and NRAS exon 3 was performed by primers #7 
to #10 (Table 2.2) (Davies H. et aI., 2(02) on genomic DNA isolated by standard 
methods from melanoma cells. BRAF and NRAS mutations were detected by direct 
sequencing of the PCR products. 
Primers for pTRE-based plasmids, mapping on the pTRE2hyg- response plasmid (see 
paragraph 2.6), were purchased by BD Biosciences, Clontech. 
All amplified products were gel purified (NucleoSpin Extract, Machinery-Nagel, DUren, 
Germany) and automatically sequenced using ABI PRISM Big Dye Terminator Cycle 
Sequencing Ready Reaction (Applied Biosystems, Foster City, CA). Sequencing primers 
for BRAF exon 15, NRAS exon 3 and full-length cDNA NRAS were #11-#16 (Table 2.3). 
2.4 Construction of constitutive and inducible expression plasmids for NRASWT 
and NRASQ6IR. 
Wild type human NRAS, amplified with primer #17-#18 (Table 2.4), was cloned 
by peR into pcDNA3.IN5/His plasmid using the Eukaryotic TOPO TA cloning Kit 
(Invitrogen, Carlsbad, CA) and sequenced to verify correspondence to the official NRAS 
cDNA sequence (RefSeq: NM_(02524). The resulting constitutive expression vector 
(pcDNA3.I-FlagNRASWf) was then digested with Bam H I and Not I restriction enzymes 
and the recovered fragment was cloned into BamH IlNotl digested response plasmid 
pTRE2hyg- (BD Biosciences, Clontech) to obtain pTRE2hyg-FlagNRASWf. pcDNA3.1-
FlagNRASWf and pTRE2hyg-FlagNRASWf were then subjected to site-directed 
mutagenesis by the QuikChange II Site-Directed Mutagenesis Kit (Stratagene, La Jolla, 
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CA) using primers #19 and #20 (Table 2.5). This yielded pcDNA3.l-FlagNRA,s.Q6IR and 
pTRE2hyg-FlagNRA,s.Q6IR plasmids containing the Q61R mutation, as result of an NG 
substitution. The single nucleotide coding change A 182G in both plasmids was 
confirmed by sequencing. 
2.5 Generation of a melanoma clone constitutively expressing NRASQ61R. 
21 cells were transfected with pcDNA3.I-FlagNRA~IR plasmid and selected for 
two weeks in complete medium containing 0418 (0.8 mglmL) (Sigma-Aldrich, St. Louis, 
MO). DNA was extracted from each of the selected colonies, with lysis buffer containing 
50 roM Tris pH 8.5, I mM EDT A and 0.5% Tween-20 and amplified with GenomiPhi 
enzyme (Amersham Bioscience, Buckinghamshire, United Kingdom). Presence of 
FlagNRA~IR insert was tested by PCR, and Q61R mutation was detected by direct 
sequencing. A stable selected clone was named 2INRASQ6IR. 
2.6 Generation of melanoma clones with inducible expression of mutated or wild 
typeNRAS. 
The Tet-Off System (Clontech Laboratories, Palo Alto, CA) includes the 
tetracycline-controlled regulatory pTet-Off vector, the pTRE2hyg- response vector as 
well as the pTRE2hyg-Luc control vector (Figure 2.1). Hygromycin B .(Hyg) and 
Doxycycline (Dox) were both purchased from Clontech. FuGENE™ 6 (Roche Molecular 
Biochemicals, Mannheim, Gennany) was used for all transfection experiments, according 
to the manufacturer's instructions. 21 cells were transfected with pTet-Off vector and 
clones were isolated as described for the constitutive transfection. Each clone was splitted 
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into two cultures in a 24-well plate and transfected with pTRE2hyg-Luc in presence or 
absence of Dox (1 IlglmL). Following a 48 hour incubation at 37°C, cells were harvested 
and lysed by Glo Lysis Buffer (Promega Corporation, Madison, WI). Steady Reagent 
(Promega) was added to cell lysates and Relative Light Units (RLU) were measured 
using a plate reader luminescence spectrophotometer (TECAN ULTRA 384, Gentronix, 
Manchester, UK). The RLU (-Dox)/ RLU (+Dox) ratio was calculated for each well. The 
clone displaying the highest RLU ratio, named 210ff, was selected as stable pTet-Off 
expressing recipient line for the second step of transfection. To this end, pTRE2hyg-
AagNRASWf or pTRE2hyg-FlagNRASJ6 IR plasmids were independently transfected into 
210ff and stable clones were selected with G418 (0.5 mg/mL) and Hyg (0.25 mglmL) for 
two weeks. Antibiotic-resistant stable transfectants were propagated and maintained in 
the same selective medium. The resulting cell lines were tested for NRASQ6IR mutation 
byPCR. 
2.7 Immunoblotting. 
Lysates were prepared from melanoma cells and subjected to sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis under reducing conditions as described (Zanon 
et aI., 2004). Proteins were transferred onto PVDF membranes (Hybond-P, Amersham) 
by standard procedures. Membrane blocking in nonfat milk and incubation with primary 
antibodies were as described (Zanon et aI., 2004). Primary antibodies were: anti-NRAS 
(1: 1(00) (Santa Cruz Biotechnology, Santa Cruz, CA), anti-~-actin (1 :2000) (Sigma-
Aldrich), anti-ERK (I :5(00) (Sigma-Aldrich), anti-activated MAPkinase (1: 10000) 
(Sigma-Aldrich); anti-phospho-AMPK-a (Thr172) (l: 1000) (Cell Signaling Technology, 
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Danvers, MA); anti-p21 (BD Biosciences. PharMingen). Membrane washing and 
incubation with the appropriate horseradish peroxidase-conjugated secondary antibody 
(goat anti-mouse IgG or goat anti-rabbit IgG) were carried out as described (Zanon et aI., 
2004). Development was done by the chemiluminescence method with the SuperSignal 
West Dura Extended Duration Substrate (Pierce Biotechnology, Rockford. ll..) and 
autoradiography. 
2.8 Ras Activation Assay. 
Activation state of NRAS was assessed by the RAS Activation Kit (Stressgen, 
San Diego, CA) according to the manufacturer's instruction. This assay uses a peptide 
corresponding to the RAS-binding domain of BRAF as a RAS-GTP-dependent probe to 
immunoprecipitate active NRAS from cell lysates (de Rooij and Bos, 1997). The 
immunoprecipitated active RAS was then detected by Western Blot analysis using the 
specific antibody included in the kit. 
2.9 Proliferation assay. 
Cells were seeded in a 96-multiwell plate (Coming Inc., Coming, NY) in their 
own selective medium with or without addition of Dox (1 ~glmL). A freshly prepared 
solution of 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-Tetrazolium inner salt (MTS)/phenazine methosulfate (PMS) (ratio 2011) was added 
(20 flL) to each well every 24 hr. between 24 and 96 hours after beginning of the cell 
culture. Colorimetric evaluation of the conversion of MTS into a soluble formazan 
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product was carried out by reading absorbance at 490 nm with a BioRad 550 plate reader 
(BioRad, Hercules, CA). 
2.10 Senescence assay. 
Cells were cultured in their own selective medium with or without addition of 
Dox (1 IlglmL) in a 12-well culture plate (Coming Inc.). Cells were fixed at 70% 
confluence and then incubated at 37°C overnight with the staining solution containing the 
X-gal substrate (Senescence Detection Kit, MBL International Corporation, Woburn, 
MA). Cells were then observed under a microscope for development of blue color. 
2.11 Cell cycle analysis. 
Cell cycle analysis was carried out in cultures at 50-60% confluency. To this end, 
cells were detached by 3 min trypsin (500 mgIL) (BioWhittaker) treatment, resuspended 
in cold EtOH 70% and kept in ice for 20 minutes. After washing in Vindelov Solution 
(3.4 mM NaCitrate, 0.01 % NP4, 1.5 mM Spermina Tetrahydrochloride, 0.5 mM Tris, 10 
IlglmL RNA-ase), cells were stained with Propidium Iodide (Sigma-Aldrich). Cell cycle 
analysis was carried out by a FACScalibur flow cytometer (BD Biosciences) and phases 
of the cell cycle were evaluated by the ModFit Software (BD Biosciences). 
2.12 Expression of cell surface and intra-cellular antigens by flow cytometry. 
Expression of cell surface or intra-cellular antigens (in saponin permeabilized 
cells) was carried out as previously described (Maccalli et ai., 1999). mAbs to Delta (SY-
5), MBI (SJJ-3), LMP2 (SY-l), LMP7 (SY-3), LMPlO (TO-7), Tapasin (TO-3), 
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Calnexin (TO-5), Calreticulin (TO-II), ERp57 (TO-2), MICB (SJJ-5) and ~2-
microglobulin (L368) have been described elsewhere (Bandoh et ai., 2005; Ogino et ai., 
2003; Lampson et ai., 1983). The TAPI-specific mAb NOB-l and the TAP2-specific 
mAb NOB-2 are secreted by hybridomas derived from the fusion of murine myeloma 
cells P3-X63-Ag8.653 with splenocytes from BALB/C mice immunized with partial 
length TAPI recombinant protein (434-735) and a keyhole limpet hemocyanin (KLH)-
conjugated TAPI peptide (717-735) and with partial length TAP2 recombinant protein 
(316-703), respectively, by the strategy described elsewhere (Ogino et ai., 2003). Staining 
for cell surface antigens was performed with mAbs directed to HLA-class I (W6/32) 
(Parham et ai., 1979), HLA-OR, HLA-OQ, HLA-DP, integrin-~ 1, -~4 (all from BO 
Biosciences, PharMingen), integrin-a3, -av~3, VLA-2, VLA-4, VLA-5, VLA-6, ICAM-
1, and LFA-3 (all from Chemicon International, Temecula, CA). Cells were then stained 
with a fluorescein-conjugated affinity purified goat anti-mouse IgG antibody (Jackson 
ImmunoResearch, West Grove, PA) and analyzed with a FACSCalibur cytofluorimeter 
(BO Biosciences). 
2.13 Cell mediated cytotoxicity and limiting dilution analysis of cytotoxic effector 
frequency. 
Non specific lymphokine activated killer (LAK) cells were generated by culturing 
peripheral blood lymphocytes (PBL) of healthy donors in RPMI 1640 -10% pooled 
human serum with 1 % PHA (Murex Biotech Ltd., Temple Hill, DA) for three days and 
then with IL-2 at 3000 IU/mL (Chiron, Emeryville, CA) for two weeks. Lysis of targets 
by LAK cells was evaluated by a 4-h 51 Cr release assay at E:T cell ratios from 100: 1 to 
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1.5: 1, as described previously (Anichini et aI., 1999). A T cell line was generated by 
culturing PBL from a HLA-mismatched healthy donor for 3 weeks in mixed 
lymphocytes-tumor culture (MLTC) with irradiated (30,000 cGy) melanoma transfectants 
bearing a silenced NRASQ6IR, in RPMI 1640 medium supplemented with 300 IU/mL IL-
2 and 10% pooled human serum. The culture was re-stimulated weekly. The resulting T 
cell line was used in a split well, limiting dilution assay, as described (Anichini et aI., 
1999). The HLA-class I antigen-restriction of the lysis was assessed by measuring its 
inhibition by the HLA-class I antigen-specific mAb W6/32, as described (Anichini et aI., 
1999). The threshold of significant lysis, criteria to score a well containing HLA class I 
antigen-restricted T cells and non-restricted cytotoxic effectors, and data analysis for 
frequency determination have been described elsewhere (Anichini et aI., 1999). 
2.14 Gene expression profiling with CodeLink system and statistical data analysis. 
Total RNA was extracted from melanoma cell lines using the TriPure Isolation 
Reagent (Roche Molecular Biochemicals, Mannheim, Germany) and its quantity and 
quality were assessed by UV spectrophotometry and gel electrophoresis. In order to 
analyze differential gene expression levels of the samples, the CodeLink Human Whole 
Genome Bioarrays (GE Healthcare, Amersham Bioscience, Buckinghamshire, United 
Kingdom) were used. Slide hybridization and processing were performed following 
manufacturer's instructions. Briefly, cDNA was prepared starting from 2 Ilg of total 
RNA; then, cRNA was synthesized by in vitro transcription using a single labeled 
nucleotide, biotin-ll-UTP, in the IVT reaction at a concentration of 1.25 mM. Unlabeled 
UTP was present at 3.75 mM, while GTP, ATP and CTP were at 5 mM. The mixture was 
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incubated at 37°C overnight for 14 hours. The labeled cRNA was then purified using the 
RNeasy mini kit (Qiagen, Hilden, Germany). Then 10 J,lg of purified cRNA was 
fragmentated in IX fragmentation buffer (CodeLink Expression Assay Reagent Kit, 
Amersham) at 94°C for 20 minutes. For hybridization with Code Link bioarrays, 10 J,lg of 
fragmented cRNA in 260 J,lL of hybridization solution was added to each bioarray and 
incubated for 18 hours at 3rC while shaking at 300 r.p.m. After washing, slides were 
stained with Cy5-streptavidin (Amersham Biosciences) and scanned using a GenePix 
4000B scanner (Axon Instruments, Downington, PA). The scanned image files were 
analyzed using CodeLink software and GeneSpring 7.2 software (SiliconGenetics, 
Agilent, Santa Clara, CA). Data analysis was performed in collaboration with and under 
the supervision of Dr. Ewan Hunter from SiliconGenetics. For each spot the raw intensity 
was calculated by the CodeLink software as the difference between the spot mean and the 
local background mean. Then raw hybridization signals were normalized on each spot as 
ratios to the median of the array for better cross array comparison. These values were 
then further Per Chip normalized by GeneSpring and a Quality Check (QC) on 
normalized data was performed. QC-passed genes were then analyzed by Anova one-way 
parametric test with none correction (T-test: 0.01). For data mining, this data set was used 
in the BiNGO software, an open-source Java tool to determine which Gene Ontology 
(GO) terms are significantly overrepresented in a set of genes, and a subsequent statistical 
analysis was performed in order to classify the list of modulated genes between the two 
samples analyzed. 
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2.15 Microarray data validation by RealTime peR. 
The Assays-on-Demand Gene Expression Products (Applied Biosystems, Foster 
City, CA) with TaqMan FAM dye-labeled probes were used for the detection and 
quantification of specific human genetic sequences in RNA samples converted to cDNA. 
Gene expression quantification was performed as the second step in a two step-reverse 
transcription-polymerase chain reaction (RT -PCR). Reactions (20IlL) contained 10 ng of 
total RNA diluted in RNase-free water, 10 ilL 2X TaqMan Master Mix, I ilL Assays-on-
Demand Gene Expression Assay Mix. The assays utilized are listed below in Table 2.6. 
Each amplification was performed using an ABI PRISM 7700 Sequence Detection 
System (Applied Biosystems) for 10 min at 95°C followed by 40 cycles of denaturation 
(15 sec at 95°C) and annealing/extension (1 min 60°C). Data were analyzed using ABI 
PRISM Sequence Detection Software (SDS) version 2.1 and then further processed using 
Microsoft Excel. Human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) served 
as the endogenous control for the normalization of input target RNA. The comparative or 
relative ~~CT method was used for quantification of target amounts. The .1.1CT value 
represents the difference between the average ~CT value of NRAS610N and the average 
~CT value of NRAS610FF, where .1CT is the difference between the threshold cycle (CT) 
value of each target gene and the CT value of the corresponding endogenous reference 
gene (GAPDH). 
Expression levels of LOXL3 protein were further validated using a monoclonal mouse 
antibody against LOXL3 0:1(00) (Abnova, Taipi City, Taiwan) by Western Blot, as 
previously described. 
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2.16 Silencing of LCN2 by siRNA. 
Melanoma cells were seeded in 6-well tissue culture plates (Coming Inc.) and after 24 
hours, when cell density was about 80%, were transfected with LCN2-specific small 
interfering RNA (siRNA) (Oharmacon, Lafayette, CO), using Lipofectamine 
(Invitrogen). Either pEGFP vector or a Luciferase-siRNA were also transfected 
respectively as positive control of the transfection procedure or as negative control for 
selective silencing of LCN2 RNA. Silenced expression of intra-cellular LCN2 protein 
was in saponin permeabilized cells was validated using a monoclonal mouse antibody 
against LCN2 (AbCam, Cambridge, UK) in flow-cytometry analysis as previously 
described (Maccalli et aI., 1999). 
2.17 Rapid lysis of cultured cells for AMPK kinase assay and for Western Blot. 
Melanoma cells, fibroblasts and melanocytes were seeded in 6 cm culture dishes 
and grown until nearly confluent in their own medium with or without AICAR or 
Phenformin treatment. Cells were lysed as previously described (Hardie et aI, 2000). 
Briefly, the culture medium was rapidly removed and replaced with ice-cold PBS, and the 
plates were placed on ice. Then the PBS was poured off, the residual medium removed 
with a Pasteur pipette and 0.2 mL of ice-cold cell lysis buffer (50 mM Tris/HCI, pH 7.4 at 
4°C, 50 mM NaF, 5 roM Na pyrophosphate, 1 roM EDTA, 1 roM EGTA, 250 mM 
mannitol, 1% (v/v) Triton X-loo, I mM OTT, I mM benzamidine, 0.1 mM 
phenylmethane sulfonyl fluoride (PMSF) 5J..lglmL soybean trypsin inhibitor (SBTI» was 
added to each plate. The cells were scraped from the dish, the lysate was centrifuged 
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(12,900xg, 4°C, 3 min) and the supernatant was snap-frozen in liquid N2 and stored at -
80aC until use. 
2.18 Assay of AMPK kinase activity. 
Kinase activity of AMPK in melanoma samples was tested as previously 
described (Davies et aI., 1989). Briefly, AMPK was immunoprecipitated from 200 /lg of 
cell lysate using 10 /lg of anti-subunit a 1 and 10 /lg of anti-subunit a2 affinity purified 
sheep anti-AMPK polyclonal antibodies (Woods et aI, 1996) in AMPK 
irnmunoprecipitation (IP) Buffer (50 mM Tri slHC 1 , pH 7.4 at 4oC, 150 mM NaCl, 50 
rnM NaP, 5 mM Na pyrophosphate, 1 mM EDTA, 1 mM EGTA, 1% (v/v) Triton X-IOO, 
1 rnM dithiothreitol (DIT), I mM benzamidine, 0.1 mM phenylmethane sulfonyl fluoride 
(PMSF), 5 /lg/mL soybean trypsin inhibitor (SBTI» for 1 hour at 4°C. 
Immunocomplexes were washed with IP buffer plus 1 M NaCI and then with Hepes 
Assay Buffer (50 mM Na Hepes, pH 7.0, I mM DIT, 0.02% Brij-35). AMPK activity in 
immunocomplexes was determined by phosphorylation of AMARA substrate peptide 
(AMARAASAAALARRR) with A TP mix (200 /lM 32P A TP/5 mM MgClz, 200 /lM 
AMARA peptide, 1 mM AMP). After 10 min at 30°C, the reactions were terminated by 
spotting 30 IlL aliquots onto Whatman PSI filter paper, followed by 2 rinses in 1 % (v/v) 
phosphoric acid with gentle stirring to remove free A TP and membranes were then dried. 
Phosphorylated substrates were measured by scintillation counting. Calculation of Units 
of enzyme activity (U) per mg of protein was carried out as previously described (Fryer et 
a1.,2(02). 
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2.19 Detection of western blots by infra-red imaging. 
Phosphorylation of either the AMPK a-subunits in Thr172 (pAMPK) or acetyl 
CoA-carboxylase in Ser79 (pACC) was evaluated in Western blot by using phospho-
specific antibody from respectively Cell Signaling Technology or kindly gifted from D.G. 
Hardie, (University of Dundee, Dundee, Scotland), as previously described (Chen et aI., 
2000). Precast Bis-Tris 4-12% gradient polyacrylamide gels (Invitrogen) for both 
phosphorylated and total AMPK, and pre-cast 3-8% Tris-acetate gels (Invitrogen) for 
both phosphorylated and total acetyl-CoA carboxylase, were used. Proteins were 
transferred onto nitrocellulose membranes (BioRad, Hemel Hempstead, UK) using the 
Xcell IT Blot Module (Invitrogen). To analyze phosphorylation levels of ACC, 
membranes were incubated in LI-COR OdysseyTM Blocking buffer (LI-COR 
Biosciences, Nebraska, USA) for 1 hour. Anti-pACC antibody (1.46 J,lg/mL in blocking 
buffer containing Tween-20 0.2% v/v) was then added and left shaking for 1 hour. The 
membranes were washed 6 times for 5 min with TBS (10 roM Tris-HCI, pH 7.4, 0.5 M 
NaCl) plus Tween-20 (0.2% v/v) (TIBS). The membranes were immersed in blocking 
buffer containing Tween-20 (0.2% v/v) and 1 J,lglmL anti-sheep antibody conjugated to 
IR dye 680 (Molecular Probes, Leiden, The Netherlands) for the detection of pACC and 1 
J.1g1mL streptavidin conjugated to IR Dye 800 (Rockland Inc., Lome Laboratories, 
Reading, UK) for ACC and left shaking for 1 hour, protected from light. The membranes 
were then washed 6 times for 5 min using TIBS and I time for 5 min in distilled H20. 
The membranes were scanned in two different channels using the Odyssey IR imager (LI-
COR Biosciences), the results quantified using Odyssey software (LI-COR Biosciences) 
and expressed as a ratio of the signal obtained with the pACC antibody to that obtained 
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with streptavidin. Analysis of phosphorylation of AMPK was similar except that the 4-
12% Bis-Tris gels were used, and the membranes were simultaneously probed for 1 hour 
with the anti-pAMPK and anti-al and a2 antibodies (Cell Signaling), followed by the 
secondary anti-rabbit IR Dye 680 and anti-sheep IT Dye800 antibodies respectively (both 
Rockland Inc.) 
2.20 Evaluation of Apoptosis. 
For the evaluation of apoptosis, I * 106 melanoma cells were seeded in 6 cm 
diameter plates (Coming Inc.) in their own medium; after 24 hours, culture medium was 
substituted with the same medium with or without different doses of AICAR or 
Phenformin and cells were maintained for 8 days. Quantification of apoptotic cells was 
done by flow cytometry with a FACScan flow cytometer (Becton Dickinson, Sunnyvale, 
CA) using the Annexin V -FITC kit (BD Biosciences, PharMingen, San Diego, CA) as 
previously described (Salvucci 0 et aI., 2(01). 
2.21 Flow-cytometric analysis of p-galactosidase expression. 
In order to measure and quantify ~-galactosidase acitivity in melanoma cells, 
fluorescein digalactoside reagent was used. Fluorescein di-~-D-galactopyranoside (FDG) 
is a fluorogenic substrate for ~-galactosidase (Sundararajan, 1963). Nonfluorescent FDG 
is sequentially hydrolyzed by the enzyme, first to fluoroscein monogalactoside (FMG) 
and then to highly fluorescent fluorescein (Fie Idler et aI., 1994). 
Melanoma cells were seeded in 60 mm plates (Coming Inc.) and after 24 hours were 
treated or not with I mM AICAR or Phenformin. On the II SI day, cells were trypsinized 
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and cell suspension in growth medium was mixed with an equal volume of FDG solution 
and then incubated at 37°C for 1 minute. The suspension was then diluted lO-fold with 
ice-cold growth medium and maintained at 4°C on ice for 15 minutes. Before analysis, 
each sample was stained with 5 ~M propidium iodide to identify those cells that did not 
survive the procedure. Fluorescence levels were read by flow cytometry in a 
FACScalibur cytofluorimeter (BD Biosciences) and data analyzed by Winmdi software. 
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FIGURES OF CHAPTER 2 
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In the absence of Dox 
Transcription 
Regulator Plasmid 
Regulator protein 
Product of tT A 
pTET-Off 
ResponsePlasmid 
In the pre ence of Dox 
Transcription 
igure 2.1 . Schematic illustrative diagram of the Tet-Offsystem used in the study. 
egulator plasmid pTet-Off encode tbe regulator protein that bind to the TRE equence in the respon e 
tJlasmid. In the absence of Dox, regul ator protein binding to TRE activates tran cription of the FLag-NRAS 
~on truct. In the pre ence of Dox the antibiotic form a complex with the regulator protein blocking 
transcription of the FLag-NRAS con truct. P M: early promoter of cytomegalovirus; tTA: tet-respon ive 
tran criptional activator; TetR: t t repre or; VPI 6: C-terminal acti vation domain of the VPl6 protein of 
herpes simplex viru ; TRE: tet-re p n i eJem nt; Do : doxycyclin ; Neo: neomycin resistance gene; Hyg: 
hygromycin resistance gene; Ph MV-I: tet-re p n ive promoter. 
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TABLES OF CHAPTER 2 
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NRASQ61R 
Specific #1 :GGTGA TITTGGTCT AGCT ACAAA #2: ATACTGGATACAGCTGGAAG 
Control #3:TAGGTGA TITTGGTCT AGCT ACAGT #4:CAT ACTGGAT ACAGCTGGAC 
Reverse #5:GGCCAAAAATTTAATCAGTGGA #6:TGACTTGCTATTATTGATGG 
Table 2.1. Primer for MASA-PCR of NRASQ61R and BRAFv600E (Xu et aI., 2002; Linard 
et ai., 2002). 
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F (5'-+ 3') R (5'-+ 3') 
BRAFexon 15 #7:AACACATTTCAAGCCCCAAA #8:AGCATCTCAGGGCCAAAAAT 
NRASexon 3 ~:GATTCTTACAGAAACAAGT #IO:AACCTAAAACCAACTCTTCCCA 
Table 2.2. Primer for the amplification of BRAF exon 15 (#7-#8) and NRAS exon 3 
(#9-#10) on genomic DNA. 
F: forward, R: reverse. 
74 
F R 
BRAF exon 15 #II:TCATAATGCTTGCTCTGATAGGA #12: GGCCAAAAATTTAATCAGTGGA 
NRAS exon 3 #13: GGTGAAACCTGTTTGTTGGA #14: ATGACTTGCTATTATTGATGG 
NRAS fuU-lenghl #15: TAATACGACTCACTATAGGG #16: TAGAAGGCACAGTCGAGG 
Table 2.3. Primer for sequencing of BRAF exon 15 (#11-#12), NRAS exon 3 (#13-#14) 
andfulilength cDNA NRAS (#15-#16). 
F: forward, R: reverse. 
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F #17:GCCACCATGGACTATAAGGATGACGATGACACTGAGTACAAACTGGTGGTGGTTGGA 
R #18: ITACATCACCACACATGG 
Table 2.4. Primer used for amplification of full-length cDNA NRAS. 
Forward primer (F) contained a Kozak consensus sequence (underlined) with an ATG 
start codon and a minimal N-terminal tag (italic bold) encoding for the Flag epitope F7 
(DYKDDDD), described (Johnson et aI., 2(02) as not interfering with RAS functions and 
stability; reverse (R) primer contained the stop codon (bold). 
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F #19: CTGGATACAGCTGGACGAGAAGAGT ACAGTGCC 
R #20:GGCACTGTACTCTTCTCGTCCAGCTGTATCCAG 
Table 2.5. Primer for achieving the A182G point mutation in NRAS exon 3 by site-
directed mutagenesis. 
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AssayID Public RefSeq Gene Name 
HsOO204885_ml NM_014324 AMACR 
HsOO231713_ml NM_13442 CREBI 
HsOOl71346 NM_181500 CUTLI 
HsOO190723_ffil NM_004675 DIRAS3 
HsOO183740_ffil NM_012242 DKKI 
Hs99999905 _ffi I NM_OO2046 GAPDH 
HsOO172878_ffil NM_OO5524 HESI 
HsOOI 94353_ffi I NM_OO5564 LCN2 
HsOO212390_m I NM_016269 LEFI 
HsOO261671_ffil NM_032603 LOXL3 
Hs00611472_m 1 NM_199072 MDFIC 
HsOO231653_m 1 NM_OO3998 NFKBI 
HsOO 173615 _m 1 NM_OO2852 PTX3 
HsOO398096_ffi 1 NM_OO584I SPRYI 
HsOO332674_m 1 NM_175866 UHMKI 
Table 2.6. TaqMan assays-on-demand used for Microarray data validation by 
RealTime peR. 
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3. CO-EXPRESSION OF ONCOGENIC NRAS AND BRAF IN 
MELANOMA CELLS ELICITS NEGATIVE SELECTION BY CELL 
AUTONOMOUS AND EXTRINSIC MECHANISMS. 
3.1 Mutual exclusivity of NRAS and BRAF oncogenic mutations at the single cell 
level. 
3.1.1 Introduction. 
The RASIRAFIMEKlERK signalling kinase cascade that transduces extra cellular 
mitogenic signals to the cell nucleus has been shown to be constitutively activated in 
human cutaneous melanoma due either to oncogenic mutations in BRAF or NRAS, or 
through autocrine growth factor stimulation (Satyamoorthy et al., 2003; Smalley, 2003; 
Sebolt-Leopold and Herrera, 2004). The BRAF gene encodes a serine/threonine kinase, 
which couples signalling from activated RAS to downstream MAPK kinases (Wellbrock 
et aI., 2004). Mutations in the BRAF gene mainly affect exons 11 and 15 encoding the 
kinase activation domain (Davies et al., 2002; Mercer and Pritchard, 2003; Garnett and 
Marais, 2004) and are found at high frequency in human melanoma. In more than 90% of 
melanomas with a mutated BRAF, a single-base mutation at nucleotide position 1799 of 
exon 15 leads to a valine to glutamate (V600E) substitution (Davies et al., 2002; Mercer 
and Pritchard, 2003; Garnett and Marais, 2004; Gray-Schopfer et al., 2005). The 
BRAFv600E mutation significantly increases kinase activity of BRAF and induces 
constitutive ERK phosphorylation and focus formation in NIH3T3 cells (Davies et aI., 
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2002; Garnett and Marais, 2004; Wan et aI., 2004). In melanoma, depletion of mutant 
BRAF by RNA interference (RNAi) techniques has been shown to inhibit MAPK 
cascade, to cause growth arrest, to promote apoptosis and to abrogate transformation 
(Gray-Schopfer et aI., 2005). Although benign nevi also display BRAFv6OOE, recent data 
suggest that such mutation is more frequent in growing nevi that tend to progress to 
malignancy (Pollock et al., 2003; Loewe et al., 2004). 
Activating mutations in the NRAS gene are the other prevalent genetic hallmarks of 
melanomas, occurring in more than 20% of primary and more than 30% of metastatic 
melanomas, and mainly in lesions from sunexposed sites (Ball et aI., 1994; Jiveskog et 
aI., 1998; Ombolt et al., 2003). The most common point mutations affect codon 61 
(Q6IR and Q61K) and result in the expression of RAS oncoproteins with a single 
substituted amino acid that remain constitutively OTP bound and active (Malumbres and 
Barbacid, 2003). Active GTP-bound RAS protein interacts with a wide range of 
signalling effectors including RAF kinases, phosphatidylinositol 3-kinase (PI3K), Ral-
guanine nucleotide exchange factors (Ral-ODS, RGL, RLF and RGL3), NOREIRASSFI 
and phospholipase C (Repasky et aI., 2004). 
In spite of the biological relevance of the RASIRAFIMEKIERK signalling cascade 
and of the high frequency of mutated BRAF or NRAS in human melanoma, simultaneous 
presence of BRAF and NRAS activating mutations in the same tumor are rare (Garnett and 
Marais, 2004). Moreover, in few exceptional cases in which a BRAF mutation was found 
together with a transforming NRAS mutation, the BRAF mutation did not include the 
V600E change (Gorden et aI., 2003). Similarly, NRAS mutations detected in BRAFv600E 
tumors were rare and not transfonning (Brose et aI., 2002). These data are consistent with 
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the hypothesis that "double mutant" tumors, harbouring both activated BRAF and NRAS, 
may not occur naturally, since such neoplastic cells may either lack a survival advantage, 
or even be selected against during tumorigenesis. Unlike melanomas, however, 
coincident activating mutations in BRAF and NRAS genes have been found in nevi 
(Pollock et aI., 2003). 
To explore the possibility that activating BRAF and NRAS mutations could coexist 
even in the same melanoma, we adopted the highly sensitive mutant allele-specific 
amplification (MAS A) peR technique (Hasegawa et aI., 1995; Linard et aI., 2002; Miller 
et aI., 2004). By screening a panel of 14 human primary and metastatic melanomas, we 
. h BRA FV600 E • h' h·' found 1 tumor carrymg t e mutation toget er Wit a translormmg NRAS 
mutation (Q61R). However, BRAF and NRAS mutations were mutually exclusive at the 
single-cell level, as shown by analysis of melanoma clones isolated from this tumor. 
3.1.2 Results. 
3.1.2.1 Identification of melanomas simultaneously expressing NRAS and 
BRAF activating mutations by MASA-PCR. 
For this study, 14 short term melanoma cell lines previously characterized for 
either NRAS or BRAF activating mutations were chosen (Daniotti et aI., 2004; Lupetti et 
aI., 1994). As detected by sequence analysis or oligonucleotide hybridization (Daniotti et 
aI., 2004; Lupetti et aI., 1994), 7 out of the 14 tumors harbour the N RASJ61 R mutation, 1 
tumor the NRASJ 12S mutation and 6 tumors the BRAFv600E mutation, all in heterozygosis 
(Table 3.1). 
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In order to assess whether any of these cell lines carried both NRAS and BRAF 
mutations, DNA isolated from these tumors was re-analyzed for the presence of both 
mutations using the sensitive MASA-PCR method (Hasegawa et aI., 1995; Linard et aI., 
2002; Miller et al., 2004). Published forward primers designed with two mismatches at 
their 3' were used to amplify mutant NRA~IR and BRAFv6OOE, and control forward 
primers, matching with the wild type genes, were used to amplify both wild type and 
mutant sequences (Linard et aI., 2002; Xu et aI., 2003). After 35-cycle amplification, 
single bands corresponding to a single mutated allele (NRA~IR and BRAFv6OOE) were 
detected with no evidence of double mutated samples. In order to show the reliability of 
MASA-PCR for genotyping, a representative experiment performed on 5 BRAFv600E (i.e. 
10538P, 15392M, 4023M, 18732M, 18588M) and 2 NRA~IR (i.e. 665/2, 8959M) 
tumors is reported in Figure 3.1 A. Only one mutated allele was detected in each tumor. 
As a control, all samples could be amplified by control primers which anneal with either 
NRAS exon 3 or BRAF exon 15 independently from the mutations (Figure 3.1 A). All 
NRAS mutated samples were re-tested for BRAFv600E mutation and all BRAFv600E for the 
most common NRASJ6 IR mutation by MASA-PCR at higher number of cycles. No NRAS 
mutations were found in BRAF mutated samples (data not shown). A BRAF amplification 
signal, representative for the BRAF mutation, could however be clearly detected when 
MASA-PCR amplification was conducted for 45 cycles (Figure 3.1 B). Similarly to 
standard MASA-PCR (35 cycles), chromatographs of amplified exon 3 NRAS and exon 
15 BRAF fragments could only confirm the AlG mutation (Q6IR) for NRAS while 
displaying a BRAF wild type sequence (Figure 3.1 C). All other NRA~6IR tumors, 
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including 2 additional metastases of the same patient (665/1 and 6651R), remained 
negative for the BRAFv600E mutation even when tested at 45 cycles (data not shown). 
A titration assay was then performed to compare sensitivity between MASA-PCR 
and direct fluorescent sequencing (Figure 3.2 A and B). Decreasing proportions of 
genomic DNA (10-0.1 %) from BRAFv600E melanoma 18732M were mixed with a fixed 
amount of genomic DNA from a human lymphoblastoid cell line (LCL) carrying only the 
wild type BRAF alleles. Both direct fluorescent sequencing and MASA-PCR were 
performed in these samples. Direct fluorescent sequencing required at least 10% of 
mutant DNA in the total mixture to clearly detect BRAFv600E mutation (Figure 3.2 A). 
Below the 10% threshold, the presence of a mutant spike could not reliably be 
distinguished from background on the electropherogram (Figure 3.2 A). As described by 
Miller et aI. (2004), standard 35 cycles MASA-PCR detected mutant DNA with higher 
sensitivity (5%) (Figure 3.2 B, left panel). When the reaction was conducted at 45 cycles, 
mutated BRAFv600E could be detected also when mutant DNA represented only 0.5% of 
the mixture (Figure 3.2 B, right panel). 
Taken together these results suggested that a minor subpopulation of cells in 
melanoma 665/2 carry BRAFv600E at frequency below detection by most standard 
methods. The presence in the same lesion of BRAF and NRAS mutated cells was not a 
feature shared by two additional metastases of the same patient (665/1 and 6651R), since 
they only displayed the NRA~IR mutation (data not shown). 
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3.1.2.2NRASQ61R and BRAFv600E mutations are mutually exclusive at the 
single cell level. 
In order to assess whether NRAS and BRAF, found mutated in the same lesion , 
could coexist at the single cell level, we examined, by MASA-PCR as well as by direct 
sequencing, 21 clones derived by cloning in soft-agar Me 655/2 cells after a few in vitro 
passages (Anichini et aI., 1986). The results obtained with both mutational analyses were 
concordant and indicated that 5 of the 21 clones (2/4, 2/14, 2117, 2/51, 2/60) displayed 
the activating Q61R mutation at one of the alleles, whereas all remaining clones had wild 
type NRAS alleles, in agreement with a previous report (Table 3.2 and Figure 3.3 A and 
B) (Lupetti et al., 1994). 
Representative results of both MASA-PCR and direct sequencing are shown in 
Figure 3.3. Strikingly, the BRAFv600E mutation was detected in all the clones with wild 
type NRAS, while clones with mutated NRAS were wild type for BRAF (Table 3.2 and 
Figure 3.3 A and B, for representative results). 
To rule out the possibility that the BRAF mutation could be gained in vitro, as an 
adaptive response to cell culture or to cloning in soft agar, 35 melanoma clones obtained 
from the two additional NRA~IR metastatic lesions (665/1 and 6651R) from the same 
patient, and from a primary NRA1J6 IR melanoma of a different patient (58 lOP), were 
analyzed. All these tumors showed to harbour exclusively NRAS mutations (Table 3.2). 
3.1.3 Discussion 
The results of this study indicate that activating mutations of both NRASX'IR and 
BRAF (hot-spot codon 600) genes can coexist in the same human melanoma. However, 
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although fluorescent sequencing or standard MASA-PCR (35 cycles) could detect one of 
the two mutations (NRASJ61R), neither of these techniques, including pyrosequencing 
(Sivertsson et aI., 2002) (data not shown). did reach the necessary sensitivity to detect the 
presence of the second mutation (BRAFv6OOE) that could be evidenced only through the 
use of 45 cycles MASA-PCR. The higher sensitivity level required to detect the BRAF 
mutation suggested that this genetic lesion affected a minor subpopulation of cells. Our 
titration experiments confirmed the increased sensitivity of MASA-PCR, even at 35 
cycles, compared to conventional sequencing approaches (Miller et aI., 2004). 
Such experiments further demonstrated that the specificity of MASA-PCR is 
maintained at high number of cycles (45 cycles) at which it could reliably detect mutated 
BRAF DNA even when diluted in wild-type DNA at percentages as low as 0.25%, 
assuming heterozygosis for this allele. 
Future studies, by exploiting MASA-PCR as well as novel techniques with even 
greater sensibility (Lilleberg et aI., 2004) in large sets of melanoma patients, are needed 
to assess the real frequency, at the population level, of tumors that contain mutations in 
both NRAS and BRAF oncogenes. 
Concomitant activation of NRAS and BRAF has been detected in microdissected 
nevi samples (Pollock et aI., 2003). However, the microdissection technique did not allow 
for assessing whether both alterations could coexist at the same cell level. This issue 
could be tested in this study through the mutational analysis of melanoma clones isolated 
from 665/2 tumor. Our data demonstrate that NRASJ6 1R and BRAFv600E mutations in 
665/2 melanoma are mutually exclusive at the single-cell level providing further support 
to the hypothesis that expression of the two mutations may not occur in the same 
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neoplastic cell. Whether concurrent NRASX'IR and BRAFv600E mutations, if present in the 
same cell, are incompatible with cell survival or contributes to an irreversible growth 
arrest remains to be determined. 
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3.2 Co-expression of oncogenic NRAS and BRAF in the same melanoma cell 
activates a senescent phenotype and increases susceptibility to cell-mediated 
cytotoxicity. 
3.2.1 Introduction. 
Activating RAS mutations. mostly at codon 61 of NRAS. have been identified in 
14% of melanoma lesions arising from soles or palms and in 20% of tumors arising from 
skin with chronic sun exposure. but in only 3-5% of tumors arising from skin areas with 
intermittent sun exposure. or from areas protected from the sun (Curtin et al.. 2005). In 
contrast, BRAF mutations. mostly at codon 600. have been found in 78% of the tumors 
from skin with intermittent UV exposure. the most common form of the disease (Curtin 
et aI., 2005). In spite of the overall high frequency of activated NRAS or BRAF in 
melanoma lesions, mutations of these two oncogenes have been found to be mutually 
exclusive in the same tumor (Curtin et al. 2005; Davies et aI.. 2002; Gray-Schopfer et aI.. 
2(05). The lack of association between KRAS and BRAF mutations has also been found 
in colon, endometrial and ovarian carcinoma lesions (Rajagopalan et aI., 2002; Feng et 
aI., 2005; Singer et aI" 2003) and between KlNIHRAS and BRAF mutations in thyroid 
carcinoma lesions (Giordano et al.. 2(05). However. human melanomas harboring both 
NRAS and BRAF mutations have been recently described (Kumar et al.. 2003; Akslen et 
aI., 2005; Sensi et aI., 2006; Goel et al.. 2(06). Nevertheless. analysis of clones isolated 
from one of such double mutant tumors indicated that the two activating mutations are 
mutually exclusive at the single cell level (Sensi et aI.. 2006). 
These findings have suggested an epistatic relationship between RAS and BRAF 
oncogenes (Rajagopalan et aI., 2(02). According to such a model. mutation of both BRAF 
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and RAS, in cells where one or the other of these oncogenes is already activated, may not 
provide an additional significant growth/survival advantage. However, an alternative 
mechanism for mutually exclusive NRAS and BRAF mutations in melanoma cells is 
represented by "synthetic lethality". As recently reviewed by Kaelin, two genes are said 
to be synthetically lethal when mutations in either one is compatible with cell survival, 
while simultaneous mutations in both genes is not (Kaelin et aI., 2005). Although 
synthetic lethality usually involves loss-of-function mutations, it could also result from 
gain-of-function changes, as in the instance of the activating NRAS and BRAF mutations 
found in melanoma cells. 
To provide insights into the mechanisms that may explain mutual exclusion of 
activated NRAS and BRAF at the single cell level, we developed a constitutive and a 
doxycycline-regulated system for expressing an oncogenic NRAS (NRASQ6IR) in a 
metastatic melanoma clone (665/2121) harboring wild type RAS alleles (HRAS, KRAS and 
NRAS) and a 1798 TIA BRAF mutation (BRAFv6OOE ) at one of the BRAF alleles. The 
results to be presented indicate that co-expression of activated NRAS and BRAF in the 
same melanoma cell activates a senescence program and boosts melanoma cell 
recognition by cytotoxic lymphocytes. 
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3.2.2 Results 
3.2.2.1 Constitutive or doxycycline-regulated expression of mutated 
NRASQ61R in a BRAFv600E melanoma clone. 
Melanoma clone 2/21 expresses wild type HRAS, KRAS, NRAS genes (Anichini et 
aI., 1989), but harbors a heterozygous BRAFv600E mutation (Figure 3.4) and bears a 
homozygous inactivating Tyr->His mutation at codon 236 in exon 7 of p53 gene 
(Anichini et aI., 1999) and a homozygous deletion of exon 3 of the CDKN2A locus that 
prevents pl61lNK4A and pl41ARF expression (Figure 3.4). This clone was used for 
generating cells with constitutive or inducible expression of an exogenous NRA~IR. 
Constitutive NRA~IR expression was achieved by transfecting with pcDNA3.1-
FlagNRA~'R. Out of 100 clones initially isolated, 54 grew in selective medium and 18 
of the latter maintained the mutated insert. However, only lout of the 18 (thereafter 
named 21NRASQ6IR) expressed the exogenous mutated NRAS at the protein level (Figure 
3.5 A). The mutated NRAS could be distinguished from the endogenous NRAS thanks to 
the reduced electrophoretic mobility caused by the addition of the Flag peptide to the 
NRAS transgene (Figure 3.6 A). To generate cells with inducible NRASQ6IR expression, 
clone 21 cells were initially transfected with the regulatory pTet-Off vector. Clones 
expressing a functional regulator tT A protein were identified by a luciferase assay 
detecting Dox-regulated light emission 48 hours after transient transfection with the 
pTRE2hyg-Luc reporter plasmid. One of the 22 responsive clones, named 2l0ff, was 
selected for subsequent experiments, since it showed Dox dose-dependent RLU 
reduction, and at 1 ~glmL Dox reached RLU values similar to those displayed by non 
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transfected cells (Figure 3.6 B). 210ff cells were then transfected with plasmids encoding 
mutated (pTRE2hyg-FlagNRA~IR) or wild type (pTRE2hyg-FlagNRASWT) NRAS. Out 
of 48 hygromycin-resistant clones, transfected with pTRE2hyg-F1agNRA~IR, 8 clones 
grew in selective medium; however, only 2 of them expressed the oncogenic NRAS 
(Figure 3.5 B). The presence of mutated NRAS and BRAF in these two clones was 
confirmed by sequence analysis (Figure 3.4 B). In contrast, 30 out of 48 clones 
transfected with pTRE2hyg-FlagNRASWT kept growing and expressed the wild-type 
inserted NRAS (Figure 3.5 B). Expression and Dox-dependent regulation of the 
transgenic mutant or wild type NRAS was evaluated by Western blotting analysis (Figure 
3.6 A). In the absence of Dox, oncogenic NRAS as well as the wild type endogenous 
NRAS, were detected using NRAS-specific mAb. Addition of Dox (1 f.lg/mL) to the 
culture medium inactivated the transcription of the exogenous NRAS in a time-dependent 
fashion. The gene was completely silenced following a 48 hours incubation (Figure 3.6 
C). In contrast, no effect was detected on the transcription of the endogenous gene. A 
clone with inducible NRASQ6IR expression (thereafter named 21NRAS61oN or 
21NRAS610FF depending on expression or not of the exogenous mutant NRAS) and a 
clone with inducible wild type NRAS expression (thereafter named 21NRASWTON or 
21NRASWTOFF depending on expression or not of the exogenous wt NRAS) were selected 
for further experiments. 
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3.2.2.2 NRAS activation, ERK and Akt phosphorylation in "double mutant" 
21NRAS6lON cells. 
To assess the function of the exogenous activated NRAS oncogene, we used the 
RAS-binding domain of BRAF as a RAS-GTP-dependent probe (de Roij et aI., 1997) to 
immunoprecipitate active NRAS from cell lysates. As shown in Figure 3.7, more 
activated NRAS protein was immunoprecipitated from 21NRAS610N than from 
21NRAS610FF cells. Dox-regulated expression of the mutated NRASQ61R led to levels of 
active NRAS protein similar to those found in the human melanoma cell line 4473M 
harboring a mutated NRA~IR allele (Figure 3.7). In addition, active NRAS levels were 
similar in 2lNRAS610FF and in the parental 2/21 cells (Figure 3.7). Since NRAS 
mutations can result in dual activation of MAPK and PI3K pathways (Curtin et aI., 1995; 
Goel et aI., 2006), we then evaluated levels of total and phosphorylated ERK and AKT in 
2121 cells with expressed or silenced NRASQ61R. Total endogenous NRAS and total 
amount of ERK proteins were similar in all cell lines (Figure 3.7). In contrast, levels of 
phosphorylated ERK were much higher in 21NRAS610N cells compared not only to 
21NRAS610FF cells, but even to the parental clone 2121 expressing only BRAFv6OOE, and 
to melanoma 4473M expressing only NRASQ61R. Moreover, level of total AKT was 
similar in all samples, while phosphorylated AKT was found only in cells bearing an 
activated in NRASQ61R (21NRAS610N cells and 4473M sample). PTEN protein expression 
was found in all the samples (Figure 3.7). Similar results were obtained by comparing the 
constitutive 21NRASQ61R transfectant with the parental clone 2/21 cells (data not shown). 
These results indicate that co-expression of activated NRAS and BRAF oncogenes in the 
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same melanoma cells is associated with over-activation of components of the RAS-
effector cascade. 
3.2.2.3 A senescent phenotype develops in BRAFv600E melanoma cells after 
constitutive or inducible expression of NRASQ61R. 
In vitro growth properties of the 21NRASQ6IR constitutive transfectant were 
similar to those of the parental clone 2/21 in the early in vitro passages. However, after 
the lih in vitro passage, 21NRASQ6IR cells began to lengthen their doubling time (data 
not shown). Cell cycle analysis between the 1 i h and the 1 i h in vitro passage indicated a 
progressive accumulation of 21NRASQ6IR cells in the GoIG 1 phase of the cell cycle (from 
25.75% to 51.90%, Figure 3.8 A) and a corresponding decrease in the fraction of cells in 
S phase (from 64.12% to 29.38%). No such changes were seen either in the parental 
clone 2121 or in a clone that underwent the same selection procedure as 21NRASQ6IR but 
did not express mutated NRAS (21NRASWTin Figure 3.8 A). Furthermore, by a 
colorimetric assay, using X-gal as a substrate at pH 6.0, 21NRASQ6IR cells at the lih in 
vitro passage began to stain positive for the senescence-associated marker SA-p-Gal 
(Figure 3.8 B), consistent with activation of cellular senescence (Dimri, 1995), while both 
21NRASWT and clone 2121 cells remained negative. 
Growth of 21NRAS610N cells, in comparison to 21NRAS6IoFF, also slowed down 
after the 10th in vitro passage. Proliferation was therefore quantified using an MTS assay. 
As shown in Figure 3.9 A, OD490nm values were similar in 2/21 cells cultured in presence 
or absence of Dox, in 21NRASWTON and 21NRASWTOFF (at different in vitro passages), in 
21NRAS610N (9th in vitro passage) and 21NRAS610FF (both at 9th and 15th in vitro 
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passages). In contrast, 00 values were significantly lower in 21NRAS61oN cells, at the 
15th in vitro passage, compared to all other samples. A reduced growth of 21NRAS610N 
cells at the 15th in vitro passage was also observed following one week culture in 
Matrigel (Figure 3.9 B, upper panel), an ECM protein gel produced by the EHS tumor 
and known to be highly effective in supporting cell proliferation (Albini, 1998; Fridman 
et aI., 1991). After seeding into Matrigel, cells expressing NRASQ6IR, either did not 
divide or formed much smaller colonies than 21NRAS610FF cells (Figure 3.9 B, upper 
panel), while 21NRASWfoN and 21NRASWfoFF could grow to a similar extent (Figure 3.9 
B, upper panel). In addition, beyond the 10th in vitro passage, 21NRAS61oN cells became 
larger and flatter than 21NRAS61oFF cells (Figure 3.9 B, middle panel), a cell morphology 
usually associated with a senescent phenotype (Campisi 2005; Shay et aI., 2004), and not 
observed in either 21NRASWfoN or 21NRASWTOFF (Figure 3.9 B, middle panel). At this 
stage, 21NRAS61oN cells, like the constitutive 2INRASQ6IR, began to stain positive for 
the senescence-associated marker SA-p-Gal activity, while 21 NRAs6 I OFF, as well as 
21NRASWfoN and 2lNRASWfoFF did not (Figure 3.9 B, lower panel). 21NRAS610N and 
21NRAS610FF cells were then evaluated for the expression of additional markers of 
senescence. Phosphorylated AMP-activated protein kinase (pAMPK), a serine/threonine 
protein kinase recently shown to be upregulated in senescent cells (Hardie 2005; Xiang et 
aI., 2004; Wang et aI., 2003), was detected in the inducible 21NRAS610N and in the 
constitutive 21NRASQ6IR transfectants, but only at late in vitro passages (15th and 14th, 
respectively, Figure 3.10), while it was not expressed in all other cells including pre-
senescent 21NRAS610N (9th in vitro passage) and 21NRASQ6IR (8th in vitro passage). 
Cyclin-dependent kinase inhibitor p21 wafllCipl (p21), a mediator of growth arrest (Chang 
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et aI., 2000), could not be detected in non-senescent 21NRAS610FF, 21NRASWTON and 
21NRASWTOFF (all passages tested), but was expressed in 2lNRAS6lON and 21NRASQ6IR, 
at the senescent and the pre-senescent stages. Both p21 and pAMPK were not detected in 
melanoma cells expressing only BRAFv600E (clone 2121), or only NRASQ6IR (4473M). 
Expression of several molecules involved in p53 and p16/pRB pathways, like p53 itself, 
PCNA, MDM2, phosphorylated and underphosphorylated RB did not change when 
activated NRAS and BRAF oncogenes were expressed both in the same cell (data not 
shown). Taken together, these results suggest that co-expression of activated NRAS and 
BRAF in the same melanoma cells can activate a senescence program that induces cell 
growth arrest. 
3.2.2.4 Co-expression of activated NRAS and BRAF impacts on immune 
recognition and antigen processing machinery phenotype of melanoma cells. 
Additional mechanisms may contribute to selection against "double mutant" 
tumor cells bearing activated NRAS and activated BRAF oncogenes. To provide evidence 
in support of this possibility, we evaluated susceptibility of constitutive and inducible 
NRASQ6IR transfectants to cell mediated cytotoxicity, as the immune system is the main 
extrinsic suppressor of tumor growth (Dunn et aI., 2002). The constitutive transfectant 
21NRASQ6IR was significantly (p=0.0078) more susceptible, in terms of lytic units, to 
cell-mediated lysis, by IL-2 activated non-specific LAK effectors generated from six 
different donors, compared to parental clone 2121 cells (Figure 3.11 A). A limiting 
dilution assay for the determination of cytotoxic T cell effector frequency (Mortarini et 
aI., 2000) was then used to compare 21NRAS6lON and 21NRAS610FF cells for HLA-
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restricted and non-restricted cytotoxic T cell-mediated lysis. To this end, an alloreactive 
T cell line, established from PBL of an HLA-mismatched donor by repeated MLTC 
stimulation with 21NRAS610FF, was used. Frequency of all lytic effectors (i.e. 
independently from inhibition of lysis by anti-HLA-class I mAb) and of HLA-class I-
restricted alloreactive cytotoxic T cell effectors cells was much higher on 21NRAS610N 
than on 21NRAS610FF targets, in spite of the fact that the effectors had been selected on 
the latter targets (Figure 3.11 B). Lysis of 21NRAS61oN was significantly higher than 
lysis of 21NRAS610FF (p=O.OI89) (Figure 3.11 C) even by the autologous HLA class I-
restricted CTL clone 8B3 that was previously isolated from tumor-infiltrating 
lymphocytes of patient 665 and was shown to be able to specifically lyse melanoma 
665/2 cells (Anichini et aI., 1989). 
To determine whether the increased susceptibility to cell mediated lysis of 
21NRAS610N cells reflected changes in the expression of molecules involved in target-
cytotoxic cell interactions, 2lNRAS610N and 21NRAS610FF cells were then compared for 
the expression of a large number of cell surface and intra-cellular molecules, including 
HLA class I antigen processing machinery (APM) components. These molecules playa 
major role in the generation of HLA class I-peptide complexes which are recognized by 
CD8+ CTL. Flow cytometry analysis of cells intracellulary stained with APM 
component-specific mAb showed a higher expression of constitutive proteasome subunits 
delta and MB 1, of immunoproteasome subunits LMP2, LMP7 and LMP 1 0 and of 
chaperones calnexin and calreticulin and ERp57 in 21NRAS610N cells than in 
21NRAS61OFF cells (Figure 3.12 A). No differences were detected between the two cell 
types in the expression of the transporter associated with antigen processing (TAP) 
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subunits TAP-l and TAP-2 and of the chaperone tapasin. Furthermore, 21NRAS61oN 
cells and 21NRAS610FF cells did not differ in the cell surface expression of HLA-c1ass I 
antigens, HLA-DR, -DQ, -DP antigens, a,v~3 integrin ~ I, ~4, (X2, a,3, a,4, as, and a,6 
integrin subunits, and adhesion molecules ICAM-l and LFA-3 (Figure 3.12 A). In 
addition, all APM molecules found differentially expressed in 21NRAS6\oN cells 
compared to 21NRAS6\oFF cells showed a similar expression pattern in 210ff cells 
treated or not with Dox (Figure 3.12 B, upper panel). Moreover, 2121 cells transfected 
with an inducible wild type NRAS (21NRASWT) did not show differential expression of 
the APM components when treated or not with Dox (Figure 3.12 B, lower panel). Lastly, 
the death receptors Fas/CD95, TRAIL-RI TRAIL-R2, TRAIL-R3 and TRAIL-R4 were 
not differentially expressed in 21NRAS610N and 21NRAS610FF cells (data not shown). 
Taken together, these data indicate that co-expression of activating NRAS and 
BRAF mutations in the same melanoma cells may impact on recognition by both non-
specific and HLA-restricted cytotoxic effectors and on expression of several APM 
molecules involved in the generation of HLA-class I-peptide complexes recognized by T 
cells. 
3.2.3 Discussion 
Early evidence on mutual exclusion of activating KRAS and BRAF mutations in 
colorectal cancer suggested that RAS and BRAF oncogenes may exert equivalent effects 
in tumorigenesis, due to the common MEK-ERK effector cascade they regulate 
(Rajagopalan et aI., 2(02). In agreement with this possibility, concomitant mutation of 
BRAF and loss of PTEN have been described in melanoma (Goel et aI., 2006; Tso et aI., 
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2000). Such condition could induce biochemical effects similar to an NRAS mutation, as 
activated NRAS can result in dual activation of MAPK and PI3K pathways (Curtin et aI., 
2005; Goel et aI., 2006). In agreement, in this study, both these pathways were activated 
in melanoma clone 2121 after expression of a mutated NRAS oncogene. However, other 
studies have identified NRAS or BRAF mutation-specific gene expression profiles in 
thyroid carcinoma and in melanoma (Giordano et aI., 2005; Pavey et aI., 2005), and a 
selective susceptibility to MEK inhibition in BRAF mutant tumors, but not in NRAS 
mutant tumors (Solit et aI., 2006). These data suggest that activated NRAS and BRAF 
oncogenes may not necessarily drive equivalent phenotypic effects. In addition, analysis 
of clones isolated from a "double mutant" melanoma indicated that NRAS and BRAF 
activating mutations do not coexist in the same cells (Sensi et aI., 2006), suggesting that 
the two mutations may be incompatible with cell survival. This possibility is in 
agreement with the concept of synthetic lethality recently reviewed by Kaelin (Kaelin, 
2005). Genes having a synthetic lethal relationship may be identified among those that 
behave as "double-edged" swords for neoplastic cells, as able to deliver signals that may 
promote or inhibit cell proliferation and/or survival (Kaelin, 2005). Interestingly, both 
activated RAS and RAF proteins can play such contrasting roles depending on cell 
context and on the function/deficiency of other pathways including PI3K, RB and the p53 
pathways. Thus, activated NRAS contributes to neoplastic transformation of human 
melanocytes and to development of invasive melanomas, when the RB and p53 pathways 
are inhibited (Chudnovsky et aI., 2005). Similarly, activated BRAF is a transforming 
oncogene in immortalized melanocytes (Wellbrock et aI., 2004). On the other hand, 
several recent papers have shown that pre-malignant cells from different tissues can 
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activate a senescence program in response to oncogenic RAS (Shay et aI., 2004), and that 
activated BRAF triggers senescence in melanocytes from nevi (Michaloglou et aI., 2005). 
In agreement with the hypothesis that oncogenic NRAS and BRAF may be 
synthetically lethal, this study shows that, after the first 9-10 in vitro passages, the 
constitutive and the Dox-regulated transfectants expressing both NRASQ6IR and 
BRAFv600E had reduced in vitro growth compared to control cells, progressive 
accumulation in 0010 1 phase of the cell cycle and positive staining for the senescence-
associated acidic ~-galactosidase (SA-~-Oal). Furthermore, analysis of the Dox-regulated 
transfectants provided additional evidence for senescence, as indicated by increased 
levels of pAMPK and of the cyclin-dependent kinase inhibitor p21. Activation of 
apoptosis, as an alternative mechanism leading to elimination of the cells expressing 
NRASQ6IR and BRAFv6°OE cannot be ruled out. However, no evidence consistent with 
programmed cell death, such as cell shrinkage, membrane blebbing and formation of 
apoptotic bodies (Kerr et aI., 1972), was observed in the cultures. Taken together, these 
findings suggest that constitutive or conditional expression of a mutant NRAS oncogene 
in a metastatic melanoma naturally expressing a BRAFv600E oncogene is sufficient, in the 
absence cell cycle regulators, like p16/pRB and p14ARF/p53 (Fridman et aI., 1991; 
Campisi, 2005), to activate senescence. 
Cellular senescence is a genetic program leading to irreversible cell cycle arrest 
and can be mediated by several genes, including some oncogenes (Campisi, 2005; Shay 
et aI., 2004). In fact, in primary murine and human cells activated components of the 
RAS-RAF-MAPK signaling cascade are known to trigger senescence responses that 
prevent the unlimited expansion of these cell types (Serrano et aI., 1995; Sewing et aI., 
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1997; Lin et aI., 1998). The selective association of senescence in 21NRAS61oN cells with 
p21 up-regulation is in agreement with the described requirement for this cell cycle 
inhibitor in senescence associated with high levels of oncogenic RAS activity (Chang et 
aI., 2000; Lin et aI., 1998). Although p2l is the main target of p53, several p53-
independent mechanisms for its induction have also been reported. They may underlie 
p2l induction in double mutant 21 NRAS610N cells, where p53 is functionally deficient 
(data not shown). For example, in the p53-negative U937 myeloid cell line, NRAS-
induced senescence was dependent on p21 upregulation mediated by interferon 
regulatory factor-l (Passioura et aI., 2005). In human diploid fibroblasts undergoing 
replicative senescence, enzymatic components of the cGMP pathway were inhibited and 
exposure of colorectal cancer cells to a pharmacological inhibitor of cGMP synthesis 
induced activation of p2l and senescence (Lodygin et aI., 2002). In melanoma cells and 
melanocytes, senescence appears to be regulated by the basic helix loop-helix leucine 
zipper microphthalmia-associated transcription factor (MITF) (Steingrimsson et aI., 
2004). MITF is able to induce a G I cell cycle arrest that is dependent on p21 activation 
through modulation of its direct transcriptional repressor Tbx2 (Carreira et aI., 2005; 
Vance et aI., 2005). BRAFv600E signaling appears to down-regulate MITF at a level 
compatible with cell proliferation, since high MITF levels have anti-proliferative effects 
(Wellbrock et aI., 2005). Low MITF levels are linked to reduced survival rates and 
increased metastases in patients with intermediate thickness melanoma (Salti et aI., 
2000). However, induction of p21 in 2lNRAS610N cells is independent from MITF up-
regulation, since both senescent 2lNRAS610N and non-senescent 21NRAS610FF cells had 
similar levels of MITF protein expression (data not shown). It cannot however be ruled 
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out that differential MITF transcriptional activity as a result of increased MAP kinase 
signaling could play some role in senescence induction (Widlund et aI., 2003). In addition 
to the induction of p21 expression, senescent 21NRAS610N cells displayed up-regulation 
of AMPK. This metabolic enzyme is a key regulator of response to low A TP levels and is 
induced to prevent ATP-consuming processes under conditions of low cellular energy 
(Hardie, 2005). Recently, AMPK activity was found to be increased in cells undergoing 
senescence, while its over-activation promoted senescence in primary human fibroblasts 
(Wang et aI., 2003; Xiang et aI., 2004). Role of pAMPK induction in melanoma cells 
needs to be further explored and will be deeper investigated in Chapter 4 of this thesis. 
Activation of senescence, by co-expression of oncogenic NRAS and BRAF in the 
same melanoma cells, may not be the only mechanism leading to selection against 
"double mutant" cells. Since the immune system is the main extrinsic tumor suppressor 
factor, we evaluated whether cells with expressed or silenced NRASQ61R had significantly 
different susceptibility to cell-mediated cytotoxicity by measuring frequencies of both 
HLA-class I-restricted and non-restricted cytotoxic effectors directed against 
21NRAS610Nor 21NRAS610FF. Due to the lack of autologous lymphocytes, these effectors 
were generated by repeated restimulation of lymphocytes from an HLA-mismatched 
donor with 21NRAS610FF cells in MLTC. The results indicated that the frequency of 
cytotoxic effectors was markedly higher on 21NRAS610N than on 21NRAS610FF either 
when the cytotoxicity assay was performed in presence or absence of w6/32 mAb to 
inhibit the HLA class I antigen restricted component of the lysis. Differential lysis of 
21NRAS610N and 2lNRAS610FF cells was observed even by using an autologous HLA 
class I-restricted CTL clone isolated from TILs and previously characterized (Anichini et 
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aI., 1993). Interestingly, increased lysability of 21NRAS610N was associated with up-
regulation of a specific set of components of the HLA antigen processing machinery that 
contribute to generation of MHC-peptide complexes recognized by T cells (Lehner et aI., 
2004). 
These data, together with those indicating activation of senescence, are consistent 
with the possibility that double mutant cells, harboring both activated NRAS and BRAF 
oncogenes, may be selected against by cell autonomous and extrinsic mechanisms. 
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3.3. Identification of proliferation arrest mediators by microarray analysis in 
melanoma cells. 
3.3.1 Introduction. 
3.3.1.1 MicroArray technology in cancer research. 
Over the past decade. the completion of human genome sequence opened the way 
to new approaches for gene analysis. Among these novel technologies, microarray 
represents an efficient approach to extract data of biomedical relevance for a wide range 
of applications. enabling the study of genome-wide expression patterns in complex 
biological systems. For these reasons, microarray technology has emerged as an 
important tool for the characterization of cancer cells (Sears et aI., 2007). 
In cancer research. this technology has several applications. Indeed, microarrays 
can provide useful insights into differences in an individual's tumor as compared with 
constitutional DNA. mRNA and protein expression; across different individuals, 
comparisons can provide tissue-specific disease signatures with important diagnostic 
implications. In this way, clusters of genes which are regulated together can be identified. 
The expression pattern of gene clusters can then be correlated with morphology, clinical 
behavior or treatment response. This results in the identification of tumor- associated and 
tumor-specific biomarkers which may help in cancer etiology, diagnosis and therapy 
investigation (Liotta et aI., 2(00). Resulting signature profiles can provide a more 
accurate prognosis and prediction of response to therapy. 
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Carcinogenesis is a multistep process that is the outcome of the accumulation of 
several genetic and epigenetic events. In this scenario, DNA Microarray is a promising 
approach that allows both qualitative and quantitative screening for sequence variations 
in the genomic DNA of cancer cells. Detection of mutations in cancer is of major 
importance for both basic understanding of the disease process and clinical practice. 
DNA array is a powerful and effective tool for detecting specific mutations, small 
insertions and deletions in non-repetitive sequences. Several studies showed that 
microarrays are more sensitive, more accurate and faster than classical sequencing 
approaches (Wen et aI., 2000). 
On the other hand, cancer phenotype is also partially determined by its 
transcriptome. Global transcript analysis could have powerful applications in cancer 
diagnosis and patient management. Microarray expression comparison allows for the 
obtainment of a panel of up- or down-regulated genes that reveals a relevant molecular 
fingerprinting of the cellular state and provides a large body of candidate molecular 
markers of the disease. Combined with knowledge of the clinical importance of disease 
process, global transcript analysis has powerful applications in cancer diagnosis and 
patient management. 
In addition, gene expression study in pharmacogenomics offers a new way to 
monitor qualitative and quantitative aspects of treatment efficacy. resistance mechanisms 
and generation of novel targets (Debouk et aI., 1999). 
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3.3.1.2 Lipocalin 2. 
The lipocalin protein family is a large group of small extracellular proteins. 
Members of this protein family are typically small secreted proteins which are 
characterized by a range of different molecular-recognition properties. Lipocalins can 
bind small hydrophobic molecules. such as retinol. or specific cell-surface receptors with 
which can form macromolecular complexes. This group of proteins exhibit great 
structural and functional diversity, both within and between species. In the past they have 
been classified primarily as transport proteins. However, it is now clear that members of 
the lipocalin family fulfill a variety of different functions. These include roles in retinol 
transport, cryptic coloration, olfaction, pheromone transport, and the enzymic synthesis 
of prostaglandins. The lipocalins have also been implicated in the regulation of the 
immune response and the mediation of cell homoeostasis (for a Review: Flower, 1996). 
Lipocalin 2 is a member of the lipocalin superfamily and is expressed in 
granulocytic precursors as well as in numerous epithelial cell types (Friedl et aI., 1999; 
Nielasen et aI., 1996). Increased expression of lipocalin 2 accompanies numerous 
transformations (induction by polyoma, SV40, phorbol ester, and the neu oncogene) and 
human carcinomas (colorectal, hepatic, pancreatic and breast carcinomas), but the action 
of the protein is not fully understood (for a review Bratt, 2000). 
Recently it has been shown that lipocalin 2 can alter the invasive and metastatic 
behavior of RAS-transformed breast cancer cells in vitro and in vivo by reversing the 
Epithelial-Mesenchimal-Transition (EMT)-inducing activity of RAS (Hanai et aI., 2005). 
Numerous pathways have been defined downstream of RAS activation (Downward, 
2(03). Moreover it has been demonstrated that lipocalin 2 can restore E-cadherin 
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expression and regulates RAS signaling. The action of lipocalin 2 on the RAS-MAPK 
signaling pathway presumably lies between RAS and RAF activation (Hanai et aI., 2005). 
In addition, lipocalin 2 can suppress the RAS-induced expression of VEGF in breast 
cancer cells via down-regulation of MAPK- and PI3K- signaling (Venkatesha et aI., 
2006). In addition, the expression of the antiangiogenetic molecule thrombospondin-l 
was found increased in tumors formed by 4Tl-ras cells into which lipocalin 2 was stably 
introduced. 
Tumor angiogenesis, assessed via an intradermal tumor angiogenesis assay, was also 
suppressed by lipocalin 2. 
3.3.1.3 LO XL3. 
Lysyl oxidase (LOX), a copper-containing amine oxidase, belongs to a 
heterogeneous family of enzymes that oxidize primary amine substrates to reactive 
aldehydes. Traditionally, the well known function assigned to LOX proteins is the 
extracellular catalysis of lysine-derived cross-links in fibrillar collagens and elastin 
(Csizar, 2001). More recently, diverse roles have been attributed to lysyl oxidase and 
these novel activities cover a spectrum of diverse biological functions such as 
developmental regulation, tumor suppression, cell motility, and cellular senescence 
(Lazarus et aI., 1994, Li et aI., 2000; Smith-Mungo et aI., 1997). Lysyl oxidase has also 
been shown to have both intracellular and intranuclear locations (Li et aI., 1997). Recent 
studies identified an up-regulation in lysyl oxidase (LOX) expression, in a highly 
invasive/metastatic human breast cancer cell line, compared with a poorly 
invasive/nonmetastatic breast cancer cell line (Kirschmann et aI., 2002). Moreover, the 
105 
correlation of LOX up-regulation and invasive/metastatic potential was additionally 
demonstrated in rat prostatic tumor cell lines, and human cutaneous and uveal melanoma 
cell lines. These results provide substantial new evidence that LOX is involved in cancer 
cell invasion. 
Recently, 4 novel members of this amine oxidase family, LOX-like (LOXL), 
LOXL2, LOXL4 and LOXL3, were identified (Molnar et aI., 2003). The LOXL3 protein 
contains four scavenger receptor cysteine-rich domains in the N terminus in addition to 
the C-terminal characteristic domains of the LOX family, such as a copper binding 
domain, a cytokine receptor-like domain and residues for the lysyl-tyrosyl quinone 
cofactor. 
So far, very little is known about the specific cellular biological functions of 
LOXL3. 
3.3.2 Results. 
3.3.2.1 NRASQ6IR/BRAFv600E double mutant cell ditTerentially expressed 
molecules as evaluated by MicroArray profiling. 
In order to delineate the molecular mechanism and identify possible mediators of 
the senescent program induced in melanoma cells co-expressing oncogenic NRAS and 
BRAF, the highly sensitive CodeLink Human Whole Genome Bioarrays were used for 
Microarray analysis. RNA extracted from 2lNRAS61oN and 21NRAS610FF cells (for 
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details about cell lines see chapter 3.2 and Petti et aI., 2006) was processed for this 
analysis. The experiment was carried out with 2 technical replicates for each sample. 
Among the 55000 analyzed probes, 321 genes resulted differentially expressed, 
where 190 were up- and 131 down-regulated (Table 3.3 and Figure 3.13 A). 
Significantly, modulated genes could be classified in different signaling pathways such as 
cell proliferation, cell cycle, cell death, response to stress, response to wound and 
immune response (Figure 3.13 B). A number of modulated genes were then selected for 
the validation of Microarray data. To this end, the up-regulated CREBl, DKKl, HICl, 
HESl, LCN2, LEFl, LOXL3, NFKBl, PTX3, SPRYl, UHMKI and the down-regulated 
AMACR, ARHI and CUTLI were amplified using TaqMan probes (Figure 3.14 A). 
Expression modulation of the mRNA levels for the 14 targets evaluated by RealTime 
PCR was similar to fold change values previously obtained from Microarray results 
(Figure 3.14 B), thus confirming the validation of Mircoarray experiment. 
As a further validation of Microarray data, the protein levels of LOXL3 were then 
tested by Western Blot. 21NRAS610N showed higher expression levels of LOXL3 protein 
than 2lNRAS610FF (Figure 3.14 C). In agreement with the Microarray results, neither 
2lNRAS610FF nor parental 2/21 cells expressed high levels of LOXL3 protein (Figure 
3.14 C). 
3.3.2.2 Lipocalin 2 and LOXL3 are differentially expressed in a panel of 
melanoma cells. 
In order to understand the physiological role of the differentially expressed 
molecules validated by RealTime PCR and to correlate their expression with melanoma 
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behavior, such differentially expressed genes as LOXL3 and lipocalin 2, potentially 
involved in cell proliferation, were chosen for further investigations. 
Expression levels of both LOXL3 and lipocalin 2 genes were evaluated in a panel 
of melanoma samples at the mRNA level (Figure 3.1S A). As evaluated by RealTime 
experiments, 3 out of IO melanoma cell lines (89S9M, 14362M, 2211Ml) expressed 
LOXL3 at higher levels (Figure 3.1S A). Similar results were obtained for LCN2, where 
2 out of IO melanoma cell lines (lS392M and 14362M) showed higher levels of mRNA 
expression. In addition, protein levels of lipocalin 2 were evaluated by FACS analysis for 
1 melanoma which showed higher and 1 melanoma lower expression at the mRNA level. 
Lipocalin 2 higher expression in 14362M sample was confirmed in comparison to 
15392M which resulted negative at the protein level (Figure 3.1S B). 
3.3.2.3 Lipocalin 2 protein expression can be silenced in melanoma cells using 
specific siRNA. 
In order to correlate its expression with tumor behavior, modulation of lipocalin 2 
protein levels was achieved in melanoma cells. Lipocalin 2 was silenced at the 
transcriptional level in 14362M which displayed higher basal protein levels compared to 
the other melanoma cell lines. Silencing of lipocalin 2 using specific siRNA was not yet 
effective 24 hours after transfection, while it was evident after 48 hours. After 72 hours 
from transfection, protein levels reached again the basal values, as tested by flow-
cytometry analysis (Figure 3.16). Control scrambled siRNA directed against lipocalin 2 
scorrelated target, did not follow the same expression modulation (data not shown), thus 
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indicating that silencing achieved with the siRNA against lipocalin 2 is specific for and 
only for lipocalin 2 protein. 
The induced down-regulation of lipocalin 2 protein will be used for further 
functional experiments which will clarify lipocalin 2 involvement in melanoma 
proliferation. 
3.4 Discussion 
In this section of the thesis. preliminary data obtained to date are shown. 
However. deep further investigation is needed in order to achieve strong evidences of the 
studied phenomenon and to obtain more consistent results. 
In the first part of this study. expression profile of NRASQ6IRIBRAFv600E double 
mutant cells was evaluated by using Microarray technology. Data analysis showed that a 
number of genes implicated in cell proliferation. cell cycle. cell death. response to stress, 
response to wound and immune response are affected by the concomitant expression of 
the two oncogenes. Among these genes. interesting molecules which might explain the 
previously shown senescent mechanism are included. This kind of molecules might play 
a relevant role in the control of cell proliferation not only in the specific presented cell 
model, but also in general in melanoma cells. For this reason, the impact of their 
expression on cell phenotype needs to be assessed in a wide panel of melanoma samples. 
Both lipocalin 2 and LOXL3 may play a role in the control of cancer cell 
proliferation. Among the functions so far reported in literature for lipocalin 2, this 
molecule has been associated to the reversion of the EMT phenotype (Hanai et aI., 2005). 
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The knowledge so far collected about this molecule suggests that lipocalin 2 might be 
relevant for a tumor suppression function. 
About LOXL3 less information are available from literature. Some reports 
correlated lysil-oxydase proteins with senescence phenotype (Smith-Mungo et aI., 1997), 
thus suggesting that also LOXL3 could be involved in a similar mechanism also in tumor 
cells. Expression of the LOX gene was found to inhibit the transforming activity of the 
ras oncogene in NIH 3T3 fibroblasts and was hence named the ras recision gene 
(Contente et a1.. 1990; Kenyon et a1.. 1991). Reduced LOX levels were observed in many 
cancers and derived cell lines (Kaneda et a1.. 2004), whereas in spontaneous revertants or 
upon induced phenotypic reversion. higher normal levels of LOX were again seen 
(Hajnal et a1.. 1993). These notions suggest that also the LOX related LOXL3 molecule 
can exploit similar functions which might drive a proliferation arrest mechanism. 
Preliminary experiments performed for lipocalin 2 and LOXL3 in a panel of 
melanoma cell lines were focused on the assessment of their potential role in proliferation 
arrest in melanoma. As revealed by microarray results obtained from the double mutant 
model system. both lipocalin 2 and LOXL3 are generally expressed at low levels in most 
melanomas. It is conceivable that most melanomas express these two molecules at low 
levels in order to achieve a growth advantage for tumor expansion. Therefore, it can be 
speculated that lipocalin 2 and LOXL3 might be involved in the promotion of 
proliferation arrest in melanoma cells thus acquiring a tumor suppressive function. 
However, this issue needs to be explored and confirmed with future work. 
To this end, for a further characterization of the role of lipocalin 2 and LOXL3 in the 
control of cell proliferation. both inhibition and over- expression of these proteins should 
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be achieved in melanoma cells. So far, preliminary experiments aimed at the setting of 
the silencing of lipocalin 2 through the use of siRNA were performed. In one melanoma 
cell line, selected for the higher basal expression levels of lipocalin 2 at both mRNA and 
protein level, inhibition of lipocalin 2 protein expression was reached after 48 hours from 
transfection with specific siRNA. Biological consequences of the induced silencing have 
to be evaluated in melanoma cells. In order to explore this issue, cell proliferation and 
cell cycle modulation will be tested. In addition, enhanced expression of lipocalin 2 
protein will be inducted by using specific constructs and the correspondent phenotype 
will be then investigated. 
Similar approaches will be used also for further explorations about the role of LOXL3 
protein in melanoma behavior. 
In this view, all the amount of data obtained from the micro array analysis 
provides a useful source of potential candidate genes which can mediate cell behavior 
characteristics as important as cell proliferation and cell cycle progression. Therefore, 
from the obtained data sets, other possible molecules which can reveal a tumor 
suppressive function can be extrapolated. The identification of new mediators of 
proliferation arrest in melanoma cells may open the way to the discovery of novel 
strategies for innovative therapeutic approaches in melanoma treatment. 
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Figure 3.1. Detection of NRASQ6JR and BRAFV6()()E mutations. 
A. Repre entati ve exp rim nt p rformed on 5 BRAFv600E (i.e. 10538P, 15392M, 4023M, 18732M, 
18588M) and 2 NRA IR i .. 665/2 , 8959M) tumor: amplification by MASA-PCR for the 
detection of NRAS06IR or BRAF E mutation (upper panels) and by standard PCR for the exon 
15 BRAF and exon RA gene lower panel ). B. Amplification by 35- and 45- cycle MASA-
PCR of BRAF 600E left panel) and amplification of exon 3 BRAF gene by tandard PCR (right 
panel). C. Electropherogram of amplified e on 3 NRAS and ex on 15 BRAF on melanoma 665/2 
obtained by tandard direct fluore cent equ ncing. 
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Figure 3.2. Titration assay for comparison between direct sequencing and MASA-PCR sensitivity. 
Decreasing proportion of genomic DNA ( I 0-0.1 ~) from BRAFv600E melanoma 18732M were mixed 
with a fixed amount of genomic DNA from a human lymphobla toid cell line (LCL) carrying only 
the wild type BRAF allele . A. Electropherogram of titrated ample obtained by fluorescent direct 
equencing. B. Amplifi ation of ti tra ted ample by 35- or 45- cycle MASA-PCR. 
114 
A 
665/2 melanoma clones 665/2 melanoma clones 
NRASQ61RI 
~"""""""'='~ .................. = 
BRAFV600E I 
B 2117 2/21 
RAS BRAF NRAS BRAF 
A G T G A 
Q61R Wild type Wild type V600E 
Figure 3.3. MutationaL anaLysis of meLanoma clones. 
Representative re ult of cI n i olated from a NRAS06IR metastatic lesion of patient 
665/2. A. Amplification by MASA-PCR of either NRAS06IR or BRAFv600E mutations. B. 
Electropherogram of amplifi d e on 3 RAS and exon 15 BRAF obtained by standard 
direct fluore cent equencing. 
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Figure 3.4. Detectioll of RA and BRAF mutations by direct sequencing in constitutive 
and inducible clolle . 
A. Electropherogram of partial e on 3 RAS and ex on 15 BRAF sequences amplified from 
genomic 0 A of lone _12 t, howing a wild type homozygou NRAS equence at codon 61 
and Aff heteroz go it for BRAF at codon 600. B. Electropherograms displaying in 
21 NRAS61 0 the pre en e of ei ther RAS NG heterozigo ity at codon 61 as well as BRAF 
Aff heterozigo it at d n 600. C. Homozygou deletion of exon 3 of the CDKN2A locu in 
melanoma clon J2 1 e aluated b peR; 20842P was u ed a positive control for CDKN2A 
locu amplificati n. 
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Figure 3.5. Selection of NRASQ61RIBRAF\'600E clones. 
A. Number of G418 reo istam cl ne: i ' olated following transfection of pcDNA3.l-FlagNRASQ61R 
(J), grown after election (1). po. ilive for the insert (3) and expressing the mutated transgene (4). 
B. Number of clone. i~olated folio\) ing tran. fection with the indicated expression vector (white), 
after G418 selection (grey or c pressing the inducible transgene (black). 
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Figure 3.6. Oil . titutive alld doxycycline-regulated expressioll of lIlutated NRASQ6JR ill 
BRAF\ 6011£ me/all oma clolle 2/2 1. 
A. E pre"..,ion or lag-lagged :'\RA. Qt>I R in 21 RA Q6IR ce iL by We lern Blot analys is usi ng 
R -"pc iii m b (upper .. UTt)\\: e\'.ogenou~ Flag-tagged NRASQ6IR; lower arrow: 
endogenou.., \\-ild I~pe \iRA ). B. Lu ' ifera~e a livity of 210ff ell either untran fected 
(empt ..,quart: ) or lri.lJl"'lcntl~ lran,fectco \\ ilh pTRE2h g-LlIc (b lack square) and cultured for 
48 h ur at 37 in at.,..,cn ' C or in pre. en 'I; of increa:ing Dox concentration. Results are 
expre~~cd a R 'Iali\ c Li ght L'nih (RL ). \\ here each va lue is the mean ± s.d. of triplicate 
mea~uremenl" . '. Time 'our..,e "ilen ing or R Q6IR transgene. 2 1NRAS610N cell s were 
cultured in the ab cnec or \\ ilh )\ ( I ~lg/lllL) r r up to 48 hours. Cell Iy ares were then 
tested by Wc..,tcrn bl )l anaIY..,I.., \\ ilh an R -. pecific III b (upper arrowS: exogenou Flag-
tagged R <)<1IR: Im\ cr .IIT)\\"': cnoogcn u.., .. ild Iype NRAS). p-actin IllAb wa II ed as 
loadi ng cOfllrol. 
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Figure 3.7. NRAS activation, ERK alld AKT phosphoryLatioll ill2lNRAS610 cells. 
Western blot analysis of a live RAS immunoprecipitated from 21NRAS61o , 21 NRAS610H:, 
clone 2121 (BRAFvtJOOC) and -t.473M ( R SQ6 IR) melanoma cell line , and of total NRAS, 
phosphorylated ERK (pERK). RK. phosphorylated AKT (pAKT), AKT and PTEN from ce ll 
Iy ate. of the ~ame sample . . 
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Figure 3.8. Accumulation ill the GIG[ phase of the cell cycle and expression of a senescence-
associated marker in BRAF 600£ melanoma cells with constitutive NRASQ6JR expression. 
A. Cell cycle analy i of 2 1 RASQ6I R cell , compared to 21NRAS WT and to parental 2/21 cells 
between the 10th and the l7 th in \ itro pa age. B. SA-p-galactosidase staining of the parental 2/21 
line, of 2 1 NRASQ6IR e ll , and 2 1NRASw T (both at the 14th in vitro passage). 
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Figure 3.9. Differelltial growth characteri tic and expression of senescence-associated 
markers ill 21 RA 610.\' and 21 RA 6JOFF cells . 
A . proliferation, evaluated b MT a ay. of 2 L RAS610 and 2 1 NRAS610FF, at both the 9th and 
at the 15th in vitro pa aoe. of _I RA \'V[O and 21NRA WTOFF (at the lyh in vitro pa age) 
and of 210ffc II: ultur d ithlwithout Do ( I ~glmL). OD490nm mean ± .d. of triplicate of 
one of thre exp riment ar h n. OD490nm value of 21NRAS610 at the 15 th in vitro pas age 
were ignificantly different at all tim point from tho of the other ample (ANDY A followed 
by S K te t. O. 1<p<O.O ). B. Growth in Matrigel for one week of 2 1NRAS61oN and 
21 RAS61 fF ell ' at th 1 th in vitro pa age (40x magnification). C. Growth on Matrigel 
upport (upper pan I). m rpholog (middle panel) and ene cence-a ociated ~-galacto idase 
activ ity (lower panel ) f 21 R 610 compared to 21 NRAS610FF cell at the 15 th in vitro 
pa age. 
121 
pAMPK 
-. 
p21 
f3-actin 
Figure 3.10. Expres iOIl of pAMPK and p21 after NRASQ6IR/BRAFv600E co-expression. 
We. tern Blot unal ys i~ of 21NR 610N and 21NRAS610FF at both the senescent (15 th ) and non 
ene 'cent (9th ) ill I 'ilm pas. age, of con ·titutive transfectunt 21 NRASQ61R at both sene cent (14th) 
and non ene. cent ( Ih) ill I'ilm pa sage, of lone 2121 (BRAF 600E), of 21NRASWTO and 
21 NRAS\\TOH at the I y h ill l 'ill"O pas age, and melanoma 4473M (NRASQ6IR) for expre ion of 
pho. phorylated MPK (p M PK). p21 and ~-actin (as loading control). 
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Figure 3.11. Increased susceptibility to cell mediated lysis of melanoma cells expressing 
constitutive or inducibLe NRASQ6IR. 
A. Lysi . of 1 1 R Q6IR compared to clone 2121 by LAK cells generated from six donors. 
Results expre~sed as I tic unit (Lytic Unit! t07 lymphocyte, based on 30~ target ce ll lysis). 
m
l
, m1 : means f the ' ix I tic unit value corre ponding to 2 1NRASQ61R and 2/21 ce ll 
respectively; p: p-vaJ ue obtai ned from a two-tailed I-test of the two data ets. B. Frequency of 
cytotox ic ce ll s (lytic effe tOt"') and of HLA-class [-restricted cytotoxic T cell effector 
recognizing 2 1 R (iIO. and 2 1NRAS610FI-' a evaluated by LDA with an alloreactive T ce ll 
line generated by MLTC aga in t 21 RAS610FF ce ll s. Frequency of cytotoxic effectors ex pres. ed 
as cytoto ic cell'/IO~ I mphocyte. C. Ly i of2INRAS610N, 21NRAS61 oFF and parental 66512 
tumor by the autologous HL cia ' I-restlictcd CTL clone 883. m l , m1: means of the % lysi 
relative to 2 1 RAS6IoN,2 1 RAS6IOFl- respec tively; p: p-value obtained by a two-tailed He ton 
the two data :el ' . 
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Figure 3.12. APM component up-regulation in BRAFv600E melanoma cells expressillg inducible NRASQ6JR, 
A. Flow cytometry analysis for cell-surface molecules (HLA class I and II antigens, avp3 integrin. PI, P4, a2, a3, a4, as, a6 inlegrin subunits, ICAM-l and 
LFA-3 adhesion molecules) and for intra-cellular APM components (delta., MEl, LMP2, LMP7, LMP1? ,. TAP-I , TA~-2 , calnexin. calreticulin, ERpS7, 
tapasin) in 21NRAS610N cells (grey histograms) and ~lNRAS610FF (empty histograms). surf.: non-per~e.abilized ce~l~ stamed with secondary antibody only; 
perm.: permeabilized cells stained with secondary an~lbody only. B. Upper row: ~ow cytometry analysIs m permeabiltzed ceLLs for se lected APM components 
in 210ff ceLLs without Dox (grey hi stograms) or wIth I J..Ig/mL Dox (em~.tY"hlstograms). Lower row: flow cytometry analysis in permeabilized ceLLs for 
selected APM components in 2lNRAS wTON (grey histograms) or 21NRAS W1 0Ff (empty histograms) . crr!: cells stained with secondary antibody only. 
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Figure 3.13. Results of Microarray comparisoll between 21NRAS61ON and 21NRAS61OFF 
double mutant cells. 
A. Differentially expre ed g ne vi uaJized as Scatter Plot by GeneSpling 7.0 software analy i . 
Each dot repre ent one gene; dot la ing above the upper and below the lower diagonal green 
line are re pectively up- (red dOl) and down- (blue dot ) regulated gene of more than l .5-fold. 
B. Schematic repre entation of the di tribution of modulated gene into the ix reported 
categorie of molecule ·. 
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Figure 3.14. Validatioll of Microarray data by ReaLTime peR. 
A. Expre sion levels or mR or up- and down-regulated gene elected from microarray analysis a 
evaluated by RealTime peR: th 2 .\C values f 21 RAS610 (li ght grey) or 21 NRAS6 10FF (dark grey) 
sample for each gene arc rcprcl,cnted in the hy, tograms; 2' c-r: normalized target gene expres ion level. 
~*: O.OS>p>O.OO I ompared to R 610 . . B. Compari on between fold change values obtained by 
RealTime validation and b Mier arm) experiment. RealTime result (left panel ): fold changes correspond 
to the ratio between 2 ~ \ alues of 21 R 610 and 21 NRAS610FF; Microcmay results: reported data 
corre pond to the fold change \alues obtained in the data analy i by Gene Spring ( ee al 0 Table 9) . C. 
Protein expre ion Ieveh of LO L as evaluated b we -tern Blot using a 'pecific monoclonoal antibody; p-
actin wa used a,' loading contr I. 
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Figure 3.15. Expre\'.\ io llle~'el oj LOX.Ll alld LCN2 ill a panel oj 111 eiall 0117 a eel/lines. 
A. XI rc ...... lon k\eJ, of mR\: ,\'- '\uluated b RealTime pe R relat ive to LOXL3 (upper panel) 
and lipocalin _ (L 1' 2 ) (Iowcr pancl) in a ~el of melanoma ell lines; each hystogram represents 
the 2 \\( val ue .... rcLltl\e to C.\ h ample. _ \.'l : normali zed larget gene ex press ion level. B. 
Flo'W 'y t )mctr~ JI1.t1y ... i ... for Intra-cell ular lipo al in 2 protein levels in 14362M cell (Iert panel) 
and 1':-39_\1 (right pand ). Jra) h)~togral1l , : perm abili zed ce ll s ' rained with econdary 
antibody onl}: empty 11) ,[ograrll'.,: perllleabilized ce ll s : lained with both primary and econdary 
antib die . 
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Figure 3.16. Silencing of LCN2 protein expression by siRNA. 
Flow cytometry analy i f r intra-cellular LCN2 protein levels in 14362M melanoma cells 
transfected (empty hy tograrn , three different ranges of blue lines) or not (empty hystogram, 
red line) with pecific iRNA for LCN2. Red colored hystogram: permeabilized cells stained 
with econdary antibody only· empty hystograms: light blue: LCN2 expression 24 hours after 
iRNA tran fection ; bright blue: LCN2 expression 48 hours after siRNA transfection; dark 
blue: LCN2 expre ion 72 hour after siRNA tran fection. 
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Melanoma cell line NRAS BRAF 
10538P wt V600E 
15392M wt V600E 
4023M wt V600E 
18732M wt V600E 
18588M wt V600E 
4686M wt V600E 
9923P 012S wt 
4405P Q61R wt 
8959M Q61R wt 
5810P Q61R wt 
4473P Q61R wt 
66512 Q61R wt 
665/1 Q61R wt 
6651R Q61R wt 
Table 3.1: NRAS and BRAF mutations in the 14 melanoma cell lines analyzed 
(Daniotti e aI., 2004). 
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Number of mutated clones/total (%) 
None 
665/2 16/21 (75) 5121 (25) 0121 (0) 0/21 (0) 
665/1 0/11 (0) II/II (100) 0/11 (0) 0/11 (0) 
6651R 0/18(0) 18/18 (100) 0/18 (0) 0118 (0) 
5810P 0/6 (0) 6/6 (100) 0/6 (0) 0/6 (0) 
Table 3.2: BRAFV6(K)E and NRASJ6 IR mutations in clones isolated from 3 NRA~IR 
metastatic lesions of the same patient (665/2, 665/1, 6651R) and from a 
different NRASJ6 IR patient (58 lOP). 
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Gene Sl:mbol Common Name Fold Change 
BP75 bromodomain comainin!,; 2rotein 75 kDa human homolog 25.23 
LCN2 li(!ocalin 2 (oncosene :!4(!3) \0 
Pl3 (!e(!tidase inhibitor 3. skin-derived (SKALP) 8 
ILlB interleukin I beta 6.84 
TGM2 transslutaminase 2 (C 1221~J:!eJ:!tide. (!rotein-glutamine-gamma-glutam~ltransferase) 6.13 
LOXL3 l~s~1 ox.idase-Iike 3 5.47 
PDUM4 PDZ and LIM domain .. 5.36 
CSTl c~statin F (ieukoc~statin) 5.29 
NRAS neuroblastoma RAS \iral (v-ras) oncogene homolog 5.19 
MGll monogl~ceride I~(!ase 5.16 
KRT/4 keratin 14 4.72 
SLC04Cl solute carrier organic anion transporter famil~. member 4CI 4.55 
MGP matrix Gla 2rotein 4.46 
NFATC2 nuclear factor of activated T-cells. c~to(!lasmic, calcineurin-de(!endent 2 4.31 
FST follistatin 4.25 
MUC7 mucin 7. saliva!}: 4.15 
AREG amJ:!hiregulin (schwannoma-derived growth factor) 4.14 
MMPI matrix. metallo~(!tidase I (interstitial collagenase) 4.13 
MB m~oglobin 4.1 
SPRYI S(!rout~ homolog I. anta!,;onist of FGF signaling 3.92 
COL6A3 collagen. t~·~ VI. al(!ha 3 3.91 
CHERP calcium homeostasis endo~lasmic reticulum (!rotein 3.89 
PTPRE (!rotein t~rosine (!hos(!hatase. rece(!tor t~~. E 3.86 
TNA tetranectin (~Iasmino!,;en bindin!,; Erotein) 3.83 
LAPTM5 I~sosomal associated multis~anning membrane Erotein 5 3.74 
SYTLS s~naEtotagmin-like 5 3.69 
FAM20C famil~ with seguence similarit~ 20, member C 3.68 
fER3 immediate earl~ res~,"se 3 3.63 
PLAUR ~Iasminogen activator. urokinase rece~tor 3.55 
SLC20Al solute carrier familv 20 «(!hos(!hate mmsporter), member I 3.48 
SERPINE2 se!Ein ~(!tida.,e inhibitor. clade E (nexin, (!Iasminogen activator inhibitor t~(!e I), member 2 3.46 
ENC) ectodermal-neural conex (with BTB-like domain) 3.39 
RECf2LS RecQ Erotein-like 5 3.38 
ARHI ras homolo!,; sene famil~. member 1 3.32 
LNK l~mEhoc~te ada(!tor Erotein 3.25 
UBCE71P5 likel~ ortholoS of mouse ubiguitin conjugating enz~me 7 interacting Erotein 5 3.22 
LENG4 leukoc~te rece(!tor cluster (LRCl member 4 3.21 
SPRR2C small J:!roline-rich (!rotein 2C 3.2 
VIPRI vasoactive intestinal ~(!tide receEtor I 3.19 
ILJl interleukin II 3.14 
SERPINEI se!Ein ~Etidase inhibitor. clade E (nexin, Elasminogen activator inhibitor t~Ee I), member I 3.13 
TNC tenascin C (hexabmchion) 3.13 
C8FW EhosEhoErotein resulated b~ mitogenic Eathwa~s 3.12 
THBS) thrombos~ndin 3.04 
TERT telomemse reverse transcriptase 3.03 
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TRAFI TNF receptor-associated factor I 2.98 
NRG} neuregulin I 2.97 
MDGAJ MAM domain containing glycosylphosphatidylinositol anchor I 2.97 
PHWA2 pleckstrin homology-like domain. family A. member 2 2.94 
HHJP hedgehog interacting protein 2.92 
MGC478J6 family with sequence similarity 80. member A 2.9 
SLC22A4 solute carrier family 22 (organic cation transporter). member 4 2.89 
MRGX4 MAS-related GPR. member X4 2.85 
ADORA3 adenosine A3 receptor 2.84 
CDKNJA cyclin-dependent kinase inhibitor I A (p21. Cip I ) 2.84 
AMPH amphiphysin (Stiff-Man syndrome with breast cancer 128kDa autoantigen) 2.81 
FOSL/ fos-like antigen I 2.78 
BIN3 bridging integrator 3 2.75 
JNHBA inhibin beta A (activin A. activin AB alpha polypeptide 2.72 
CEGFJ CUB domain and EGF-like repeat containing 3 2.7 
KCNN4 potassium intermediate/small conductance calcium-activated channel. subfamily N. member 4 2.68 
PTX3 pentraxin-related gene. rapidly induced by IL-I beta 2.63 
CHS12 carbohydrate (N-acetylglucosamine-6-0) sulfotransferase 2 2.62 
TIMP3 TIMP metallopeptidase inhibitor 3 2.61 
NFKBJ nuclear factor of kappa light polypeptide gene enhancer in B-cells I 2.6 
HR hairless homolog (mouse) 2.6 
DUSP6 dual specificity phosphatase 6 2.57 
COL/3Al collagen. type XIII. alpha I 2.57 
DKKJ dickkopfhomolog I (Xenopus laevis) 2.51 
ENTPD7 ectonudeoside triphosphate diphosphohydrolase 7 2.5 
HESJ hairy and enhancer of split I 2.49 
FGFRLl fibroblast growth factor receptor-like I 2.49 
COLl9AJ collagen. type XIX. alpha I 2.48 
FBXLl4 F-box and leucine-rich repeat protein 14 2.45 
NCR3 natural cytotoxicity triggering receptor 3 2.42 
CCL20 chemokine (C-C motif) ligand 20 2.42 
ADARBJ adenosine deaminase. RNA-specific. B I (REDI homolog rat) 2.42 
CIASJ cold autointlammatory syndrome I 2.41 
MPZ myelin protein zero (Charcot-Marie-Tooth neuropathy IB) 2.41 
KIF4A kinesin family member 4A 2.41 
EM/UN2 elastin microfibril interfacer 2 I 2.4 
MIDI midline I (Opitz/BBB syndrome) 2.39 
PDE2A phosphodiesterase 2A. cGMP-stimulated 2.38 
CPA3 carboxypeptidase A3 (mast cell) 2.38 
RASD2 RASD family. member 2 2.38 
PHWAl pleckstrin homology-like domain. family A. member I 2.37 
PFKFB4 6_phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 2.36 
Lrz lysozyme (renal amyloidosis) 2.33 
SlOOA7 S I 00 calcium binding protein A 7 (psoriasin I) 2.32 
TGFBI transforming growth factor. beta-induced 2.31 
COLl2Al collagen. type XII. alpha I 2.31 
CA9 carbonic anhydrase IX 2.31 
ATP2A2 ATPa~e. Ca++ transporting. cardiac muscle. slow twitch 2 2.28 
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ARAP3 ARF-GAP. RHO-GAP. ankyrin repeat and plekstrin homology domains-containing protein 3 2.28 
ADAMTS5 ADAM metallopeptidase with thrombospondin type I motif. 5 (aggrecanase-2) 2.21 
EEFlA2 eukaryotic translation elongation factor I alpha 2 2.19 
UBE2D3 ubiquitin-conjugating enzyme E2D 3 (U8C4/5 homolog, yeast) 2.18 
ART3 ADP-ribosyltransferase 3 2.18 
CTSE cathepsin E 2.16 
HIC I-mfa domain-containing protein 2.16 
IGFl insulin-like growth factor I (somatomedin C) 2.14 
GNAl3 guanine nucleotide binding protein (G protein). alpha inhibiting activity polypeptide 3 2.14 
NTRKl neurotrophic tyrosine kinase. receptor. type I 2.14 
PHWA3 pleckstrin homology-like domain. family A. member 3 2.13 
THAPJO THAP domain containing 10 2.12 
SF3B4 splicing factor 3b. subunit 4. 49kDa 2.11 
TIE tyrosine kinase with immunoglobulin and epidermal growth factor homology domains 2.11 
MSCP solute carrier family 25. member 37 2.1 
RlSl Ras-induced senescence I 2.1 
SLC26A2 solute carrier family 26 (sulfate transporter). member 2 2.1 
PRKDC protein kinase. DNA-activated. catalytic polypeptide 2.!l9 
CTGF connective tissue growth factor 2.08 
NOTCH2 Notch homolog 2 2.08 
MYOZ2 myozenin 2 2.07 
CHGN chondroitin beta 1.4 N-acetylgalactosaminyltransferase 2.06 
SYTI synaptotagmin I 2.06 
PTGFRN prostaglandin F2 receptor negative regulator 2.05 
GCMl glial cells missing homolog I (Drosophila) 2.05 
WNT5B wingless-type MMTV integration site family. member 58 2.05 
/TGB3 integrin beta3 2.05 
NES nestin 2.04 
SLC37A3 solute carrier family 37 (glycerol-3-phosphate transporter), member 3 2.03 
IFNGR2 interferon gamma receptor 2 (interferon gamma transducer I) 2.02 
RGS5 regulator of G-protein signalling 5 2.02 
LEFI lymphoid enhancer-binding factor I 2.02 
TGFA transforming growth factor. alpha 2.01 
FCERlG Fc fragment of IgE. high affinity I. receptor for; gamma polypeptide 2 
ACTNl actinin. alpha I 2 
APXL apical protein-like (Xenopus laevis) 2 
CIP98 CASK-interacting protein CIP98 2 
HYPM Huntingtin interacting protein M 2 
DEFB/24 defensin. beta 124 1.99 
RWl RWI protein 1.99 
DHX9 DEAH (Asp-Glu-Ala-His) box polypeptide 9 1.98 
MSN moesin 1.98 
ARHE ras homolog gene family. member E 1.98 
ZNFl61 zinc finger protein 161 1.97 
BOK BCL2-related ovarian killer 1.97 
AK3 adenylate kinase 3 1.97 
DKFZP434F03l8 hypothetical protein DKFZp434F0318 1.97 
PFN2 profilin 2 1.96 
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HRB2 HIV -I rev binding protein 2 1.96 
TNFRSFJOB tumor necrosis factor receptor superfamily. member 1.95 
PHCl polyhomeotic-like I (Drosophila) 1.95 
RBM3 RNA binding motif (RNPI. RRM) protein 3 1.95 
ZFP36 zinc linger protein 36. C3H type. homolog (mouse) 1.95 
AFURSl ATPase family homolog up-regulated in senescence cells 1.95 
MU17 myeloid/lymphoid or mixed-lineage leukemia 1.94 
SIPA1L2 signal-induced proliferation-associated I like 2 1.94 
RAJ3 retinoic acid induced 3 1.93 
SIAT4 sialyltransferase 4A (beta-galactoside alpha-2.3-sialyltransferase) 1.93 
UBE2El ubiquitin-conjugating enzyme E2E I (UBC4/5 homolog. yeast) 1.92 
MCL} myeloid cell leukemia seguence I (BCLZ-related) 1.9 
BHUlB2 basic helix-loop-helix domain containing. class B. 2 1.9 
PSMD5 proteasome (prosome. macropain) 26S subunit. non-ATPase. 5 1.9 
SlOOA4 SIOO calcium binding protein A4 (calcium protein. calvasculin. metastasin. murine placental homolog) 1.9 
GAL galactosidase 1.89 
CCNE2 cyclin E2 1.89 
CST6 cystatin ElM 1.89 
LPL lipoprotein lipase 1.89 
SlOOA2 SIOO calcium binding protein A2 1.89 
SETBPl SET binding protein I 1.89 
RAPGEF4 Rap guanine nucleotide exchange factor (GEF) 4 1.88 
CYP26Al cytochrome P450. family 26. subfamily A. polypeptide I 1.88 
PLOD procollagen-Ivsine. 2-oxoglutarate 5-dioxygenase (lysine hydroxylase. Ehlers-Danlos syndrome type VI) 1.88 
FIBL-6 hemicentin I 1.87 
SLCI5A4 solute carrier family 15. member 4 1.87 
DC-TM4F2 tetraspanin similar to TM4SF9 1.87 
NHS Nance-Horan syndrome (congenital cataracts and dental anomalies) 1.87 
EMP2 epithelial membrane protein 2 1.86 
CAPN5 calpain 5 1.86 
SYN3 synapsin III 1.85 
HMGA2 high mobility group AT-hook 2 1.85 
DGCR8 DiGeorge syndrome critical region gene 8 1.85 
EIF4G2 eukaryotic translation initiation factor 4 gamma. 2 1.84 
HWEP3 human immunodeliciency virus type I enhancer binding protein 3 1.82 
HTR7 5-hydroxytryptamine (serotonin) receptor 7 1.81 
SLC39AI2 solute carrier family 39 (zinc transporter), member 12 1.81 
GPRJOl G protein-coupled receptor 101 1.8 
SAAl serum amyloid AI 1.79 
PPP1RI5A protein phosphatase I. regulatory (inhibitor) subunit 1.78 
ADSS adenylosuccinate synthase 1.76 
FAT FAT tumor suppressor homolog I (Drosophila) 1.74 
DPFI 04. zinc and double PHD fingers family I 1.71 
SDCCAG33 serologicallv defined colon cancer antigen 33 1.71 
POPDC2 popeye domain containing 2 
1.71 
HNRPAI heterogeneous nuclear ribonucleoprotein A I 1.7 
PRPS2 phosphoribosyl pyrophosphate synthetase 2 
1.69 
Y1'521 
1.69 
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BIRC6 baculovirallAP repeat-containing 6 (apollon) 1.53 
SlRT4 sirtuin (silent mating type infonnation regulation 2 homolog) 4 -1.78 
WARS2 tryptophanyl tRNA synthetase 2 (mitochondrial) -1.85 
RNFl49 ring finger protein 149 -1.88 
NME5 non-metastatic cells 5. protein expressed in (nucleoside-diphosphate kinase) -1.88 
CARDI5 caspase recruitment domain family. member 15 -1.88 
TBXIS T-box 18 -1.88 
RBM4 RNA binding motif protein 4 -1.88 
SRPI4 signal recognition particle 14kDa (homologous Alu RNA binding protein) -1.88 
JTGBIBPJ integrin beta I binding protein I -1.88 
ABHD2 abhydrolase domain containing 2 -1.88 
CHRNB3 cholinergic receptor. nicotinic. beta polypeptide 3 -1.92 
RPI21 ribosomal protein L21 -1.92 
RPI2J ribosomal protein L21 -1.92 
M12A metallothionein 2A -1.92 
HlST1H2BI synonyms: H2BIk. H2BFK: Homo sapiens histone I. H2bi (HI5T1H2BI). mRNA. -1.92 
TUBDJ tubulin. delta I -1.96 
STAU staufen. RNA binding protein (Drosophila) -1.96 
BTN3A2 butyrophilin. subfamily 3. member A2 -1.96 
CDC42 CDC42 binding protein k.inase alpha (DMPK-like) - 2 
RPLlO ribosomal protein L10 - 2 
HIBCH 3-hydroxyisobutyryl-Coenzyme A hydrolase - 2 
IFJTMI interferon induced transmembmne protein I - 2.04 
CDH23 cadherin-Iike 23 - 2.04 
LGP2 likely ortholog of mouse D IIIgp2 - 2.04 
HIAN3 human immune associated nucleotide 6 - 2.04 
lRF2BP2 interferon regulatory factor 2 binding protein 2 - 2.04 
RAPGEFI Rap guanine nucleotide exchange factor (GEF) I - 2.04 
ZNF434 zinc finger protein 434 - 2.08 
COBL cordon-bleu homolog (mouse) - 2.08 
FAM3JC family with sequence similarity 31. member C - 2.08 
HLXB9 homeo box HB9 - 2.12 
MUT7 myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog. Drosophila); translocated to. 7 - 2.12 
RPS23 ribosomal protein 523 - 2.12 
ZNF222 zinc finger protein 222 - 2.12 
PCDHGC3 protocadherin gamma subfamily C. 3 - 2.12 
NACA nascent-polypeptide-associated complex alpha polypeptide - 2.12 
IMID3 jumonji domain containing 3 - 2.12 
CPEB2 cytoplasmic polyadenylation element binding protein 2 - 2.12 
TM4SF4 transmembrane 4 L six family member 4 - 2.17 
MAX MYC associated factor X - 2.17 
HIS12H3C Histone 2. H3c (HIST2H3C) - 2.17 
MTF mitochondrial ferritin - 2.17 
UPF3B UPF3 regulator of nonsense transcripts homolog B (yeast) - 2.22 
ACATJ acetyl-Coenzyme A acetyltransferase I (acetoacetyl Coenzyme A thiolase) - 2.22 
HPGD hydroxyprostaglandin dehydrogenase 15-(NAD) - 2.22 
PRG-3 plasticity related gene 3 - 2.22 
UBE2V2 ubiquitin-conjugating enzyme E2 variant 2 - 2.27 
l36 
DDX42 DEAD (Asp-Glu-Ala-Asp) box polypeptide 42 
- 2.27 
KlS kinase interJcting with leukemia-associated gene (stathmin) 
- 2.27 
FUTIO fucosyltransferase I 0 
- 2.32 
CD33 CD33 antigen (gp67) 
- 2.32 
MRPLSI mitochondrial ribosomal protein LSI 
- 2.32 
AEBP2 AE binding protein 2 
- 2.32 
AAKI An associated kinase I 
- 2.32 
FES feline sarcoma oncogene 
- 2.38 
TUBEI tubulin. epsilon I 
- 2.38 
ZNF347 zinc finger protein 347 
- 2.38 
COX7B2 cytochrome c oxidase subunit V IIb2 
- 2.38 
STMNI stathmin l/oncoprotein 18 
- 2.38 
RAB4A RAB4A. member RAS oncogene family 
- 2.38 
BPILI bactericidal1penneability-increasing protein-like I 
- 2.38 
RPLIOL ribosomal protein Ll O-like 
-2.43 
RPL36AL ribosomal protein L36a-like 
-2.43 
HIST1H4D histone I. H4d 
-2.43 
GPR2 G protein-coupled receptor 2 
-2.43 
SNAPC5 small nuclear RNA activating complex. polypeptide 5. 19kDa 
- 2.5 
CREBI cAMP responsive element binding protein I 
- 2.5 
SCOl SCQ cytochrome oxidase deficient homolog I (yeast) 
- 2.5 
CECR5 cat eye syndrome chromosome region. candidate 5 
- 2.5 
SNX/2 sorting nexin 12 
- 2.5 
ZNF263 zinc finger protein 263 
- 2.56 
TRPCI transient receptor potential cation channel. subfamily C. member I 
- 2.56 
WBPIl WW domain binding protein II 
- 2.56 
KRTHAI keratin. hair. acidic. I 
- 2.63 
N1MU-Rl protein kinase Njmu-RI - 2.63 
COX6C cytochrome c oxidase subunit Vic - 2.63 
CGI-38 brain specific protein - 2.63 
KPNB3 karyopherin (importin) beta 3 - 2.63 
THAP9 THAP domain containing 9 - 2.63 
RPS7 ribosomal protein S7 - 2.70 
WALS3 lectin. galactoside-binding. soluble. 3 (galectin 3) - 2.70 
RPP38 ribonuclease P/MRP 38kDa subunit - 2.70) 
TTCJ2 tetratricopeptide repeat domain 12 - 2.70 
NARG7 NMDA receptor· regulated gene 2 - 2.70 
NAT5 N-acetyltransferase 5 (ARDI homolog. S. cerevisiae) - 2.70 
AHSG alpha-2-HS-glycoprotein - 2.77 
H41 hypothetical protein H41 - 2.77 
CUTLI cut-like I. CCAAT displacement protein (Drosophila) - 2.77 
CDTI DNA replication factor - 2.77 
RASGRPI RAS guanyl releasing protein I (calcium and DAG-regulated) - 2.77 
NEKJ NIMA (never in mitosis gene a)-related kinase I - 2.77 
CALM2 calmodulin 2 (phosphorylase kinase. delta) - 2.77 
PEX7 peroxisomal biogenesis factor 7 - 2.77 
DNAJAl DnaJ (Hsp40) homolog. subfamily A. member I - 2.85 
ZP4 zona pellucida glycoprotein 4 - 2.85 
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RPL26 ri bosomal protei n L~o - 2.85 
TXNRDI thioredoxin reducta~ I - 2.85 
SIPAILl signal-induc.:d proliferation-associated I like I - 2.85 
LRRC2 leucine rich repeat <:ontaining 2 - 2.85 
ATRN attractin - 2.94 
RPLl7 ri bosoma I protei n LI 7 - 2.94 
RPLl7 ribosomal protein L17 - 2.94 
MlZF MBD2 ~methyl-CpG·binding protein I-interacting zinc finger protein - 2.94 
CASCI cancer susceptibility candidate I - 2.94 
PIAC9 placenta-specilic 9 - 2.94 
SLC6Al3 solute carrier fami'" ° ~ neurotransmitter transponer, GABA), member 13 - 2.94 
SRD5AI steroid-5-alpha-reductase. alpha polypeptide I (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha I) - 3.03 
USPl6 ubiquitin specilic peptidase 1o - 3.03 
CNGA3 cyclic nucleotide gat.-d channel alpha 3 - 3.12 
HSDl7B7 hydroxysteroid (17-beta) dchydrogenase 7 - 3.22 
HlMAP2 immunity associated protein :! - 3.22 
STK22D serinclthreonine kinase ~~D (spermiogenesis associated) - 3.22 
ZNFl5Ll zinc finger protein 708 ~ KOX8) - 3.33 
ARID4B AT rich interacti\e domain 4B ~RBPI-like) - 3.33 
TNNTI troponin n. skeletal. slow - 3.44 
GLS glutaminase - 3.44 
SWAP70 SWAP-70 protein - 3.44 
ZNFl9 zinc lingcr protein 19 ~ KOX 12) - 3.70 
ILl5 interleukin 15 - 3.84 
SPA 17 sperm autoantigenic protein 17 - 3.84 
GALNTl3 UDP- N .acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 13 (GaINAc-T 13) -4 
P29 GClP-interacting protein p29 isoform I -4 
SST somatostatin - 4.16 
PSIPI PC4 and SFRSI interacting protein I - 4.16 
ZNF237 zinc finger protein 237 - 6.25 
APOBEC3G apolipoprotein B mRNA editing enzyme. catalytic polypeptide-like 3G -7.14 
PVALB parvalbumin - 7.14 
TTUI tubulin tyrosine ligase-like family. member I - 8.33 
HlSTIH2BG histone I. H2bg - 9.09 
TMOD2 tropomodulin ~ ~neuronal) - 12.5 
AMACR alpha-methylacyl-CoA racemase - 16.66 
Table 3.3. List of the 321 modulated genes resulting from the MicroArray 
• 610N d 2 NRAS610FF d companson between 21NRAS an 1 . Fol changes are calculated as 
• SoION/2 N S610FF the ratIo of the raw values 21 NRA I RA . 
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IV. AMPK ROLE IN MELANOMA. 
4.1 Introduction 
The AMP-activated protein kinase (AMPK) is a fuel-sensing enzyme with a 
major role in the regulation of cellular lipid and protein metabolism. It is activated under 
conditions that deplete cellular A TP and elevate AMP levels leading to the rise of 
AMP:A TP ratio. such as glucose deprivation, heat shock, hypoxia and ischemia (Davies 
et aI., 1989; Kemp et al.. 2(03). and also by hormones such as leptin (Minokoshi et aI., 
2(02), adiponectin (Yamauchi et al.. 2(02), catecholamine (Ruderman et aI., 2003), and 
interleukin-6 (Kelly et aI.. 2004). AMPK is activated through phosphorylation by at least 
two upstream AMP-activated protein kinase kinase (AMPKK) which are the tumor 
suppressor LKBI (Hawley et aI., 2003) and the Ca2+/calmodulin-dependent protein 
kinase kinase (CaMKK) (Hurley et aI., 2005). Once activated, AMPK switches on 
catabolic pathways, which generate A TP while switching off A TP-consuming processes. 
Mammalian AMPK is a heterotrimer complex containing the catalytic u- subunit and the 
regulatory p- and y- subunits (Hardie et aI., 2003.). Each of these subunits exists in at 
least two isoforms (al, a2, PI. p2. yl, y2. y3) encoded by distinct genes (Figure 4.1). The 
al and u2 subunits contain a conventional kinase domain at the N-terminus while the C-
terminus regions are required to form a complex with the p and the y subunits (Figure 
4.1) (Crute et al.. 1998). The p-subunits contain two conserved regions: the ASC domain, 
which is involved in the interaction with a and y subunits, and the KIS domain, which is a 
glycogen-binding domain (GBD). The y subunit contain four tandem repeats of the 
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cystathionine p-synthase (CBS) sequence motif (Bateman, 1997), which represent the 
regulatory AMP- and ATP- binding sites of the AMPK complexes (Scott et aI., 2004). A 
diverse array of different AMPK complexes arises from the possible combinations of the 
isoforrns along with splice variants and the use of different promoters. 
The activation of AMPK through 5'-AMP can occur in three different ways, all of which 
are antagonized by high A TP concentrations. First, AMP binding causes allosteric 
activation of mammalian AMPK with a magnitutide of this effect variable between the 
different AMPK isofonns. Complexes containing the al and a2 subunits, which differ in 
their subcellular localization. have also different dependence on AMP activation: 
complexes containing the a2 subunit are partly localized in the nucleus and are activated 
5- to 6- fold by AMP. whereas complexes with al are not in the nucleus and are only 
activated 1.5 to 2-fold by AMP (Salt et a1.. 1998). Second, AMP binding makes AMPK a 
better substrate for the upstream kinase. As previously shown (Hawley et aI., 1996), the 
tumor suppressor LKB I activates AMPK by phosphorylation of a subunit at a specific 
threonine residue (Thr 172) within the activation loop domain. The Thrl72 
phosphorylation causes at least 50- to 100- fold activation and it is stimulated by AMP 
while it is inhibited by high A TP concentrations. AMP stimulation occurs only if the 
intact uPr complex. and not the isolated kinase domain which lacks the AMP-binding 
sites. is used as the substrate (Hawley et al.. 2003). This shows that the effect is due to 
binding of AMP to the substrate AMPK and not to the upstream kinase. The third way 
through which AMP regulates AMPK activation is that AMP binding inhibits 
dephosphorylation of Thrl72 by protein phosphatases (Davies et aI., 1995). 
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Activation of AMPK through phosphorylation by an upstream protein kinase exerts 
different effects on various downstream targets, either by direct phosphorylation of 
metabolic enzymes or by acting on either gene expression or mRNA stability or protein 
translation. In general, activated AMPK can down-regulate biosynthetic pathways such as 
fatty acid and cholesterol biosynthesis, as well as can switch on catabolic pathways which 
generate ATP, such as fatty acid oxidation, glucose uptake and glycolysis (Figure 4.2). 
For example, AMPK upregulates the expression of the co-activator paCla (Terada et aI., 
2002) which is involved in the increased expression of mitochondrial genes in muscles 
(Zong et aI., 2002), yet it downregulates the transcription factors SREBP-I c (Zhou et aI., 
2001) and HNF4a (Leclerc et aI., 2001) which are related to the decreased expression of 
genes involved in lipogenesis, glucose uptake and glycolysis in liver. In addition, AMPK 
phosphorylates the ubiquitous co-activator p300 at Ser89, reducing its ability to bind to 
nuclear hormone receptors and thus activate their target genes (Yang et aI., 200 I). 
AMPK activation can also affect protein expression by regulating mRNA stability. 
Although the mechanism is not yet defined, it has been shown that activated AMPK 
reduces cytoplasmatic levels of the RNA-binding protein HuR which stabilizes specific 
mRNAs in the cytoplasm by binding to their 3' -un translated regions (Wang et aI., 2(02). 
Among HuR target mRNAs there are proteins, which regulate cell cycle like cyclin A, 
cyclin Bland p21. It has been shown (Wang et aI., 2003) that activation of AMPK by an 
elevated AMP:ATP ratio in senescent fibroblasts can explain many features of the 
senescent phenotype in vitro. In addition, inhibition of translation as a consequence of 
AMPK activity can occur by at least two mechanisms: phopshorylation and activation of 
elongation factor-2 kinase which stops the elongation step in translation (Horman et al.. 
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2002; Browne et aI., 2004), and inhibition of the mammalian target of rapamycin 
(mTOR) pathway (Bolster et aI., 2002; Kimura et aI., 2(03), which is a major positive 
stimulus for protein synthesis, cell growth and cell size. 
Several recent findings report a link between AMPK and the growth and/or survival of 
cancer cells. The relationship between AMPK and cancer is due to the fact that many 
cancers are characterized by increased expression or activity of enzymes, like fatty acid 
synthase (FAS), acetyl-CoA carboxylase (ACC) and mTOR, which are inhibited through 
phosphorylation by AMPK. Moreover, AMPK signaling involves two tumor suppressors: 
LKB I, upstream, and TSC2, downstream. LKB 1 was first identified as the gene mutated 
in Peutz-Jeghers syndrome (PJS), an autosomal-dominant genetic disorder characterized 
by multiple hamartomatous polyps in the gastrointestinal tract and an increase risk of 
developing malignant tumors (Boudeau et aI., 2(03). The mechanism by which LKBI 
suppresses tumorigenesis is unclear but, at least in part, appears to be mediated by 
inhibition of PI3K and mTOR. TSC2, also known as tuberin, is phosphorylated by 
AMPK and negatively regulates protein synthesis by inhibiting mTOR (lnoki et aI., 
2(03). In addition. TCS2 is inhibited through phosphorylation by AKT, leading to 
activation of mTOR and an increase of protein synthesis. The regulation of mTOR and 
TSC2 by AMPK might have important implications because the PI3K-AKT signaling 
pathway is constitutively active in many cancers, most notably those that have 
inactivating mutations of the PTEN gene. For these reasons, AMPK activation can be of 
relevant impact in cancer cells where PI3K-mTOR pathway is often dysregulated. 
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4.2 Results 
4.2.1 AICAR and Phenformin activate and phosphorylate AMPK. 
As presented in Chapter 3.2.2.3, Thr 172-phosphorylated AMP-activated protein 
kinase (AMPK) was expressed in both senescent inducible 21NRAS610N (15th in vitro 
passage) and constitutive 2INRASQ6IR (14th in vitro passage) "double mutant" cells, but 
was not detected in both pre-senescent 21NRAS61oN (9th in vitro passage) and 
21NRASQ6IR (8th in vitro passage) as well as in 2lNRAS610FF cells (9th and 15th in vitro 
passage). These data have suggested that AMPK may represent a possible mediator of 
proliferation arrest in human melanoma. Therefore, the role of AMPK molecule, 
previously shown as modulated in the double mutated model system, was further 
investigate in a panel of human melanoma cell lines in order to eventually identify 
possible mechanisms that might reactivate a senescent program in tumor cells. 
5-aminoimidazole-4-carboxamide-I-p-D-ribofuranoside (AICAR) is a synthetic 
activator of AMPK. Upon entering the cell, AICAR is converted by adenosine kinase to 
ZMP, a cellular mimetic of AMP, which activates AMPK (Corton et aI., 1995). 
Phenformin is a closely related analog of Metformin, which activates AMPK by an 
unknown mechanism likely not involving changes in intracellular levels of AMP or the 
ATP:ADP ratio (Hawley et aI., 2002; Fryer et al., 2002). 
In order to achieve exogenous activation of AMPK, melanoma cells were treated with 
different doses of either AICAR or Phenformin drugs. Increase of both kinase enzymatic 
activity and phosphorylation levels of AMPK as well as increase of phosphorylation 
levels of its downstream target acetyl-CoA carboxylase (ACC) were tested in those 
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samples. To this end. total AMPK protein was immunoprecipitated from melanoma cell 
lysates using antibodies against a I and a2 subunits of the protein. Immunocomplexes 
were then tested by a specific kinase assay using the AMARA peptide 
(AMARAASAAALARRR) as a substrate of AMPK. As a consequence of either AICAR 
or Phenformin treatment. AMPK kinase activity was boosted. Representative results of 
the IP kinase assay in two melanoma cell lines (l402R, lOO7P) treated or not with 
different doses of Phenformin are shown in Figure 4.3. AMPK kinase activity increased 
in a drug dose-dependent manner. The highest levels of AMPK activity could be 
achieved after 2 hour treatment with 5 mM Phenformin. Similar results were obtained in 
the same panel of melanoma cells after AICAR treatments with the same range of doses 
(data not shown). However. as Figure 4.3 shows. both basal and drug-induced kinase 
activities were lower in melanoma cells than in control cells, i.e. Hek293 cells treated or 
not with 5 mM Phenformin for 2 hours. This observation suggests that melanoma cells 
might have an intrinsic mechanism to prevent AMPK activation or to impair drug 
response in the cell. 
In order to assess whether the observed enzymatic activation upon either AICAR or 
Phenformin treatment was concomitant with increment of AMPK phosphorylation levels, 
melanoma cells were treated with different doses of either drugs. In response to drug 
treatment. phosphorylation levels of both the AMPK a-subunit in Thr 172 (pAMPK) and 
acetyl CoA-carboxylase in Ser79 (pACC) were evaluated by Western blot. Since ACC is 
a direct downstream target of AMPK, increment of pACC levels represents a direct 
measurement of AMPK phosphorylation state. As shown in Figure 4.4 A, pACC and 
pAMPK levels were up-regulated in 4405P after treatment with 5 mM AICAR for 2 
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hours. Increased expre~sion levels of pAMPK and pACC are shown in 20842P and 
1402R melanoma cells treated with I mM.5 mM and to mM AICAR for 2 hours (Figure 
4.4 A). Modulation of phosphorylation levels of both pACC and pAMPK was quantified 
by infra-red imaging using Li-Cor Odyssey system. as the ratio of the signal band 
intensity relative to the phosphorylated protein and the correspondent band relative to the 
total protein. Resultant values are visualized as hystogram graphs (Figure 4.4 B). In each 
experiment. lysates from human liver cells treated or not with 5 mM AICAR were used 
as a control for increased phosphorylated ACC and AMPK expression. Other melanoma 
cell lines resulted similarly sensitive to I mM. 5 mM and to mM AICAR treatment for 2 
hours. In addition. similar results were also obtained upon Phenformin treatment (data not 
shown). 
Taken together. these data indicated that both AICAR and Phenformin compounds are 
effective in activating AMPK in melanoma cells in term of both enzymatic activity and 
phosphorylation levels. 
4.2.2 Drug induced·AMPK activation impacts on cell proliferation in melanoma 
cells. 
In dtm growth propenies of melanoma cells after treatment with either AICAR or 
Phenformin differed from correspondent non treated cells. As evaluated by MTSIPMS 
test. OD.s~lnm of eight melanoma cell lines. human fibroblasts and normal melanocytes 
gradually decrea~ed in dose- and time-dependent manner. In Figure 4.5 A growth curves 
relative to two representative melanoma cell lines are shown. 4405P and 20842P samples 
were treated with AICAR or Phenformin for 8 days. Since the 3rd day of treatment, 
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OD~9Onm of melanoma cells cultured with I mM, 2 mM and 5 mM AICAR were 
significantly lower than non treated cells (Figure 4.5 A, left panel). Similar behavior was 
observed when cells were treated with Phenformin, even before the 3rd day (Figure 4.5 A, 
right panel). Interestingly AICAR and Phenformin at the concentrations of 1 mM, 2 mM 
and 5 mM induced progressive decrease of cell proliferation in normal human fibroblasts 
and in normal melanocytes as well (Figure 4.5 A and B, lowest panels), indicating that 
neoplastic cells retain responsiveness to AICAR and Phenformin as the normal cells. 
Maximal levels of cell proliferation inhibition, measured as the decrease of OD490nm, 
were reached after 8 days of treatment with either AICAR or Phenformin. The reduction 
of OD.tYOnm was calculated for each dose of AMPK activators as the percentage of the 
ratio of OD.t'Xlnm values between treated and not treated cells. In the 8th day since 
treatment. proliferation rate in treated cells was significantly lower than in not treated 
cells. OD.t'Xlnm values decrea.."ied in dose-dependent manner, as summarized for two 
representative melanoma cell lines in Figure 4.5 B. 
For both AICAR and Phenformin drugs, the effects of additional doses were 
verified. Lower doses such as 0.1 mM, 0.2 mM and 0.5 mM of both AMPK activators 
were tested and did not seem to affect proliferation rate of either melanoma cells or 
fibroblasts and normal melanocytes (Figure 4.6 A, for representative results relative to 
fibroblasts). On the other hand. concentrations higher than 5 mM of both drugs clearly 
induced cell detachment and apoptotic cell death (data not shown). Notably, melanoma 
cells treated with I mM AICAR remained viable, as assessed by the observation of 
trypan-blue colored cells. and did not die for apoptosis even after 8 days of treatment 
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(Figure 4.6 B). In contrast, the same dose of Phenformin was effective in inducing cell 
death by apoptosis and necrosis (Figure 4.6 B). 
Taken together, these data showed that drug-induced AMPK activation 10 
melanoma cells is effective in the induction of a reduction of cell proliferation at least in 
vitro. In particular, upon AICAR- (I mM for eight days) but not Phenformin-induced 
AMPK activation. melanoma cells remain viable, still not undergo to apoptotic process 
and stop proliferating as assessed by MTSIPMS test. 
4.2.3 Activated AMPK regulates cell cycle progression through the up-regulation 
of the cell cycle inhibitor p21. 
The observed decrease of proliferation rate as a consequence of AMPK activation 
in melanoma cells was accompanied by a progressive cell cycle arrest. A panel of 
melanoma cell lines was tested for cell cycle profile upon 1 mM AICAR and 0.5 mM 
Phenformin treatment for 8 days. In such conditions, all the tested melanoma cell lines 
blocked cell cycle progression in either the GoIG, phase or the S phase. Representative 
cell cycle profiles for such behaviors are shown Figure 4.7 A, upper or lower panel 
respectively. Among a group of 16 analyzed melanoma cell lines, a subset of 5 samples 
stopped cycling by reducing the percentage of cells in S phase after 8 days of 1 mM 
AICAR treatment. from 37.97-54% to 7.67-14.53% (AICAR) or 8.93-15.40% 
(Phenformin). (Figure 4.7 B, left panel). This was not observed in non treated cells. 
Similar effects were seen upon Phenformin treatment at 0.5 mM (Figure 4.7 B, left 
pane)), which dose is not associated to apoptosis, as previously observed. The second 
subset of melanoma samples displayed 11 out of 16 cell lines which accumulated in the S 
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phase with almost no cells detected in G2/M phase: from 44.49-48.1 % to 78.24-80.91 
(AICAR) or 69.86-71.26Ck (Phenfonnin) (Figure 4.7 B, right panel). 
To better unravel the molecular mechanisms of cell cycle arrest in AMPK-
activated melanoma cells. expression levels of some signaling molecules was tested. So 
far, in agreement with the observed cell cycle arrest, an increase of expression levels of 
the cell cycle inhibitor protein p21 was observed as a consequence of AICAR treatment 
in a dose-dependent manner in all melanoma samples (Figure 4.7 C). Upon AICAR 
treatment, ACC phosphorylation was up-regulated as a consequence of AMPK activation, 
and an increment of p21 levels was observed after 24 hours treatment with 1 mM and 2 
mM AICAR. Figure 4.7 C shows a representative experiment for 4405P melanoma cell 
line. 
These data showed that drug-induced AMPK activation in melanoma cells leads to 
the block of cell cycle progression. Cell cycle arrest is achieved through the up-regUlation 
of the cell cycle inhibitor p21. which occurs after 24 hours of AMPK activation. Other 
molecules involved in the presented cell cycle arrest mechanism remain to be identified. 
4.2.4 Evaluation of the SA-p-galactosidase activity upon AMPK activation. 
As previously shown for the "double mutant" NRAS/BRAF cell model (see 
Chapter 3.2.2.3). beside cell proliferation arrest presented in the previous paragraph, 
AMPK activation could be related to cellular senescence in melanoma samples. In order 
to test this hypothesis, SA-p-galactosidase (p-gal) activity as a marker for cell senescence 
(Dimri et aI.. 1995) was measured in different melanoma samples treated or not with 
AICAR. Measurements of p-galactosidase activity was perfonned either by testing for 
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development of blue color after cellular staining with the X-gal substrate, or by 
measuring fluorescence intensity of the fluorescein di -~-D-galactopyranoside (FOG) 
substrate by flow-cytometry. 
By either X-gal staining or FOG fluorescence intensity, variable basal levels of ~-gal 
activity in a panel of melanoma samples were detected. In Figure 4.8 A, representative 
images relative to one ~-gal negative (Dauv) and one positive (440SP) melanoma cell 
line displaying respectively lower and higher fluorescence intensity by FACS analysis are 
shown (Figure 4.8 A. upper panel). Such variability in ~-gal basal activity was evident 
also by X-gal staining (Figure 4.8 A. lower panel). Melanoma cells were then treated 
with I mM Phenformin and the development of blue color or the increase of fluorescence 
intensity were evaluated after II days. No visible differences were notable by cellular X-
gal staining. However. by using the more sensitive FDG fluorescent method, 
discrimination and quantification of the increment of ~-gal activity was possible. As 
shown in Figure 4.8 C. Dauv reached higher fluorescence intensity after II days of I mM 
Phenformin treatment. 
These results indicate that. in a panel of different melanoma samples showing 
different basal ~-gal activity. increased levels of such senescence marker can be achieved 
upon AMPK activation by Phenformin treatment for II days. Possibly, longer treatment 
time would allow for the achievement of a more striking effect, which could be 
detectable also by the standard X-gal cellular staining. Moreover. these data need to be 
considered preliminary and should be corroborated in a wider panel of melanoma cell 
lines. 
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4.2.5 Modulation of adhesion molecules as a response of pAMPK induction upon 
drug treatment. 
As observed in chapter 4.2.2. melanoma cells treated or not with either AICAR or 
Phenformin showed different cell morphology (data not shown). When treated with 
Phenformin. since the 3rd day of treatment melanoma cells assumed a more spherical 
shape in comparison to the not treated cells. This effect was not detected upon AICAR 
treatment (data not shown). After the 3rd day of treatment, Phenformin-treated cells 
spontaneously detached from the plate surface, while AICAR-treated ones still remain 
flat and anchored to the plastic. 
In order to evaluate the potential effects of AICAR and Phenformin treatment on 
cell adhesion. expression of such cell surface molecules as integrins and VE-Cadherin 
was evaluated in melanoma cell lines. As a confirmation of the reported observations. 
upon 4 days of Phenformin treatment, a2~1. a4~1. a5~1. a6~1. a4~4. ex3, ~4, exl~l and 
VE-Cadherin decreased their expression (Figure 4.9 A). In contrast, all the tested 
adhesion molecules were slightly up-regulated or not modulated upon AICAR treatment. 
in different melanoma cell lines (Figure 4.9 B). 
These data suggest that Phenformin and AICAR do not work through the same 
way on melanoma cells. Indeed, the two drugs have different mechanisms of action in 
cells. Hence. they might induce different cell effects independently of AMPK activation. 
Phenformin treatment demonstrated to produce more toxic effects on cells. Therefore. in 
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order to achieve the expected effects of reduced cell proliferation and cell cycle arrest 
without undesirable toxic side effects, AICAR treatment is preferable. 
4.3 Discussion 
Results obtained in this section of the thesis showed that AMPK activity and its 
phosphorylation levels can be in l'itro modulated in melanoma cells by using AICAR or 
Phenformin treatment. However, both basal and drug-induced kinase activities appeared 
to be lower in melanoma cells than in control non neoplastic cells, thus suggesting that 
melanoma cells might have an intrinsic mechanism to prevent AMPK activation or to 
impair drug response in tumor cells. The increment of AMPK phosphorylation causes 
elevated phosphorylated acetyl-CoA carboxylase (pACC) levels, which are indicative of 
AMPK activation. When AMPK is activated and phosphorylated, melanoma cells 
decrease proliferation rate and progressively arrest the cell cycle. The observed block of 
cell cycle in a panel of melanoma samples was in agreement with previous reports in 
literature. In more details. a number of studies showed an AICAR-dependent cell cycle 
arrest in the Go/G( phase (Jones et aI., 2005; Xiang et aI., 2004), as emerged in one subset 
of melanoma samples analyzed in the present work, while others reported cell cycle block 
with cell accumulation in the S-phase (Zakikhani et aI., 2006; Rattan et aI., 2(05), as the 
case of the second subset of melanoma cell lines. Furthermore, upon AMPK activation, 
the progressive inhibition of cell proliferation is accompanied by the up-regUlation of cell 
cycle inhibitor p21. 
Present data so far collected suggested that Phenformin and AICAR are likely not 
to work through the same pathway on melanoma cells. Although they both succeed in 
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activating AMPK protein. they seem to induce different cellular additional effects. Yet 
Phenformin treatment showed more toxic collateral effects on melanoma cells. In 
contrast. proliferation of melanoma cells can be inhibited by AICAR treatment without 
inducing apoptosis or necrosis. For this reason, in order to achieve the expected effects of 
reduced cell proliferation and cell cycle arrest upon AMPK activation without 
undesirable toxic side effects. AICAR treatment is preferred to be used. 
Given previous observation on the induction of senescence upon AMPK 
phosphorylation in the NRAS/BRAF "double mutant" melanoma cells (Petti et aI., 2006), 
AMPK activation in melanoma cells could be related to the senescent phenotype. 
Notably, the quantitative FDG method. which can be used for p-gal activity revealing, 
indicated that fluorescence intensity increases upon Phenformin treatment in melanoma 
samples. This effect suggests a progression towards senescence phenotype as a 
consequence of drug-induced AMPK activation. However, further evidence of such an 
effect has to be provided. 
Recent data from literature showed that AMPK activation results in proliferation 
inhibition and cell cycle arrest in both cancer and normal cells. After either AICAR 
treatment or cell infection with a vector expressing constitutive active AMPK, cell cycle 
of mouse embryonic fibroblasts (MEFs) arrested at the GdS transition despite sufficient 
glucose conditions involving a p53-dependent mechanism (Jones et aI., 2005). In 
agreement. AICAR stimulation inhibits cell growth and increases expression of p21 in 
human prostate cancer cells (Xiang et at.. 2004). Further evidence of the anti-proliferative 
AMPK-mediated effects of AICAR are provided from Rattan et aI., (2005) which show 
that activated AMPK can block different tumor cell lines in the S-phase of cell cycle by 
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inducing the expression of p21, p27 and p53 proteins and by inhibiting Akt 
phosphorylation. Also Metformin, a biguanide as well as Phenformin, commonly used in 
the treatment of type 2 diabetes mellitus, acts as a growth inhibitor in epithelial cells 
activating AMPK pathway (Zakikhani et al., 2006). These reports also supported the 
hypothesis that the mechanism of cell cycle arrest by AMPK activation involves 
accumulation of the tumor suppressor protein p53 by phosphorylation of its Ser-15 
residue. and the accumulated p53 protein up-regulates at least one of the CDKIs, such as 
p21. by a transcriptional mechanism. Whether phosphorylation of Ser-I5 on p53 is 
mediated by AMPK itself or by another protein kinase, which is co-immunoprecipitated 
with AMPK. has not been elucidated. Importantly, the aminoacidic sequence around Ser-
15 does not fit best with the AMPK consensus recognition motif. In agreement, in our 
study the induction of p21 levels after AICAR stimulation is likely to be p53-
independent. since no increase of Ser 15-p53 phosphorylation was observed in some 
treated melanoma cell lines (data not shown). Future studies are needed to provide the 
complete understanding for the regulation ofp53 protein by AMPK activation. 
Some evidences also show that LKB I associates with p53 (Karuman et aI., 2001) 
and induces p21 up-regUlation resulting in cell cycle arrest in a p53-dependent manner in 
G361 melanoma cells (Tiainen et al.. 2(02). Overexpression of wild type LKBI in two 
cancer cell lines. HeLa and G361. which do not express endogenous LKB I, suppressed 
the proliferation of these cells by inducing a G, cell cycle arrest (Tiainen et aI., 1999). 
Catalytically inactive LKB I mutants fail to suppress cell growth. indicating the 
proliferation-inhibitory and anti-tumor effects of LKB 1. This failure of LKB I activity 
impairs its downstream signalling on AMPK (Forcet et al.. 2005), but so far no published 
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work has shown the direct evidence for LKB I-AMPK association in AMPK-dependent 
cell cycle arrest. However, all melanoma cell lines analyzed in the present study 
expressed LKB I at protein level (data not shown), thus ruling out the possibility that the 
effects on cell proliferation upon AMPK activation can be impaired. 
An additional pathway potentially implicated in the cell growth inhibition 
dependent on AMPK activation is the PI3K-Akt pathway. Constitutive activation of this 
signaling pathway has been reported in many cancers including glioblastoma, melanoma, 
and advanced prostate cancer. AMPK inhibits mTOR signaling downstream of Akt, and 
inhibition of mTOR pathway has been reported to inhibit tumor growth and metastasis in 
experimental animal models as well as in cultured cells. In the next future, the 
involvement of such a pathway, which might have relevant importance in the control of 
cell growth. will be deeply investigated in melanoma cells. 
As discussed above, AMPK can regulate a variety of signaling pathways. 
Therefore, it will be interesting to determine which pathways regulated by AMPK are 
most involved in the inhibition of cancer cell proliferation. To this aim, further studies are 
required for a full comprehension of this issue. Deeper investigations about the molecular 
targets of activated AMPK are needed in order to elucidate the mechanism leading to the 
cell cycle arrest. Nevertheless, given the central role of AMPK in the control of cell 
proliferation and cell cycle. as supported also by our latest results, AMPK activation 
could represent a possible new target for the development of novel potential therapeutic 
strategy for cancer treatment. 
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dru g.., i.., indicated a.., pcrcel1lagt: I' positive cells. 
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6. CONCLUSIONS AND FUTURE PLANS 
The aim of the present study was to identify new possible molecular targets for 
inducing proliferation arrest in melanoma cells. In spite of their high frequency in human 
melanoma. oncogenic BRAF and NRAS mutations are generally mutually exclusive. The 
mutual exclusivity of NRA~IR and BRAFVtl..KlE suggests that their coexistence may not 
provide a selective advantage for tumor growth. or may even be selected against during 
tumorigenesis. In the first part of the project the mutual exclusion of the two mutations at 
the single cell level was demonstrated. Subsequently. in order to verify whether NRAS 
and BRAF activating mutations were synthetic lethal. a model system with constitutive or 
conditional co-expression of oncogenic NRAS and BRAF in the same cell was created. 
Growth arrest and senescence occurred in such double mutant cells. Further research was 
then focused on the identification of genes which are significantly modulated when both 
oncogenic NRAS and BRAF are expressed in the same cell. compared to cells with single 
mutations. Such modulated genes could represent relevant targets for suppressing cell 
proliferation. To this aim. molecular profiling by MicroArray analysis of double mutant 
cells compared to cells with a single mutated oncogene was performed. Such analysis led 
to the identification of candidate genes implicated in cell proliferation. cell cycle, cell 
death. response to stress. response to wound and immune response. Among these 
molecules. two specific targets. such as Lipocalin2 (LCN2) and LOXL3. were selected 
for further studies. Such molecules might play a relevant role in the control of cell 
proliferation not only in the double mutant cell model. but also in general in melanoma 
cells. For this reason. the impact of LCN2 and LOXL3 expression on tumor cell 
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phenotype need to be assessed in a wide panel of melanoma samples. Preliminary results 
showed that LeN2 can be silenced in melanoma cells expressing high basal levels of the 
protein. Biological consequences of the induced silencing have to be evaluated in 
melanoma cells. To this aim. in the next future a number of melanoma cell lines 
constitutively expressing high levels of LCN2 will be selected and transfected with 
specific siRNA in order to silence its expression. On the other hand, a set of melanoma 
cell lines identified as low expressors of LCN2 will be transfected with specific 
constructs for the expression of LCN2. Low and high LCN2 induced-expressor 
melanoma cells will be tested for different cell features such as cell proliferation, cell 
cycle. senescence. With this strategy it might be possible to clarify the role of LCN2 
protein in influencing tumor cell behavior. An analogous approach should be used for 
LOXL3 as well. In the optic of the investigation about proliferative impairment in 
melanoma cells. all the amount of data obtained from the microarray analysis provides a 
rich source of potential candidate genes which can mediate cell behavior characteristics 
as important as cell proliferation and cell cycle progression. Therefore, from the obtained 
data sets. other possible molecules which can reveal a tumor suppressive function can be 
extrapolated. Hence. further investigations may be focused on additional genes from this 
list, in order to enlarge the panel of potential mediators of cell proliferation arrest. The 
identification of new mediators of proliferation arrest in melanoma cells may open the 
way to the discovery of novel strategies for innovative therapeutic approaches in 
melanoma treatment. 
As presented in the second part of the thesis, AMPK was previously identified as a new 
possible mediator of the senescence/growth-arrest mechanism observed in the double 
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mutant model. Therefore. AMPK might play a relevant role in melanoma cells as 
concerning to cell proliferation control. So far, collected data showed that AMPK 
activation can lead to growth arrest in melanoma cells. Furthermore, AMPK activation in 
melanoma cells could be related to the senescent phenotype. For these reasons, in order to 
identify a possible mediator of proliferation arrest in human melanoma, the role of 
AMPK molecule was further investigated in a panel of human melanoma cell lines. 
AMPK expression and activation upon drug treatment in melanoma cells was evaluated 
and its role was tested as tumor suppressor. In addition to cell proliferation and cell cycle 
arrest evaluated by standard methods. the quantitative FDG assay, which can be used for 
p-gal activity revealing. indicated that upon AICAR or Phenformin treatment in 
melanoma samples there is a progression towards senescence phenotype. However, 
further evidence of such an effect has to be provided, testing the same effect on various 
melanoma cell lines. As discussed above. AMPK can regulate a variety of signaling 
pathways. Therefore. it will be interesting to determine which pathways regulated by 
AMPK are most involved in the inhibition of cancer cell proliferation. To this aim, in 
order to elucidate the mechanism leading to the cell cycle arrest, a macroarray study 
focused on cell cycle related molecules will be performed in the very next future. In 
addition. in ";\'0 consequences of the activation of AMPK upon AICAR treatment in 
mice need to be evaluated. Previous evidences suggest that injected tumors in mice 
treated with AICAR should stop growing or at least should modulate the expression of 
typical markers of proliferation such as PCNA, Ki67 and, on the opposite way, J3-gal. 
As a future implication of this study. given the central role of AMPK in the control of cell 
proliferation and cell cycle. which evidence is supported also by our latest results, AMPK 
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activation could represent a possible new target for the development of novel potential 
therapeutic strategy for cancer treatment. 
In conclusion. starting from a double mutant cellular model for inducing melanoma cells 
growth arrest. candidate genes linked to the NRASIBRAF mutations were identified as 
potentially involved in cell cycle and proliferation arrest and senescence in melanoma 
cells. Interesting targets. such as LCN2, LOXL3 and additional genes which can be 
extrapolated from all these amount of data, may be tested for their role in proliferation 
inhibition in melanoma cells. In addition, preliminary evidences already exist that AMPK 
might be a valid new possible target for drug therapy of human melanoma. 
168 
REFERENCES 
Adjei AA. Ras signaling pathway proteins as therapeutic targets. CUff Pharm Des 
2001:7:1581. 
Aitken J. Welch J. Duffy D. et al. CDKN2A variants in a population-based sample of 
Queen~land families with melanoma. J Natl Cancer Inst 1999;91 :446. 
Akslen LA. Angelini S. Straume O. et al. BRAF and NRAS mutations are frequent in 
nodular melanoma but are not associated with tumor cell proliferation or patient 
survival. J Invest Derrnatol 2005: 125:312. 
Albini A. Tumor and endothelial cell invasion of basement membranes. The matrigel 
chemoinvasion assay as a tool for dissecting molecular mechanisms. Pathol Oncol 
Res I 998;.t:230. 
AI-Hajj M. Wicha ~S. Benito-Hernandez A, et al. Prospective identification of 
tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100:3983. 
Anichini A, Mazzocchi A. Fossati G, Parrniani G. Cytotoxic T lymphocyte clones from 
peripheral blood and from tumor site detect intratumor heterogeneity of melanoma 
cells. Analysis of specificity and mechanisms of interaction. J Immunol 
1989: 1.t2:3692. 
Anichini A. Molla A. Mortarini R, et al. An expanded peripheral T cell population to a 
cytotoxic T lymphoc}1e (CTL>-defined, melanocyte-specific antigen in metastatic 
melanoma patients impacts on generation of peptide-specific CTLs but does not 
overcome tumor escape from immune surveillance in metastatic lesions. J Exp Med 
1999: 190:651. 
169 
Anichini A. Mortarini R. Maccalli C. et al. Cytotoxic T cells directed to tumor antigens 
not expressed on normal melanocytes dominate HLA-A2.1-restricted immune 
repertoire to melanoma. 1 Immunol 1996;156:208. 
Balch CM. Buzaid Ae. Soong Sl, et al. Final version of the American Joint Committee 
on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001 ;19:3635. 
Balch CM. Soong Sl. Gershenwald lE. et al. Prognostic factors analysis of 17,600 
melanoma patients: validation of the American 10int Committee on Cancer melanoma 
staging system. 1 Clin Oncol. 200 I; 19:3622. 
Ball Nl. Yohn 11. Morelli lG, et al. Ras mutations in human melanoma: a marker of 
malignant progression. 1. Invest. Dermatol 1994; 102:285. 
Bandoh N. Ogino T. Cho HS. et al. Development and characterization of human 
constitutive proteasome and immunoproteasome subunit-specific monoclonal 
antibodies. Tissue Antigens 2005:66: 185. 
Bamier lV. Papin e. Eychene A. et al. The mouse 8-raf gene encodes multiple protein 
isoforms with tissue-specific expression. 1 Bioi Chern. 1995;270:23381. 
Bartkova 1. Horejsi Z. Koed K. et al. DNA damage response as a candidate anticancer 
barrier in early human tumorigenesis. Nature 2005;434:864. 
Bastian Be. LcBoit PE. Pinkel D. Mutations and copy number increase of HRAS in Spitz 
nevi with distinctive histopathological features. Am 1 Pathol 2000; 157:967. 
Bateman A. The structure of a domain common to archaebacteria and the homocystinuria 
disease protein. Trends Biochem Sci 1997;22: 12. 
Becker Jc. Kirkwood 1M. Agarwala SS. Molecularly targeted therapy for melanoma: 
current reality and future options. Cancer 2006;107:2317. 
170 
Bennett DC. Genetics. development, and malignancy of melanocytes. Int Rev Cytol 
1993:146:191. 
Bennett DC. Human melanocyte senescencea and melanoma susceptibility genes. 
Oncogene 2003:22:3063. 
Bergers G. Hanahan D. Coussens LM. Angiogenesis and apoptosis are cellular 
parameters of neoplastic progression in transgenic mouse models of tumorigenesis. 
Int J Dev BioI 1998:42:995. 
Berns K. Hijmans EM, Mullenders 1. et al. A large-scale RNAi screen in human cells 
identifies new components of the p53 pathway. Nature 2004;428:431. 
Bhatia M. Wang Jc. Kapp U. et al. Purification of primitive human hematopoietic cells 
capable of repopUlating immune-deficient mice. Proc Natl Acad Sci USA 
1997:94:5320. 
Bittner M. Meltzer P. Chen Y. et al. Molecular classification of cutaneous malignant 
melanoma by gene expression profiling. Nature 2000;406:536. 
Blair A. Hogge DE. Ailles LE. et al. Lack of expression of Thy-l (CD90) on acute 
myeloid leukemia cells with long-tenn proliferative ability in vitro and in vivo. Blood 
1997:89:3104. 
Bloethner S. B. Chen. K. Hemminki, 1, et al. Effect of common B-RAF and N-RAS 
mutations on global gene expression in melanoma cell lines. Carcinogenesis 
2005:26: 1224. 
Boguski MS. McCnnick F. Proteins regulating Ras and its relatives. Nature 
1993:366:643. 
171 
Bolster DR. Crozier SJ. Kimball SR, Jefferson LS. AMP-activated protein kinase 
suppresses protein synthesis in rat skeletal muscle through down-regulated 
mammalian target ofrapamycin (mTOR) signaling. J Bioi Chern. 2002;277:23977. 
Bonnet D and Dick JE. Human acute myeloid leukemia is organized as a hierarchy that 
originates from a primitive hematopoietic cell. Nat Med 1997;3:730. 
Bos JL. Ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682. 
Boudeau J. Sapkota G. Alessi DR. LKB I, a protein kinase regulating cell proliferation 
and polarity. FEBS Lett 2003;546: 159. 
Box NF. Duffy DL. Chen W. et al. MCIR genotype modifies risk of melanoma in 
families segregating CDKN2A mutations. Am J Hum Genet 2001;69:765. 
Braig M. Lee S. Loddenkemper C. et al. Oncogene-induced senescence as an initial 
barrier in lymphoma development. Nature 2005;436:660. 
Bratt T. Lipocalins and cancer. Biochim Biophys Acta 2000;1482:318. 
Bringold F. Serrano M. Tumor suppressors and oncogenes in cellular senescence. Exp 
Gerontol 2000:35: 317. 
Brookes S. et al. INK4a-deficient human diploid fibroblasts are resistant to RAS-induced 
senescence. EMBO J 2002:21 :2936. 
Brose MS. Volpe P. Feldman M. et al. BRAF and RAS mutations in human lung cancer 
and melanoma. Cancer Res 2002;62:6997. 
Brown PO. Botstein D. Exploring the new world of the genome with DNA microarrays. 
Nat Genet 1999:21 :33. 
172 
Browne G1, Finn SG, Proud CG. Stimulation of the AMP-activated protein kinase leads 
to activation of eukaryotic elongation factor 2 kinase and to its phosphorylation at a 
novel site, serine 398. 1 BioI Chern 2004;279: 12220. 
Busca R, Ballotti R. Cyclic AMP a key messenger in the regulation of skin pigmentation. 
Pigment Cell Res 2000;13:60. 
Campisi 1. Cellular senescence as a tumor-suppressor mechanism. Trends Cell BioI 
2001; II :S27. 
Campisi 1. Senescent cells, tumour suppression, and organismal aging: good citizens, bad 
neighbors. Cell 2005; 120:513. 
Carr KM, Bittner M, Trent 1M. Gene-expression profiling in human cutaneous 
melanoma. Oncogene 2003;22:3076. 
Carreira S, Goodall 1. Aksan I, et a1. Mitf cooperates with RbI and activates p21Cipi 
expression to regulate cell cycle progression. Nature 2005;433:764. 
Casalino L. De Cesare D. Verde P. Accumulation of Fra-l in ras-transformed cells 
depends on both transcriptional autoregulation and MEK-dependent posttranslational 
stabilization. Mol Cell BioI 2003;23:4401. 
Castelli C. Sensi M, Lupetti R, et al. Expression of interleukin I alpha, interleukin 6, and 
tumor necrosis factor alpha genes in human melanoma clones is associated with that 
of mutated N-RAS oncogene. Cancer Res 1994;54:4785. 
Chang BD. Broude EV, Dokmanovic M. et at. A senescence-like phenotype distinguishes 
tumor cells that undergo terminal proliferation arrest after exposure to anticancer 
agents. Cancer Res 1999:59:3761. 
173 
Chang BD. Swift ME. Shen M. Fang J. Broude EV, Roninson m. Molecular 
detenninants of tenninal growth arrest induced in tumor cells by a chemotherapeutic 
agent. Proc Natl Acad Sci USA 2002:99:389. 
Chang BD. Watanabe K. Broude EV et a1. Effects of p2lWafl/CipllSdii on cellular 
gene expression: implications for carcinogenesis, senescence, and age-related 
diseases. Proc Natl Acad Sci USA 2000:97:4291. 
Chen ZP. McConell GK. Michell BJ. et al. AMPK signaling in contracting human 
skeletal muscle: acetyl-CoA carboxylase and NO synthase phosphorylation. Am J 
Physiol Endocrinol Metab 2000:279:EI202. 
Chen Z. Trotman LC. Shaffer 0, et a1. Crucial role of p53-dependent cellular senescence 
in suppression of Pten-deficient tumorigenesis. Nature 2005;436:725. 
Chin L. The genetics of malignant melanoma: lessons from mouse and man. Nat Rev 
Cancer 2003:3:559. 
Chin L. Garraway LA. Fisher DE. Malignant melanoma: genetics and therapeutics in the 
genomic era. Genes Dev 2006;20:2149. 
Chong H. Vikis HG. Guan KL. Mechanisms of regulating the Raf kinase family. Cell 
Signal 2003: 15:463. 
Chudnovsky Y. Adams AE. Robbins PB. et al. Use of human tissue to assess the 
oncogenic activity of melanoma-associated mutations. Nat Genet 2005;37:745. 
Collado M. Gil J. Efeyan A. et a1. Tumour biology: senescence in premalignant tumours. 
Nature 2005:436:642. 
Collins T. Berry PA. Hyde C. et al. Prospective identification of tumorigenic prostate 
cancer stem cells. Cancer Res 2005:65: 10946. 
174 
Contente S. Kenyon K. Rimoldi D. Friedman RM. Expression of gene rrg is associated 
with reversion of NIH 3T3 transfonned by LTR-c-H-ras. Science 1990;249:796. 
Corton JM. Gillespie JG. Hawley SA. Hardie DG. 5-aminoimidazole-4-carboxamide 
ribonucleoside. A specific method for activating AMP-activated protein kinase in 
intact cells? Eur J Biochem. 1995:229:558. 
Counter CM. Hirte HW. Bacchetti S. Harley CB. Telomerase activity in human ovarian 
carcinoma. Proc Natl Acad Sci USA 1994;91:2900. 
Cozzi SJ. Parsons PG. Ogbourne SM. et al. Induction of senescence in diterpene ester-
treated melanoma cells via protein kinase C-dependent hyperactivation of the mitogen-
activated protein kinao;e pathway. Cancer Res 2006;66: 10083. 
Crute BE. Seefeld K. Gamble J. et al. Functional domains of the alphal catalytic subunit 
of the AMP-activated protein kinase. J BioI Chern. 1998;273:35347. 
Csiszar K. Lysyl oxidases: a novel multifunctional amine oxidase family. Prog Nucleic 
Acid Res Mol BioI 200 I :70: I. 
Curtin JA. Fridlyand J. Kageshita T, et al. Distinct sets of genetic alterations in 
melanoma. N Engi J Med 2005:353:2135. 
Dancey JE. Therapeutic targets: MTOR and related pathways. Cancer BioI Ther 
2006:5: 1065. 
Danioni M. Oggionni M. Ranzani T. et al. BRAF alterations are associated with complex 
mutational profiles in malignant melanoma. Oncogene 2004;23:5968. 
Dannenberg JH. van Rossum A, Schuijff L, et al. Ablation of the retinoblastoma gene 
family deregulates G( I) control causing immortalization and increased cell turnover 
under growth-restricting conditions. Genes Dev 2000; 14:3051. 
175 
Davies H. Bignell GR. Cox C. et al. Mutations of the BRAF gene in human cancer. 
Nature 2(X)2:.t 17:949. 
Davies SP. Carling D. Hardie DG. Tissue distribution of the AMP-activated protein 
kinase. and lack of activation by cyclic AMP-dependent protein kinase, studied using 
a specific and sensitive peptide assay. Eur J Biochem 1989; 186: 123. 
Davies SP. Helps NR. Cohen PT. Hardie DG. 5'-AMP inhibits dephosphorylation, as well 
as promoting phosphorylation. of the AMP-activated protein kinase. Studies using 
bacterially expressed human protein phosphatase-2C alpha and native bovine protein 
pho!'\phatase-2AC. FEBS Lett 1995:377:421. 
Debouck C. Goodfellow PN. DNA microarrays in drug discovery and development. Nat 
Genet 1999:21 :S48. 
de Rooij J. Bos JL. Minimal Ras-binding domain of Rafl can be used as an activation-
specific probe for Ras. Oncogene 1997; 14:623. 
Di Leonardo A. Linke SP. Clarkin K. Wahl GM. DNA damage triggers a prolonged p53-
dependent G 1 arrest and longtenn induction of Cip 1 in normal human fibroblasts. 
Genes Dev 1994:8:2540. 
Dimri GP. Lee X. Basile G. et al. A biomarker that identifies senescent human cells in 
culture and in aging skin in vivo. Proc Natl Acad Sci USA 1995;92:9363. 
Di Micco R. Fumagalli M. Cicalese. Oncogene-induced senescence is a DNA damage 
response triggered by DNA hyper-replication. Nature 2006;444:638. 
Dobrowolski R. Hein R. Buettner R and Bosserhoff AK. Loss of pl4ARF expression in 
melanoma. Arch. Dennatol. Res 2002:293:545. 
176 
Dong J. Phelps RG. Qiao R. et a1.BRAF oncogenic mutations correlate with progression 
rather than initiation of human melanoma. Cancer Res 2003;63:3883. 
Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 
2003:3: II. 
Duncan EL. Reddel RR. Genetic changes associated with immortalization, a review. 
Biochemistry 1997:62: 1263. 
Dunn GP. Bruce AT. Ikeda H. et al.. Cancer immunoediting: from immunosurveillance to 
tumor escape. Nat Immunol 2002;3:991. 
Evan G. Littlewood T. A matter of life and cell death. Science 1998;281: 1317. 
Fang D. Nguyen TK. Leishear K. et al. A tumorigenic subpopulation with stem cell 
properties in melanomas. Cancer Res 2005;65:9328. 
Feinberg AP. Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004;4: 143. 
Feng YZ. Shiozawa T. Miyamoto T. et a1. BRAF mutation in endometrial carcinoma and 
hyperplasia: correlation with KRAS and p53 mutations and mismatch repair protein 
expression. Clin Cancer Res 2005: II :6133. 
Fieldler F. Hinz H. No intermediate channelling in stepwise hydrolysis of fluorescein di-
beta-D-galactoside by beta-galactosidase. Eur J Biochem 1994;222:75. 
Ranagan N. Healy E. Ray A. Pleiotropic effects of the melanocortin I receptor (MCIR) 
gene on human pigmentation. Hum Mol Genet 2000;9:2531. 
Rower DR. The lipocalin protein family: structure and function. Biochem J 1996;318; 1. 
Forcet C. Etienne-Manneville S. Gaude H. et at. Functional analysis of Peutz-Jeghers 
mutations reveals that the LKB 1 C-terminal region exerts a crucial role in regulating 
both the AMPK pathway and the cell polarity. Hum Mol Genet 2005;14: 1283. 
177 
Foulds L. The Experimental Study of Tumor Progression. Volumes I-ill. Academic Press 
1954. London. 
Fountain JW. Bale SJ. Housman DE. Dracopoli NC. Genetics of melanoma. Cancer Surv 
1990:9:645. 
Fox E. Curt GA. Balis FM. Clinical trial design for target-based therapy. Oncologist 
2002:7:40 I. 
Franza BR Jr. Maruyama K. Garrels 11. Ruley HE. In vitro establishment is not a 
sufficient prerequisite for transformation by activated ras oncogenes. Cell 
1986:44:409. 
Fridman R. Kibbey Me. Royce LS. et aI. Enhanced tumor growth of both primary and 
established human and murine tumor cells in athymic mice after coinjection with 
Matrigel. J Natl Cancer (nst 1991 :83:769. 
Friedberg EC. DNA damage and repair. Nature 2003;421:436. 
Friedl A. Stoesz SP. Buckley P. Gould MN. Neutrophil gelatinase-associated lipocalin in 
normal and neoplastic human tissues. Cell type-specific pattern of expression. 
Histochem J 1999:31 :4.H. 
Fryer LG. Parbu-Patel A. Carling D. The Anti-diabetic drugs rosiglitazone and metformin 
stimulate AMP-activated protein kinase through distinct signaling pathways. J BioI 
Chern 2002:277:25226. 
Garcia-Bormn Jc. Sanchez-Laorden BL, Jimenez-Cervantes C. Melanocortin-l receptor 
structure and functional regulation. Pigment Cell Res 2005: 18:393. 
Garnett MJ. Marais R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell 
2004:6:31.l 
178 
Garnett M1. Rana S. Paterson H. et al. Wild-type and mutant B-RAF activate C-RAF 
through distinct mechanisms involving heterodimerization. Mol Cell 2005;20:963. 
Garraway LA. Widlund HR. Rubin MA, et al. Integrative genomic analyses identify 
MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 
2005;436: 117. 
Gibbs CPo Kukekov VG. Reith 1D. et al. Stem-like cells in bone sarcomas: implications 
for tumorigenesis. Neoplasia 2005;7:967. 
Giblin AV. Thomas 1M. Incidence, mortality and survival in cutaneous melanoma. J Plast 
Reconstr Aesthet Surg 2007:60:32. 
Giordano T1. Kuick R. Thomas DG, et al. Molecular classification of papillary thyroid 
carcinoma: distinct BRAF. RAS, and RETIPTC mutation-specific gene expression 
profiles discovered by DNA microarray analysis. Oncogene 2005;24:6646. 
Goel VK. Lazar AJ. Warneke CL, et al. Examination of mutations in BRAF, NRAS, and 
PTEN in primary cutaneous melanoma. J Invest Dermatol 2006; 126: 154. 
Goldstein AM. Struewing 1P. Chidambaram A, et al. Genotype-phenotype relationships 
in U.S. melanoma-prone families with CDKN2A and CDK4 mutations. 1 Nat! Cancer 
Inst 2000:92: 1006. 
Gonzalez-Suarez E. Samper E. Flores 1M, Blasco MA. Telomerase-deficient mice with 
short telomeres are resistant to skin tumorigenesis. Nat Genet 2000;26: 114. 
Gorden A. Osman I. Gai W, et al. Analysis of BRAF and N-RAS mutations in metastatic 
melanoma tissues. Cancer Res 2003:63:3955. 
179 
Gorgoulis VG, Vassiliou LV, Karakaidos P, et al. Activation of the DNA damage 
checkpoint and genomic instability in human precancerous lesions. Nature 2005; 
434:907. 
Gray-Schopfer Ve. Cheong SC, Chong H, et al. Cellular senescence in naevi and 
immortalisation in melanoma: a role for p16? Br J Cancer 2006;95:496. 
Gray-Schopfer Ve. da Rocha Dias S, Marais R. The role of B-RAF in melanoma. Cancer 
Metastasis Rev 2005;24: 165. 
Gruis NA. van der Velden PA, Sandkuijl LA, et al. Homozygotes for CDKN2 (p16) 
germline mutation in Dutch familial melanoma kindreds. Nat Genet 1995;10:351. 
Gudjonsson T. Magnusson MK. Stem cell biology and the cellular pathways of 
carcinogenesis. APMIS 2005; 113:922. 
Guldberg P. thor Straten P. Birck A, et a1. Disruption of the MMACIIPTEN gene by 
deletion or mutation is a frequent event in malignant melanoma. Cancer Res 
1997:57:3660. 
Gupta PB. Kuperwasser e. Brunet JP, et al. The melanocyte differentiation program 
predisposes to metastasis after neoplastic transformation. Nat Genet 2005;37: 1047. 
Gwosdz e. Scheckenbach K. Lieven 0, et al. Comprehensive analysis of the p53 status in 
mucosal and cutaneous melanomas. Int J Cancer 2006;118:577. 
Hagemann e. Rapp UR. Isotype-specific functions of Raf kinases. Exp Cell Res 
1999:253:34. 
Hahn We. Counter CM. Lundberg AS, et al. Creation of human tumor cells with defined 
genetic elements. Nature 1999;400:464. 
Hahnan D. Weinberg RA. The Hallmarks of Cancer. Cell 2000; I 00:57. 
180 
Hajnal A. Klemenl R. Schafer R. Up-regulation of Iysyl oxidase in spontaneous 
revenants of H-ms-lmnsformed rol fibroblasts. Cancer Res 1993;53:4670. 
Hanai J. Mammolo T. Selh P. et al. Lipocalin 2 diminishes invasiveness and metastasis of 
Ra'HransfomK-d cells. J Bioi Chern. 2005;280: 13641. 
Haqq C. !'josr.lti ~1. Sudilovsky D. et al.The gene expression signatures of melanoma 
progression. Proc ~at1 Acad Sci USA 2005; 102:6092. 
Hardie DG. ~cw roles for the LKB I-->AMPK pathway. CUIT Opin Cell Bioi 
2(X)5: 17: 167. 
Hardie DG. Salt IP. Davies SP. Analysis of the role of the AMP-activated protein kinase 
in the response to cellular stress. Methods Mol Bioi 2000;99:63. 
Hardie DG. Scott JW. Pan DA. Hudson ER. Management of cellular energy by the AMP-
activated protein kinase system. FEBS Lett 2003;546: 113. 
Harley CB. FUlcher AB. Greider CWo Telomeres shorten during ageing of human 
fibrobla,ts. ~alure 1990:345:458. 
Ha~gawa Y. Takeda S. Ichii S. et aI. Detection of K-ras mutations in DNAs isolated 
from feces of patients with colorectal tumors by mutant-allele-specific amplification 
(MASA). Oncogene 1995: 10: 1441. 
Hayflick L. The limited in vitro lifetime of human diploid cell strains. Exp Cell Res 
1965:37:61". 
Hawley SA. Boudeau J. Reid JL. et al. Complexes between the LKBI tumor suppressor, 
STRAD alphalbeta and M025 alphalbeta are upstream kinases in the AMP-activated 
protein kina\C cascade. J Bioi 2003;2:28. 
181 
Hawley SA. Davison M, Woods A, et a1. Characterization of the AMP-activated protein 
kinase kinase from rat liver and identification of threonine 172 as the major site at 
which it phosphorylates AMP-activated protein kinase. 1 BioI Chern 1996;271 :27879. 
Hawley SA. Gadalla AE, Olsen GS, Hardie DG. The antidiabetic drug metformin 
activates the AMP-activated protein kinase cascade via an adenine nucleotide-
independent mechanism. Diabetes 2002;51 :2420. 
Hingorani SR. 1acobetz MA, Robertson GP, et a1. Suppression of BRAF(V599E) in 
human melanoma abrogates transformation. Cancer Res 2003;63:5198. 
Hoekstra R. Verweij 1, Eskens FA. Clinical trial design for target specific anticancer 
agents. Invest New Drugs 2003;21 :243. 
Horman S. Browne G. Krause U, et al. Activation of AMP-activated protein kinase leads 
to the phosphorylation of elongation factor 2 and an inhibition of protein synthesis. 
Curr BioI. 1002;12:1419. 
Hurley RL. Anderson KA, Franzone 1M, et al. The Ca2+/calmodulin-dependent protein 
kina'\e kinases are AMP-activated protein kinase kinases. 1 BioI Chern 
2005 :280: 29060. 
Hurst EA. Harbour 1W. Cornelius LA. Ocular melanoma: a review and the relationship to 
cutaneous melanoma. Arch Dermatol2003;139: 1067. 
Kaelin WG 1r. The concept of synthetic lethality in the context of anticancer therapy. Nat 
Rev Cancer 2005;5:689. 
Kahlem P. Dorken B. Schmitt CA. Cellular senescence in cancer treatment: friend or foe? 
1 Clin Invest 2004;113:169. 
182 
Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved 
in genesis of many tumor types. Science 1994;264:436. 
Kaneda A, Wakazono K, Tsukamoto T, et aI. Lysyl oxidase is a tumor suppressor gene 
inactivated by methylation and loss of heterozygosity in human gastric cancers. 
Cancer Res 2004;64:6410. 
Karuman p, Gozani 0, Odze RD, et al. The Peutz-Jegher gene product LKBI is a 
mediator of p53-dependent cell death. Mol Cell 2001 ;7: 1307. 
Kelly M, Keller C. Avilucea PRo AMPK activity is diminished In tissues of ll..-6 
knockout mice: the effect of exercise. Biochem Biophys Res Commun 2004;320:449. 
Kemp BE, Stapleton D, Campbell DJ. AMP-activated protein kinase, super metabolic 
regulator. Biochem Soc Trans 2003;31:162. 
Kenyon K, Contente S, Trackman PC, et al. Lysyl oxidase and rrg messenger RNA. 
Science 1991:253:802. 
Kerr JF, Wyllie AH. Currie AR. Apoptosis: a basic biological phenomenon with wide-
ranging implications in tissue kinetics. Br J Cancer 1972;26:239. 
Khosravi-Far R, Campbell S, Rossman KL, Der CJ, et al. Increasing complexity of Ras 
signal transduction: involvement of Rho family proteins. Adv Cancer Res 
1998;72:57. 
Kim R. Emi M, Tanabe K, Toge T. Therapeutic potential of antisense Bc1-2 as a 
chemosensitizer for cancer therapy. Cancer 2004;101:2491. 
Kim CF. Jackson EL, Woolfenden AE, et al. Identification of bronchioalveolar stem cells 
in normal lung and lung cancer. Cell 2005;121:823. 
183 
Kimura N, Tokunaga C, Dalal S. A possible linkage between AMP-activated protein 
kinase (AMPK) and mammalian target of rapamycin (mTOR) signalling pathway. 
Genes Cells 2003;8:65. 
King AJ. Wireman RS, Hamilton M, Marshall MS. Phosphorylation site specificity of the 
Pak-mediated regulation of Raf-I and cooperativity with Src. FEBS Lett 2001 ;497:6. 
Kinzler KW. Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87: 159. 
Kirkwood TB. Austad SN. Why do we age? Nature 2000;408:233. 
Kirkwood JM. Bedikian A Y, Millward MJ, et a1. Long-term survival results of a 
randomized multinational phase 3 trial of dacarbazine (DTIC) with or without BcI-2 
anlisense (oblimersen sodium) in patients with advanced malignant melanoma (MM). 
J Clin Oncol 2005;23:7506. 
Kirschmann DA, Seftor EA, Fong SFf, et a1. A Molecular Role for Lysyl Oxidase in 
Breast Cancer Invasion. Cancer Research 2002;62:4478. 
Kisseleva T. Bhattacharya S, Braunstein J, Schindler CWo Signaling through the 
JAKISTAT pathway. recent advances and future challenges. Gene 2002;285: l. 
Klasa RJ. Gillum AM, Klem RE, Frankel SR. Oblimersen Bcl-2 antisense: facilitating 
apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev 2002; 12: 193. 
Krasilnikov M. Ivanov VN, Dong J, Ronai Z. M. ERK and PI3K negatively regulate 
STAT-transcriptional activities in human melanoma cells: implications towards 
sensitization to apoptosis. Oncogene 2003;26:4092. 
Krtolica A. Parrinello S, Lockett S, et a1. Senescent fibroblasts promote epithelial cell 
growth and tumorigenesis: a link between cancer and aging. Proc Natl Acad Sci USA 
200 I ;98: 12072. 
184 
Kumar R. Angelini S., Hemminki K. Activating BRAF and N-Ras mutations in sporadic 
primary melanomas: an inverse association with aIIeIic loss on chromosome 9. 
Oncogene 2003;22:92 17. 
Kuwata T, Kitagawa M, Kasuga T. Proliferative activity of primary cutaneous 
melanocytic tumours. Virchows Arch A Pathol Anat Histopathol 1993;423:359. 
Jansen B, H. Schlagbauer-Wad, Brown BD, et a1. Bcl-2 antisense therapy 
chemosensitizes human melanoma in SCID mice. Nat Med 1998;4:232. 
Jimbow K, Quevedo WC Jr, Fitzpatrick TH, Szabo G. Some aspects of melanin biology: 
1950-1975. J Invest DermatoI 1976;67:72. 
Jiveskog S, Ragnarsson-Olding B, Platz A, Ringborg U. N-ras mutations are common in 
melanomas from sun-exposed skin of humans but rare in mucosal membranes or 
unexposed skin. J Invest. Dermatol 1998; III :757. 
Johnson GL. Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, 
JNK. and p38 protein kinases. Science 2002;298: 1911. 
Johnson KY, Liu L, Vincent TS. Minimal FLAG sequence useful in the functional 
epitope tagging of H-Ras. Biotechniques 2002;32: 1270. 
Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev 
Genet 2002;3:415. 
Jones RG, Plas DR, Kubek S, et a1. AMP-activated protein kinase induces a p53-
dependent metabolic checkpoint. Mol Cell 2005; 18:283. 
Inoki K. Zhu T. Guan KL. TSC2 mediates cellular energy response to control cell growth 
and survival. Cell 2003;115:577. 
185 
Lampson LA. Fisher CA. Whelan JP. Striking paucity of HLA-A. B. C and beta 2-
microglobulin on human neuroblastoma cell lines. J Immunol 1983;130:2471. 
Land H. Parada LF. Weinberg RA. Tumorigenic conversion of primary embryo 
fibroblasts requires at least two cooperating oncogenes. Nature 1983;304:596. 
Landi MT. Bauer 1. Pfeiffer RM, et al. MCIR germline variants confer risk for BRAF-
mutant melanoma. Science 2006;313:521. 
Lapidot T. Sirard C, Vormoor 1, et al. A cell initiating human acute myeloid leukaemia 
after transplantation into SCID mice. Nature 1994;367:645. 
Lazarus HM. Cruikshank WW, Narasimhan N, et al. Induction of human monocyte 
motility by lysyl oxidase. Matrix BioI 1994; 14:727. 
Lazzerini Denchi E. Attwooll C. Pasini D, Helin K. Deregulated E2F activity induces 
hyperplasia and senescence-like features in the mouse pituitary gland. Mol Cell BioI 
2005;25:2660. 
Leclerc I, Lenzner C. Gourdon L. et al. Hepatocyte nuclear factor-4alpha involved in type 
1 maturity-onset diabetes of the young is a novel target of AMP-activated protein 
kinase. Diabetes 2001;50:1515. 
Lee BY. Han lA. 1m IS. et al. Senescence associated beta-galactosidase is lysosomal 
beta-galactosidase. Aging Cell 2006;5: 187. 
Lehner Pl. Cresswell P. Recent developments in MHC-class-I-mediated antigen 
presentation. Curr Opin Immunol 2004; 16:82. 
Li W. Liu G. Chou IN. Kagan HM. Hydrogen peroxide-mediated, lysyl oxidase-
dependent chemotaxis of vascular smooth muscle cells. 1 Cell BioI 2000;78:550. 
186 
Li W. Nellaiappan K, Strassmaier T, et aI. Localization and activity of lysyl oxidase 
within nuclei offibrogenic cells. Proc Natl Acad Sci USA 1997;94:2817. 
Lin AW, Barradas M, Stone lC, et al. Premature senescence involving p53 and p16 is 
activated in response to constitutive MEKlMAPK mitogenic signaling. Genes Dev 
1998: 12:3008. 
Linard B. Bezieau S, Benlalam H, et al. A ras-mutated peptide targeted by CTL 
infiltrating a human melanoma lesion. J Immuno12002;168:4802. 
Liotta L. Petricoin E. Molecular profiling of human cancer. Nat Gen 2000; I :48. 
Lodygin D. Menssen A, Henneking H. Induction of the Cdk inhibitor p21 by LY83583 
inhibits tumor cell proliferation in a p53-independent manner. J Clin Invest 
2002:110:1717. 
Loewe R. Kittler H, Fischer G, et al. BRAF kinase gene V599E mutation in growing 
melanocytic lesions. J Invest DennatoI2004;123:733. 
Lowe SW. Cepero E. Evan G. Intrinsic tumour suppression. Nature 2004;432:307. 
Lowe SW. Sherr Cl. Tumor suppression by Ink4a-Arf: progress and puzzles. Curr 
Opin Genet Dev 2003:13:77. 
Lupetti R. Sensi M. Mortarini R, et aI. N-RAS mutations and susceptibility to 
Iymphokine-activated killer (LAK) cells in human melanoma. Melanoma Res 
1994:4: II. 
Maccalli C. Pisarra P. Vegetti C. et al. Differential loss of T cell signaling molecules in 
meta'\tatic melanoma patients' T lymphocyte subsets expressing distinct TCR variable 
regions. J Immunol 1999: 163 :6912. 
187 
Maldonado JL, Timmerman L, Fridlyand J, Bastian BC. Mechanisms of cell cycle arrest 
in Spitz nevi with constitutive activation of the MAP-kinase pathway. Am J Pathol 
2004; 164: 1783. 
Maley CC, Galipeau PC, Li X, et a1. Selectively advantageous mutations and hitchhikers 
in neoplasms: pl6 lesions are selected in Barrett's esophagus. Cancer Res 
2004;64:3414. 
Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat 
Rev Cancer 200 I; I : 222. 
Marais R. Light y, Paterson HF, et a1. Differential regulation of Raf-I, A-Raf, and B-Raf 
by oncogenic ras and tyrosine kinases. J BioI Chern. 1997;272:4378. 
McCormick F. Signalling networks that cause cancer. TmS 1999;24:M53. 
McGill GG, Horstmann M, Widlund HR, et a1. Bcl2 regulation by the melanocyte master 
regulator Mitf modulates lineage survival and melanoma cell viability. Cell 
2002;109:707. 
Meadows KN, Bryant P, Vincent PA, Pumiglia KM. Activated Ras induces a 
proangiogenic phenotype in primary endothelial cells. Oncogene 2004;23: 192. 
Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. 
Oncogene 2000; 19:6550. 
Mercer KE, Pritchard CA. Raf proteins and cancer: B-Raf is identified as a mutational 
target. Biochim Biophys Acta 2003; 1653:25. 
Michaloglou C. Vredeveld LC, Soengas MS, et a1. BRAFE600-associated senescence-
like cell cycle arrest of human naevi. Nature 2005;436:720. 
188 
Midgley RS, Kerr DJ. Ras as a target in cancer therapy. Crit Rev Dncol Hematol 
2002;44: 109. 
Miller Cl, Cheung M, Sharma A, et al. Method of mutation analysis may contribute to 
discrepancies in reports of (V599E)BRAF mutation frequencies in melanocytic 
neoplasms.J Invest DermatoI2004;I23:990. 
Minokoshi y, Kim YB, Peroni OD, et al. Leptin stimulates fatty-acid oxidation by 
activating AMP-activated protein kinase. Nature 2002;415:339. 
Miracco C, De Santi M, Schurfeld K, et al. Quantitative in situ evaluation of telomeres in 
fluorescence in situ hybridization-processed sections of cutaneous melanocytic 
lesions and correlation with telomerase activity. Br 1 Dermatol 2002; 146:399. 
Molnar 1. Fong KS, He QP, et al. Structural and functional diversity of lysyl oxidase and 
the LOX-like proteins. Biochim Biophys Acta 2003; 1647:220. 
Mooi Wl. Peeper DS. Oncogene-induced cell senescence--halting on the road to cancer. 
N Engl 1 Med 2006;355: 1037. 
Mortarini R. Borri A, Tragni G. et al. Peripheral burst of tumor-specific cytotoxic T 
lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in 
melanoma patients receiving interleukin 12. Cancer Res 2000;60:3559. 
Muntoni A. Reddel RR. The first molecular details of ALT in human tumor cells. Hum 
Mol Genet 2005;14:R191. 
Narita M. Nunez S, Heard E, et al. Rb-mediated heterochromatin formation and silencing 
of E2F target genes during cellular senescence. Cell 2003; 113:703. 
189 
Nielsen BS. Borregaard N, Bundgaard JR, et al. Induction of NGAL synthesis in 
epithelial cells of human colorectal neoplasia and inflammatory bowel diseases. Gut 
1996:38:414. 
Nowell PC. Tumor progression: a brief historical perspective. Semin Cancer BioI 
2002: 12:261. 
Ogino T. Wang X. Kato S, et al. Endoplasmic reticulum chaperone-specific monoclonal 
antibodies for flow cytometry and immunohistochemical staining. Tissue Antigens 
2003:62:385. 
Olsen MF. Marais R. Ras protein signaling. Semin ImmunoI2000;12:63. 
Omholt K. Platz A. Kanter Let al. NRAS and BRAF mutations arise early during 
melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer 
Res 2003:9:6483. 
Ortega S. Malumbres M, Barbacid M. Cyelin D-dependent kinases, INK4 inhibitors and 
cancer. Biochim Biophys Acta 2002;1602:73. 
Palmero l. Pantoja C, Serrano M. p 19ARF links the tumour suppressor p53 to Ras. 
Nature 1998:395:125. 
Parham P. Barnstable CJ, Bodmer WF. Use of monoclonal antibody (W6/32) in structural 
studies of HLA-A, -B, -C antigens. J ImmunoI1979;123:536. 
Passioura T. Dolnikov A, Shen S, Symonds G. N-ras-induced growth suppression of 
myeloid cells is mediated by IRF-I. Cancer Res 2005;65:797. 
Pavey S. Johansson p, Packer L, et a1. Microarray expression profiling in melanoma 
reveals a BRAF mutation signature. Oncogene 2004;23:4060. 
190 
Peeper OS. Dannenberg JH. Douma S. et aI. Escape from premature senescence is not 
sufficient for oncogenic transformation by Ras. Nat Cell BioI 2001 ;3: 198. 
Peeper OS. Shvarts A. Brummelkamp T, et al. A functional screen identifies hDRILI as 
an oncogene that rescues RAS-induced senescence. Nat Cell BioI 2002;4: 148. 
Petti C. ~olla A. Vegeni C, et al. Coexpression of NRASQ61R and BRAFV600E in 
human melanoma cells activates senescence and increases susceptibility to cell-
mediated cytotoxicity. Cancer Res 2006;66:6503. 
Pollock PM. Harper UL. Hansen KS, et al. High frequency of BRAF mutations in nevi. 
Nat Genet 2003:33: 19. 
Polsky D. Cordon-Cardo C. Oncogenes in melanoma. Oncogene 2003;22:3087. 
Polyak K. Riggins GJ. Gene discovery using the serial analysis of gene expression 
technique: implications for cancer research. J Clin Oncol 2001; 19:2948. 
Poser I. Bosserhoff AK. Transcription factors involved in development and progression 
of malignant melanoma. Histol Histopathol 2004; 19: 173. 
Pritchard CA. Samuels ML. Bosch E. McMahon M. Conditionally oncogenic forms of 
the A-Raf and B-Raf protein kinases display different biological and biochemical 
properties in NIH 3T3 cells. Mol Cell BioI 1995;15:6430. 
Rajagopalan H. Bardelli A. Lengauer C. et al. Tumorigenesis: RAFIRAS oncogenes and 
mismatch-repair status. Nature 2002;418:934. 
Randerson-Moor JA. Harland M. Williams S. et al. A germline deletion ofpl4 (ARF) but 
not CDKN2A in a melanoma-neural system tumour syndrome family. Hum Mol 
Genet 2001:10:55. 
191 
Rattan R. Giri S. Singh AK, Singh I. 5-Arninoirnidazole-4-carboxarnide-I-beta-D-
ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-
activated protein kinase. 1 BioI Chern 2005;280:39582. 
Rebbaa A. Targeting senescence pathways to reverse drug resistance in cancer. Cancer 
Lett 2005:219: I. 
Rees JL. Genetics of hair and skin color. Annu Rev Genet 2003;37:67. 
Repasky GA. Chenette EJ. Der Cl. Renewing the conspiracy theory debate: does Raf 
function alone to mediate Ras oncogenesis? Trends Cell BioI 2004;14:639. 
Reuter CWM. Morgan MA. Bergmann L. Targeting the Ras signalling pathway: a 
rational. mechanism-based treatment for haematological malignancies? Blood 
2<X)():96: 1655. 
Rizos H. Puig S. Badenas C. et al. A melanoma-associated germline mutation in exon 
I beta inactivates p 14ARF. Oncogene 200 1;20:5543. 
Rodolfo M. Daniotti M. Vallacchi V. Genetic progression of metastatic melanoma. 
Cancer Lett 2004;214: 133. 
Ruderman NB. Park H. Kaushik VK. AMPK as a metabolic switch in rat muscle, liver 
and adipose tissue after exercise. Acta Physiol Scand 2003;178:435. 
Sage J. Mulligan Gl. Attardi LD. et al. Targeted disruption of the three Rb-related genes 
leads to loss of G(l) control and immortalization. Genes Dev 2000; 14:3037. 
Saldanha G. Purnell D. Fletcher A. et al. High BRAF mutation frequency does not 
chamcterize all melanocytic tumor types. lot 1 Cancer 2004; III :705. 
192 
Salt I, Celler 1W, Hawley SA, et a1. AMP-activated protein kinase: greater AMP 
dependence, and preferential nuclear localization, of complexes containing the alpha2 
isoform. Biochem 1 1998;334: 177. 
Salti G1, Manougian T, Farolan M, et a1. Micropthalmia transcription factor; a new 
prognostic marker in intermediate-thickness cutaneous malignant melanoma. Cancer 
Res 2000;60:5012. 
Salvucci 0, Carsana M, Bersani I, et a1. Antiapoptotic role of endogenous nitric oxide in 
human melanoma cells. Cancer Res 200 1 ;61 :318. 
Satyamoorthy K, Li G, Gerrero MR, et al. Constitutive mitogen-activated protein kinase 
activation in melanoma is mediated by both BRAF mutations and autocrine growth 
factor stimulation. Cancer Res 2003;63:756. 
Santarosa M, Ashworth A. Haploinsufficiency for tumour suppressor genes: when you 
don't need to go all the way. Biochim Biophys Acta 2004;1654:105. 
Savitsky K, Bar-Shira A, Gilad S, et a1. A single ataxia telangiectasia gene with a product 
similar to PI-3 kinase. Science 1995;268: 1749. 
Schmitt CA, Fridman 1S, Yang M, et a1. A senescence program controlled by p53 and 
pl6INK4a contributes to the outcome of cancer therapy. Cell 2002;109:335. 
Schulze A, Lehmann K, 1efferies HB, et al. Analysis of the transcriptional program 
induced by Rafin epithelial cells. Genes Dev 2001;15:981. 
Scott 1W, Hawley SA, Green KA, et a1. CBS domains form energy-sensing modules 
whose binding of adenosine ligands is disrupted by disease mutations. 1 Clin Invest 
2004;113:274. 
193 
Sears C, Annstrong SA. Microarrays to identify new therapeutic strategies for cancer. 
Adv Cancer Res 2007:96:51. 
Seholt-Leopold JS. Herrera R. Targeting the mitogen-activated protein kinase cascade to 
treat cancer. Nat Rev Cancer 2004;4:937. 
Sell S. Cancer stem cells and differentiation therapy. Tumour Bioi 2006;27:59. 
Selzer E, Schlagbauer-Wadl H, Okamoto I, et al. Expression of Bcl-2 family members in 
human melanocytes. in melanoma metastases and in melanoma cell lines. Melanoma 
Res 1998;8: 197. 
Sensi M. Nicolini G. Petti C, et al. Mutually exclusive Q6 IRNRAS and v600EBRAF 
mutations at single cell level in the same human melanoma. Oncogene 2006;25:335. 
Serrano M. Lin AW, McCurrach ME. et al. Oncogenic ras provokes premature cell 
senescence associated with accumulation ofp53 and p16INK4a. Cell 1997;88:593. 
Serrano M, Hannon GJ. Beach D. A new regulatory motif in cell-cycle control causing 
specific inhibition of cyclin D/CDK4. Nature 1993;366:704. 
Serrano M, Lin A W. McCurrach ME, et al. Oncogenic ras provokes premature cell 
senescence associated with accumulation ofp53 and p16INK4a. Cell 1997;88:593. 
Sewing A. Wiseman B, Lloyd AC, Land H. High-intensity Raf signal causes cell cycle 
arrest mediated by p21 Cip l. Mol Cell BioI 1997; 17:5588. 
Sharpless E, Chin L. The INK4a1ARF locus and melanoma. Oncogene 2003;22:3092. 
Shay JW, Roninson lB. Hallmarks of senescence in carcinogenesis and cancer therapy. 
Oncogene 2004;23:2919. 
Shay JW, Wright WE. Hayflick. his limit, and cellular ageing. Nat Rev Mol Cell BioI 
2000;1:72. 
194 
Sherr CJ, DePinho RA. Cellular senescence: mitotic clock or culture shock? Cell 
2000; 102:407. 
Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2002;2: 103. 
Singer G, Oldt R 3rd, Cohen y, et al. Mutations in BRAF and KRAS characterize the 
development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 2003;95:484. 
Singh SK. Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human 
brain tumors. Cancer Res 2003;63:5821. 
Slominski A, Tobin DJ, Shibahara S, Wortsman J. Melanin pigmentation in mammalian 
skin and its hormonal regulation. Physiol Rev 2004;84: 1155. 
Smalley KS. A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? 
Int J Cancer 2003;10:527. 
Smith-Mungo LI, Kagan HM. Lysyl oxidase: Properties, regulation and multiple 
functions in biology. Matrix BioI 1997: 16:387. 
Soengas MS, Capodieci P, Polsky D, et al. Inactivation of the apoptosis effector Apaf-l 
in malignant melanoma. Nature 2001;409:207. 
Solit DB, Garraway LA, Pratilas CA, et al. BRAF mutation predicts sensitivity to MEK 
inhibition. Nature 2006;439:358. 
Sprang SR. G proyein mechanisms: insights from structural analysis. Annu Rev Biochem 
1997;66:639. 
Stampfer MR, Garbe J, Niijar T, et a1. Loss of p53 function accelerates acquisition of 
telomerase activity in indefinite lifespan human mammary epithelial cell lines. 
Oncogene 2003;22:5238. 
195 
Steingrimsson E. Copeland NG. Jenkins NA. Me1anocytes and the microphthalmia 
transcription factor network. Annu Rev Genet 2004;38:365. 
Sturm RA. Duffy DL. Box NF. et al. Genetic association and cellular function of MCIR 
variant alleles in human pigmentation. Ann NY Acad Sci 2003;994:348. 
Sundararajan T A. Interference with glycerokinase induction in mutants of E. Coli 
accumulatin gal-I-P. Proc Natl Acad Sci USA 1963;50:463. 
Tanaka N, Ishihara M, Kitagawa M,et al. Cellular commitment to oncogene induced 
transformation or apoptosis is dependent on the transcription factor IRF. Cell 
1994;77:829. 
Teng DH. Hu R. Lin H. D. et al. MMAC 1IPTEN mutations in primary tumor specimens 
and tumor cell lines. Cancer Res 1997;57:522l. 
te Poele RH, Okorokov AL, Jardine L, et al. DNA damage is able to induce senescence in 
tumor cells in l'itro and in vivo. Cancer Res 2002;62: 1876. 
Terada S, Goto M, Kato M. et al. Effects of low-intensity prolonged exercise on PGC-l 
mRNA expression in rat epitrochlearis muscle. Biochem Biophys Res Commun 
2002;296:350. 
Tiainen M, Vaahtomeri K, Ylikorkala A, Makela TP. Growth arrest by the LKB I tumor 
suppressor: induction of p21(WAFlICIP1). Hum Mol Genet 2002; 11: 1497. 
Tsao H, Zhang X, Fowlkes K, Haluska FG. Relative reciprocity of NRAS and 
PTENIMMAC I alterations in cutaneous melanoma cell lines. Cancer Res 
2000;60: 1800. 
Tuveson DA. Weber BL, Herlyn M. BRAF as a potential therapeutic target in melanoma 
and other malignancies. Cancer Cell 2003;4:95. 
196 
Tyner SD, Venkatachalam S, Choi J, et al. p53 Mutant mice that display early ageing-
associated phenotypes. Nature 2002;415:45. 
Tysnes BB, Bjerkvig R. Cancer initiation and progression: Involvement of stem cells and 
the microenvironment. Biochim Biophys Acta 2007; [Epub ahead of print]. 
Valverde P, Healy E, Sikkink S, et al. The Asp84Glu variant of the melanocortin 
receptor (MC IR) is associated with melanoma. Hum Mol Genet 1996;5: 1663. 
Vance KW, Carreira S, Brosch G, Goding CR. Tbx2 is overexpressed and plays an 
important role in maintaining proliferation and suppression of senescence in 
melanomas. Cancer Res 2005;65:2260. 
Van Heemst D, Mooijaart SP, Beekman M, et al. Variation in the human TP53 gene 
affects old age survival and cancer mortality. Exp Gerontol 2005;40: 11. 
Venkatesha S, Hanai J, Seth P, et al. Lipocalin 2 Antagonizes the Proangiogenic Action 
of Ras in Transformed Cells. Molecular Cancer Research 2000;4:821. 
Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307. 
Xiang X, Saha AK, Wen R, et al. AMP-activated protein kinase activators can inhibit the 
growth of prostate cancer cells by multiple mechanisms. Biochem Biophys Res 
Commun 2004;321: 161. 
Xu X, Quiros RM, Gattuso P, et al. High prevalence of BRAF gene mutation in papillary 
thyroid carcinomas and thyroid tumor cell lines. Cancer Res 2003;63:4561. 
Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization 
and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 
2002;8: 1288. 
197 
Yanase H, Ando H, Horikawa M, et al.Possible involvement of ERK 112 in UVA-
induced melanogenesis in cultured normal human epidermal melanocytes. Pigment 
Cell Res 200 I; 14: 103. 
Yang W, Hong YH, Shen XQ, et al. Regulation of transcription by AMP-activated 
protein kinase: phosphorylation of p300 blocks its interaction with nuclear receptors. 
J Bioi Chern 200 1;276:38341. 
Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling 
pathway by oncogenic mutations of B-RAF. Cell 2004;116:855. 
Wang E. Senescent human fibroblasts resist programmed cell death, and failure to 
suppress bcl2 is involved. Cancer Res 1995;55:2284. 
Wang W, Fan J, Yang X, et al. AMP-activated kinase regulates cytoplasmic HuR. Mol 
Cell Bioi 2002;22:3425. 
Wang W, Yang X, Lopez de Silanes I, et al. Increased AMP:ATP ratio and AMP-
activated protein kinase activity during cellular senescence linked to reduced HuR 
function. J Bioi Chern 2003;278:27016. 
Weber CK, Slupsky JR, Kalmes HA, Rapp UR.Active Ras induces heterodimerization of 
cRaf and BRaf. Cancer Res 200 1 ;61 :3595. 
Weiss B, Bollag G, Shannon K. Hyperactive Ras as a therapeutic target m 
neurofibromatosis type l. Am J Med Genet 1999;89: 14. 
Wellbrock C, Karasarides M, Marais R. The RAF proteins take centre stage. Nat. Rev 
Mol Cell Bioi 2004;5:875. 
Wellbrock C, Marais R. Elevated expression of MITF counteracts B-RAF-stimulated 
melanocyte and melanoma cell proliferation. J Cell Bioi 2005; 170:703. 
198 
Wellbrock C, Ogilvie L, Hedley D, et al. v599EB_RAF is an oncogene in melanocytes. 
Cancer Res 2004;64:2338. 
Wen WH, Bernstein L. Lescallett J, et al. Comparoson of TP53 mutations identified by 
oligonucleotide micrarray and conventional DNA sequence analysis. Cancer Res 
2000;60:2716. 
Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea--a paradigm shift. Cancer Res 
2006;66: 1883. 
Widlund HR, Fisher DE. Microphthalamia-associated transcription factor: a critical 
regulator of pigment cell development and survival. Oncogene 2003;22:3035. 
Willmore-Payne C, Holden JA, Tripp S, Layfield U. Human malignant melanoma: 
detection of BRAF- and c-kit-activating mutations by high-resolution amplicon 
melting analysis. Hum PathoI2005;36:486. 
Woods A, Salt I, Scott J. et al. The al and a2 isoforms of the AMP-activated protein 
kinase have similar activities in rat liver but exhibit differences in substrate specificity 
in vitro. FEBS Lett 1996;397:347. 
Wu H. Goel V, Haluska FG. PTEN signaling pathways in melanoma. Oncogene 
2003:22:3113-22. 
Wu WS. Heinrichs S, Xu D. et al. Slug antagonizes p53-mediated apoptosis of 
hematopoietic progenitors by repressing puma. Cell 2005;123:641. 
Zakikhani M, Dowling R, Fantus IG. Sonenberg N. Pollak M. Metformin is an AMP 
kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006;66: 10269. 
199 
Zanon M, Piris A, Bersani I, et al. Apoptosis protease activator protein-l expression is 
dispensable for response of human melanoma cells to distinct proapoptotic agents. 
Cancer Res 2004;64:7386. 
Zhang y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes 
p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression 
pathways. Cell 1998;92:725. 
Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of 
metformin action. 1 Clin Invest 200 I; 108: 1167. 
Zong H, Ren 1M, Young LH, et al. AMP kinase is required for mitochondrial biogenesis 
in skeletal muscle in response to chronic energy deprivation. Proc Natl Acad Sci USA 
2002;99: 15983. 
Zuber 1, Tchemitsa 01, Hinzmann B, et al. A genome-wide survey of RAS 
transformation targets. Nat Genet. 2000;24: 144. 
200 
